
<html lang="en"     class="pb-page"  data-request-id="29db7aa6-9d4c-465f-b5a2-98a3e4d3ae91"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2017.60.issue-24;article:article:10.1021/acs.jmedchem.7b01044;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases" /></meta><meta name="dc.Creator" content="Laura  Carzaniga" /></meta><meta name="dc.Creator" content="Gabriele  Amari" /></meta><meta name="dc.Creator" content="Andrea  Rizzi" /></meta><meta name="dc.Creator" content="Carmelida  Capaldi" /></meta><meta name="dc.Creator" content="Renato  De Fanti" /></meta><meta name="dc.Creator" content="Eleonora  Ghidini" /></meta><meta name="dc.Creator" content="Gino  Villetti" /></meta><meta name="dc.Creator" content="Chiara  Carnini" /></meta><meta name="dc.Creator" content="Nadia  Moretto" /></meta><meta name="dc.Creator" content="Fabrizio  Facchinetti" /></meta><meta name="dc.Creator" content="Paola  Caruso" /></meta><meta name="dc.Creator" content="Gessica  Marchini" /></meta><meta name="dc.Creator" content="Loredana  Battipaglia" /></meta><meta name="dc.Creator" content="Riccardo  Patacchini" /></meta><meta name="dc.Creator" content="Valentina  Cenacchi" /></meta><meta name="dc.Creator" content="Roberta  Volta" /></meta><meta name="dc.Creator" content="Francesco  Amadei" /></meta><meta name="dc.Creator" content="Alice  Pappani" /></meta><meta name="dc.Creator" content="Silvia  Capacchi" /></meta><meta name="dc.Creator" content="Valentina  Bagnacani" /></meta><meta name="dc.Creator" content="Maurizio  Delcanale" /></meta><meta name="dc.Creator" content="Paola  Puccini" /></meta><meta name="dc.Creator" content="Silvia  Catinella" /></meta><meta name="dc.Creator" content="Maurizio  Civelli" /></meta><meta name="dc.Creator" content="Elisabetta  Armani" /></meta><meta name="dc.Description" content="Phosphodiesterase 4 (PDE4) is a key cAMP-metabolizing enzyme involved in the pathogenesis of inflammatory disease, and its pharmacological inhibition has been shown to exert therapeutic efficacy in..." /></meta><meta name="Description" content="Phosphodiesterase 4 (PDE4) is a key cAMP-metabolizing enzyme involved in the pathogenesis of inflammatory disease, and its pharmacological inhibition has been shown to exert therapeutic efficacy in..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 14, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01044" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01044" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01044" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01044" /></link>
        
    
    

<title>Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01044" /></meta><meta property="og:title" content="Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0022.jpeg" /></meta><meta property="og:description" content="Phosphodiesterase 4 (PDE4) is a key cAMP-metabolizing enzyme involved in the pathogenesis of inflammatory disease, and its pharmacological inhibition has been shown to exert therapeutic efficacy in chronic obstructive pulmonary disease (COPD). Herein, we describe a drug discovery program aiming at the identification of novel classes of potent PDE4 inhibitors suitable for pulmonary administration. Starting from a previous series of benzoic acid esters, we explored the chemical space in the solvent-exposed region of the enzyme catalytic binding pocket. Extensive structural modifications led to the discovery of a number of heterocycloalkyl esters as potent in vitro PDE4 inhibitors. (S*,S**)-18e and (S*,S**)-22e, in particular, exhibited optimal in vitro ADME and pharmacokinetics properties and dose-dependently counteracted acute lung eosinophilia in an experimental animal model. The optimal biological profile as well as the excellent solid-state properties suggest that both compounds have the potential to be effective topical agents for treating respiratory inflammatory diseases." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01044"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01044">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01044&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01044&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01044&amp;href=/doi/10.1021/acs.jmedchem.7b01044" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 10026-10046</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00883" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b01117" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Laura++Carzaniga">Laura Carzaniga</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-2426-1526" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gabriele++Amari">Gabriele Amari</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrea++Rizzi">Andrea Rizzi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carmelida++Capaldi">Carmelida Capaldi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Renato++De+Fanti">Renato De Fanti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eleonora++Ghidini">Eleonora Ghidini</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gino++Villetti">Gino Villetti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chiara++Carnini">Chiara Carnini</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nadia++Moretto">Nadia Moretto</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fabrizio++Facchinetti">Fabrizio Facchinetti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paola++Caruso">Paola Caruso</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gessica++Marchini">Gessica Marchini</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Loredana++Battipaglia">Loredana Battipaglia</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Riccardo++Patacchini">Riccardo Patacchini</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Valentina++Cenacchi">Valentina Cenacchi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Roberta++Volta">Roberta Volta</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Francesco++Amadei">Francesco Amadei</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alice++Pappani">Alice Pappani</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Silvia++Capacchi">Silvia Capacchi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Valentina++Bagnacani">Valentina Bagnacani</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maurizio++Delcanale">Maurizio Delcanale</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paola++Puccini">Paola Puccini</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Silvia++Catinella">Silvia Catinella</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maurizio++Civelli">Maurizio Civelli</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Elisabetta++Armani">Elisabetta Armani</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>§</sup>Chemistry Research and Drug Design, <sup>∥</sup>Pharmacology and Toxicology, <sup>‡</sup>Pharmacokinetics Biochemistry and Metabolism, <sup>†</sup>Analytics and Early Formulations, <sup>#</sup>Project Leader Corporate Drug Development, and <sup>⊥</sup>Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div><div class="corresp-info"><strong>*</strong>Phone: +39 0521 279652. Fax: +39 0521 279880. E-mail: <a href="/cdn-cgi/l/email-protection#e28ecc81839098838c8b8583a2818a8b87918bcc818d8f"><span class="__cf_email__" data-cfemail="adc183ceccdfd7ccc3c4caccedcec5c4c8dec483cec2c0">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>Phone: +39 0521 279477. Fax: +39 0521 279880. E-mail: <a href="/cdn-cgi/l/email-protection#bbde95dac9d6dad5d2fbd8d3d2dec8d295d8d4d6"><span class="__cf_email__" data-cfemail="a1c48fc0d3ccc0cfc8e1c2c9c8c4d2c88fc2cecc">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01044&amp;href=/doi/10.1021%2Facs.jmedchem.7b01044" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 10026–10046</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 4, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 July 2017</li><li><span class="item_label"><b>Published</b> online</span>14 December 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 December 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01044" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01044</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10026%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DLaura%2BCarzaniga%252C%2BGabriele%2BAmari%252C%2BAndrea%2BRizzi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D24%26contentID%3Dacs.jmedchem.7b01044%26title%3DDiscovery%2Band%2BOptimization%2Bof%2BThiazolidinyl%2Band%2BPyrrolidinyl%2BDerivatives%2Bas%2BInhaled%2BPDE4%2BInhibitors%2Bfor%2BRespiratory%2BDiseases%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10046%26publicationDate%3DDecember%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01044"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2146</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">9</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01044" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Laura&quot;,&quot;last_name&quot;:&quot;Carzaniga&quot;},{&quot;first_name&quot;:&quot;Gabriele&quot;,&quot;last_name&quot;:&quot;Amari&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;Rizzi&quot;},{&quot;first_name&quot;:&quot;Carmelida&quot;,&quot;last_name&quot;:&quot;Capaldi&quot;},{&quot;first_name&quot;:&quot;Renato&quot;,&quot;last_name&quot;:&quot;De Fanti&quot;},{&quot;first_name&quot;:&quot;Eleonora&quot;,&quot;last_name&quot;:&quot;Ghidini&quot;},{&quot;first_name&quot;:&quot;Gino&quot;,&quot;last_name&quot;:&quot;Villetti&quot;},{&quot;first_name&quot;:&quot;Chiara&quot;,&quot;last_name&quot;:&quot;Carnini&quot;},{&quot;first_name&quot;:&quot;Nadia&quot;,&quot;last_name&quot;:&quot;Moretto&quot;},{&quot;first_name&quot;:&quot;Fabrizio&quot;,&quot;last_name&quot;:&quot;Facchinetti&quot;},{&quot;first_name&quot;:&quot;Paola&quot;,&quot;last_name&quot;:&quot;Caruso&quot;},{&quot;first_name&quot;:&quot;Gessica&quot;,&quot;last_name&quot;:&quot;Marchini&quot;},{&quot;first_name&quot;:&quot;Loredana&quot;,&quot;last_name&quot;:&quot;Battipaglia&quot;},{&quot;first_name&quot;:&quot;Riccardo&quot;,&quot;last_name&quot;:&quot;Patacchini&quot;},{&quot;first_name&quot;:&quot;Valentina&quot;,&quot;last_name&quot;:&quot;Cenacchi&quot;},{&quot;first_name&quot;:&quot;Roberta&quot;,&quot;last_name&quot;:&quot;Volta&quot;},{&quot;first_name&quot;:&quot;Francesco&quot;,&quot;last_name&quot;:&quot;Amadei&quot;},{&quot;first_name&quot;:&quot;Alice&quot;,&quot;last_name&quot;:&quot;Pappani&quot;},{&quot;first_name&quot;:&quot;Silvia&quot;,&quot;last_name&quot;:&quot;Capacchi&quot;},{&quot;first_name&quot;:&quot;Valentina&quot;,&quot;last_name&quot;:&quot;Bagnacani&quot;},{&quot;first_name&quot;:&quot;Maurizio&quot;,&quot;last_name&quot;:&quot;Delcanale&quot;},{&quot;first_name&quot;:&quot;Paola&quot;,&quot;last_name&quot;:&quot;Puccini&quot;},{&quot;first_name&quot;:&quot;Silvia&quot;,&quot;last_name&quot;:&quot;Catinella&quot;},{&quot;first_name&quot;:&quot;Maurizio&quot;,&quot;last_name&quot;:&quot;Civelli&quot;},{&quot;first_name&quot;:&quot;Elisabetta&quot;,&quot;last_name&quot;:&quot;Armani&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;14&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;10026-10046&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01044&quot;},&quot;abstract&quot;:&quot;Phosphodiesterase 4 (PDE4) is a key cAMP-metabolizing enzyme involved in the pathogenesis of inflammatory disease, and its pharmacological inhibition has been shown to exert therapeutic efficacy in chronic obstructive pulmonary disease (COPD). Herein, we describe a drug discovery program aiming at the identification of novel classes of potent PDE4 inhibitors suitable for pulmonary administration. Starting from a previous series of benzoic acid esters, we explored the chemical space in the solvent-exposed region of the enzyme catalytic binding pocket. Extensive structural modifications led to the discovery of a number of heterocycloalkyl esters as potent in vitro PDE4 inhibitors. (S*,S**)-18e and (S*,S**)-22e, in particular, exhibited optimal in vitro ADME and pharmacokinetics properties and dose-dependently counteracted acute lung eosinophilia in an experimental animal model. The optimal biological profile as well as the excellent solid-state properties suggest that both compounds have the potential to be eff&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01044&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01044" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01044&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01044" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01044&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01044" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01044&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01044&amp;href=/doi/10.1021/acs.jmedchem.7b01044" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01044" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01044" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01044%26sid%3Dliteratum%253Aachs%26pmid%3D29200281%26genre%3Darticle%26aulast%3DCarzaniga%26date%3D2017%26atitle%3DDiscovery%2Band%2BOptimization%2Bof%2BThiazolidinyl%2Band%2BPyrrolidinyl%2BDerivatives%2Bas%2BInhaled%2BPDE4%2BInhibitors%2Bfor%2BRespiratory%2BDiseases%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D24%26spage%3D10026%26epage%3D10046%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292178" title="Organic compounds">Organic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=291161" title="Inflammation">Inflammation</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/jmcmar.2017.60.issue-24/20171228/jmcmar.2017.60.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Phosphodiesterase 4 (PDE4) is a key cAMP-metabolizing enzyme involved in the pathogenesis of inflammatory disease, and its pharmacological inhibition has been shown to exert therapeutic efficacy in chronic obstructive pulmonary disease (COPD). Herein, we describe a drug discovery program aiming at the identification of novel classes of potent PDE4 inhibitors suitable for pulmonary administration. Starting from a previous series of benzoic acid esters, we explored the chemical space in the solvent-exposed region of the enzyme catalytic binding pocket. Extensive structural modifications led to the discovery of a number of heterocycloalkyl esters as potent <i>in vitro</i> PDE4 inhibitors. (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b>, in particular, exhibited optimal <i>in vitro</i> ADME and pharmacokinetics properties and dose-dependently counteracted acute lung eosinophilia in an experimental animal model. The optimal biological profile as well as the excellent solid-state properties suggest that both compounds have the potential to be effective topical agents for treating respiratory inflammatory diseases.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24165" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24165" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Phosphodiesterases (PDEs) are intracellular enzymes responsible for the degradation of cyclic nucleotides (cAMP and/or cGMP) to their inactive forms through the cleavage of a phosphodiester bond. PDEs have been classified in 11 families based on sequence homogeneity, inhibitor sensitivity, and biochemical properties. This large number of PDE splicing variants serve to fine-tune intracellular levels of cyclic nucleotides, which are key intracellular second messengers regulating a wide range of cellular processes.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">The PDE4 family, which consists of four subtypes (PDE4A, PDE4B, PDE4C, and PDE4D) sharing a highly conserved catalytic domain, has received particular attention due to the fact that it represents the most prominent cAMP-metabolizing enzyme in immune cells, including neutrophils, monocytes, macrophages, and T cells, the main inflammatory cells involved in the pathophysiology of lung inflammation underlying asthma and chronic obstructive pulmonary diseases (COPD). In particular, PDE4 plays a key role in regulating the biosynthesis of several pro-inflammatory mediators and in modulating chemotaxis of leukocytes to sites of inflammation.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Moreover, PDE4 regulates the function of structural lung cells such as fibroblasts, airway smooth muscle, airway epithelium, vascular endothelium, and airway sensory nerves.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">These potential beneficial actions of PDE4 inhibitors have been proven in various experimental models of airway inflammation, thus generating a considerable interest in utilizing PDE4 inhibitors to target inflammation underlying pulmonary diseases such as COPD and asthma.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a></div><div class="NLM_p">Prototypical PDE4 inhibitors, designed for oral administration (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), suffered from the high prevalence of gastrointestinal side effects such as nausea and emesis, which greatly limited their clinical application.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Furthermore, the disappointing results of the second generation PDE4 inhibitor cilomilast (<b>1</b>) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) Phase III clinical program raised major concerns about the therapeutic utility of this class of compounds in COPD. Indeed, it is likely that the highest tolerated dose of cilomilast (i.e., 15 mg bid) was on the leading edge of the dose–response curve and that the low therapeutic ratio of this compound prevented efficacy from being realized.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0001.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of oral PDE4 inhibitors: cilomilast (<b>1</b>), roflumilast (<b>2</b>), apremilast (<b>3</b>), and tetomilast (<b>4</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The latest generation of oral PDE4 inhibitors such as roflumilast<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a><b>2</b> and apremilast<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a><b>3</b> seems to have a better therapeutic index than cilomilast. Indeed, cilomilast is 10-fold more potent in inhibiting PDE4D in comparison with the other PDE4A, PDE4B, and PDE4C isoforms,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and such subtype selectivity has been associated with emesis-inducing effects of PDE4 inhibitors.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Unlike cilomilast, both roflumilast and apremilast do not preferentially inhibit the PDE4D subtype, and this might contribute to their improved therapeutic ratio when compared with cilomilast and possibly other predecessors.</div><div class="NLM_p">Roflumilast has been licensed in EU and US for once-daily treatment of severe and very severe COPD associated with chronic bronchitis and frequent exacerbations as add-on to standard of care, making PDE4 inhibitors a reliable anti-inflammatory therapy for COPD,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> while apremilast has recently been approved for the treatment of adult patients with active psoriatic arthritis. Furthermore, among oral PDE4 inhibitors, tetomilast (<b>4</b>) has been reported to be under clinical development in COPD, although nausea and vomiting are frequent side effects, but the results have not been published yet.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">However, even roflumilast is fraught with dose-limiting adverse effects like diarrhea, nausea, weight loss, back pain, headache, and psychiatric adverse events, resulting in 9% to 16% of patients discontinuing therapy. At this stage, it is still unclear whether the dose limiting side effects of roflumilast allow the use of doses that provide full therapeutic efficacy in COPD patients.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Indeed, there are no published clinical data on the use of roflumilast at doses higher than 500 μg/day in this patient population.</div><div class="NLM_p">This has prompted the search for PDE4 inhibitors with a better therapeutic ratio.</div><div class="NLM_p">In the respiratory field, a logical way to improve the therapeutic index is to deliver drugs directly into the lung via the inhalation route. This route of delivery could provide prolonged inhibition of the target at the therapeutic site of action with limited systemic exposure and consequently lower potential for target-related side effects. However, only compounds specifically designed for topical treatment can be successfully administered using the inhalation route. Therefore, a successful medicinal chemistry strategy aimed at identifying an inhaled PDE4 inhibitor with limited side effects potential should be directed to obtain (1) potent anti-inflammatory effects with convincing activity after topical administration; (2) long persistence in the lung but no significant accumulation; (3) minimal systemic exposure; and (4) production of inactive metabolites.</div><div class="NLM_p">Some inhaled PDE4 inhibitors that progressed to the clinic have been reported so far; these include AWD 12–281 (<b>5</b>),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> tofimilast (<b>6</b>),<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and UK-500,001 (<b>7</b>)<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). These drugs proved to be potent <i>in vitro</i> PDE4 inhibitors and showed efficacy in preclinical pathology models, but no positive effects were reported in the clinic in patients suffering from moderate to severe COPD and have been discontinued. GSK-256066 (<b>8</b>),<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> a highly potent and selective inhaled PDE4 inhibitor, demonstrated potent and long-lasting anti-inflammatory effects in preclinical in vivo models. In a phase 2a study in mild asthmatics, <b>8</b> exhibited inhibition of forced expiratory volume (FEV1) decrease both in the late asthmatic response (LAR) and in the early asthmatic response (EAR) after 1 week of treatment. Nevertheless, <b>8</b> is no longer reported in the company’s pipeline. To date, CHF 6001 (<b>9</b>)<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> is the only example of inhaled PDE4 inhibitor currently under active clinical development for COPD, and its efficacy and safety have been proved in a phase 2a study in mild asthmatics where it significantly attenuated allergen challenge response.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of representative inhaled PDE4 inhibitors in clinical development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">More recently, Astra Zeneca and Merck reported the design and discovery of highly potent and preclinically efficacious inhaled PDE4 inhibitors with low emetic potential<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a> as candidates for treatment of COPD, but no clinical development has been reported to date (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures of Astra Zeneca (<b>10</b>) and Merck (<b>11</b>) inhaled PDE4 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Following a structure-based design, we have synthesized and characterized a novel class of inhaled PDE4 inhibitors. These efforts have led to the identification of two potent compounds that effectively counteracted allergen-induced airway inflammation and showed a pharmacokinetic profile suitable for lung delivery, when tested upon intratracheal administration in the rat.</div><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i2" class="anchor-spacer"></div><h3 class="article-section__title" id="_i2"> Rationale</h3><div class="NLM_p">We previously disclosed a class of highly potent benzoic acid esters as PDE4 inhibitors, of which <b>9</b> is the most representative example.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> This article describes the search for a structurally differentiated backup series to access a previously unexplored region of the chemical space and to prepare for possible unpredictable nonmechanism-based, chemotype-specific liabilities.</div><div class="NLM_p">New compounds were designed on the basis of the above-mentioned series of esters showing potent PDE4 inhibitory activity.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In particular, the crystal structure of the human PDE4B catalytic domain in complex with roflumilast<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> was used as a starting structure to perform molecular docking experiments of the benzoic ester series. Analyzing the binding pose of the unsubstituted inhibitor (<i>S</i>)-<b>14a</b><a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>), it was observed that a deep pocket was available for the insertion of substituents not only in the <i>para</i> and <i>meta</i> positions, as seen for compound <b>9</b> (CHF6001) and its close analogues,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> but also in the <i>ortho</i> position of the phenyl ring (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). Nonetheless, when <i>ortho</i> substitution was addressed in our former program, we observed a decrease in the cell-based potency or even a complete loss of activity. We envisaged that alternative central cores could provide the scaffolding of exit <i>ortho</i>-vectors in the appropriate geometrics to achieve potency while avoiding any cellular drop-off. We therefore focused our efforts on new structural classes of <i>ortho</i>-substituted compounds.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Docking pose of (<i>S</i>)-<b>14a</b> in the catalytic site of the PDE4B crystal structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMU">1XMU</a>). A pocket for the insertion of substituents on the phenyl ring of the ligand is available in the solvent exposed region of the catalytic binding site (magenta).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Compounds <b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) EDC, DMAP, DCM or DMF, rt; (b) mCPBA, DCM, rt, 48h.</p></p></figure><div class="NLM_p">In addition to this, since we aimed at potential candidates for pulmonary administration, our strategy targeted new scaffolds whose features could be able to minimize the systemic exposure due to the swallowed dose. Foreasmuch as previous benzoate esters<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> were poorly metabolized <i>in vitro</i>, we focused on obtaining molecules endowed with high intrinsic clearance, a predictive tool for high systemic clearance, in addition to low free fraction in human plasma and reduced gut wall permeability. With this purpose we pursued the replacement of benzoyl group gradually increasing the three-dimensional morphology of the compound (aryl → heteroaryl → heterocycloalkyl) to probe if it was feasible maintaining potency while, at the same time, achieving an effectively turned-over series.</div><div class="NLM_p last">At first we synthesized a new series of ester derivatives where structural modifications were achieved functionalizing the <i>ortho</i> position of aromatic rings with sulfonyl and carbonyl substituents. Encouraging results from these compounds prompted us to expand our exploration toward the replacement of the aryl esters with 5- and 6-membered heterocycloalkyl rings, investigating the steric and stereochemical requirements for optimal activity. Newly synthesized compounds were at first assessed in a cell-free assay and structure–activity relationships of the most promising classes were further investigated. Our efforts were focused on obtaining derivatives able to retain their activity in the cell-based assay, overcoming any potency drop-off likely to occur in a cellular system, to identify a suitable lead compound whose optimization could be profitably developed. In addition, we looked for a candidate able to exert sustained in vivo efficacy in animal models of inflammation through its persistence in the pulmonary district along with high stability in human lung.</div></div><div id="sec1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">All compounds described in this article were synthesized starting from common intermediates (<i>S</i>)-<b>12</b> and (<i>R</i>)-<b>12</b>, which were prepared as described in ref <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">23</a>.</div><div class="NLM_p">The synthesis of aryl esters (<i>S</i>)-<b>14a</b>–<b>d</b> is shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Esters (<i>S</i>)-<b>14a</b>–<b>c</b> were obtained by coupling the intermediate (<i>S</i>)-<b>12</b> with suitable carboxylic acids using EDC and DMAP as condensing agents, while ester (<i>S</i>)-<b>14d</b> was achieved performing a further oxidation step using mCPBA. Aryl acids <b>13a</b>–<b>d</b> where either commercially available or prepared as detailed in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</div><div class="NLM_p">The synthetic pathway for the synthesis of pyrrolidinyl derivatives <b>18a</b>-<b>f</b> and <b>19</b> is depicted in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Chiral alcohol (<i>S</i>)-<b>12</b> was condensed with either (<i>R</i>)- or (<i>S</i>)-enantiomerically pure Boc-protected proline, then removal of <i>tert</i>-butoxycarbonyl group under acidic conditions led to the versatile intermediates (<i>S</i>*,<i>S</i>**)-<b>15</b> and (<i>R</i>*,<i>S</i>**)-<b>15</b>, which underwent <i>N</i>-sulfonylation to afford sulfonamides <b>18a</b>–<b>f</b>. Further amidation of <b>18f</b> using CDI as condensing agent afforded amide (<i>S</i>*,<i>S</i>**)-<b>19</b>.</div><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Compounds <b>18</b> and <b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (<i>S</i>)-1-(<i>tert</i>-butoxycarbonyl)pyrrolidine-2-carboxylic acid or (<i>R</i>)-1-(<i>tert</i>-butoxycarbonyl)pyrrolidine-2-carboxylic acid, EDC, DMAP, DMF, rt, 48 h; (b) HCl/dioxane 4 M, rt, 8 h; (c) Py or Py/DCM, rt; (d) dimethylamine 2 M in THF, CDI, DMF, rt.</p></p></figure><div class="NLM_p">An analogous synthetic route was followed for <i>N</i>-thiazolidinyl-sulfones <b>22b</b>–<b>m</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Thiazolidinyl esters <b>20</b> were prepared by coupling either alcohol (<i>S</i>)-<b>12</b> or (<i>R</i>)-<b>12</b> with the suitable thiazolidine-carboxylic acid isomer in the presence of EDC and DMAP followed by Boc cleavage. The subsequent sulfonylation in pyridine gave sulfonamides <b>22b</b>–<b>m</b>. Carboxylic acid <b>22f</b> was further converted into amides <b>22m</b> reacting the appropriate amine with CDI in DMF. Alternatively, amidation of intermediate <b>21</b> with acids <b>23a</b>–<b>b</b> afforded compounds <b>24a</b>–<b>b</b>. Sulfonyl chlorides <b>17</b> and carboxylic acids <b>23</b> were either commercially available or prepared as described in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</div><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Compounds <b>22</b> and <b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (<i>S</i>)-3-(<i>tert</i>-butoxycarbonyl)thiazolidine-2-carboxylic acid or (<i>R</i>)-3-(<i>tert</i>-butoxycarbonyl)thiazolidine-2-carboxylic acid, EDC, DMAP, DMF, rt; (b) HCl/AcOEt 5 M, rt; (c) Py, rt; (d) EDC, DMAP, DCM or DMF, rt; (e) alkylamine, CDI, DMF, rt.</p></p></figure><div class="NLM_p">A synthetic pathway for the preparation of compounds <b>28</b> bearing a differently decorated catecholic moiety is summarized in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Enantiomerically pure alcohols (<i>S</i>)-<b>25a-b</b>, obtained as described in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>, were coupled with the suitable thiazolidine-carboxylic acid isomer in the presence of EDC and DMAP, and the subsequent Boc cleavage led to esters (<i>S</i>*,<i>S</i>**)-<b>27a</b>–<b>b</b>. Sulfonamides (<i>S</i>*,<i>S</i>**)-<b>28a</b>–<b>b</b> were finally achieved via sulfonylation as described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. A modified procedure was followed to obtain compound (<i>S</i>*,<i>S</i>**)-<b>28c</b>, which was achieved via acidic cleavage of the catecholic ether of thiazolidinyl ester (<i>S</i>*,<i>S</i>**)-<b>22e</b>, prepared as described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>.</div><figure id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Compounds <b>28</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (<i>S</i>)-3-(<i>tert</i>-butoxycarbonyl)thiazolidine-2-carboxylic acid, EDC, DMAP, DCM, rt; (b) HCl/AcOEt 4 M, rt; (c) Py, DCM, rt; (d) TFA, rt, overnight.</p></p></figure><div class="NLM_p">Sulfonamides <b>35</b>, <b>36</b>, and <b>37</b> were obtained by sulfonylation of the corresponding heterocycloalkylamino intermediates <b>32</b>, <b>33</b>, and <b>34</b> according to <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. Intermediates <b>32</b>, <b>33</b>, and <b>34</b> were prepared by coupling of (<i>S</i>)-<b>12</b> with suitable <i>N</i>-Boc heterocycloalkyl carboxylic acids followed by acidic deprotection. (<i>S</i>*,<i>S</i>**)-<b>36b</b> underwent further amidation with dimethylamine to afford (<i>S</i>*,<i>S</i>**)-<b>36c</b>.</div><figure id="sch5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0013.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Preparation of Compounds <b>35</b>, <b>36</b>, and <b>37</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (<i>R</i>)-3-(<i>tert</i>-butoxycarbonyl)thiazolidine-4-carboxylic acid or (<i>R</i>)-1-(<i>tert</i>-butoxycarbonyl)piperidine-3-carboxylic acid or (<i>S</i>)-1-(<i>tert</i>-butoxycarbonyl)piperidine-2-carboxylic acid, EDC, DMAP, DMF, rt; (b) HCl/dioxane 4 M, rt; (c) Py, rt; (d) dimethylamine 2 M in THF, CDI, DMF, rt.</p></p></figure></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01250" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01250" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> SAR Analysis</h3><div class="NLM_p">Our initial hypothesis, based on additional available space in the solvent-exposed region of the catalytic binding pocket of PDE4, was confirmed by the potency achieved by the first series of analogues. The phenyl ester (<i>S</i>)-<b>14d</b> and its thienyl (<i>S</i>)-<b>14b</b> and pyrrolyl (<i>S</i>)-<b>14c</b> bioisosteric analogues, carrying a phenyl-sulfonyl or a phenyl-carbonyl substituent in the position adjacent to the ester function, showed limited reduction of PDE4 inhibitory potency compared to unsubstituted derivative (<i>S</i>)-<b>14a</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structure and Inhibitory Activity in Cell-Free and Cell-Based Assays of Aryl Esters</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0014.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Data are the mean ± SD of three to four experiments performed in duplicate.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Data are presented as IC<sub>50</sub> values followed by their 95% confidence intervals obtained by nonlinear regression.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Compound (<i>S</i>)-<b>26a</b>; ref <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">23</a>.</p></div></div><div></div></div><div class="NLM_p">To verify if a subtle geometrical variation in the arrangement of the ester portion could improve the inhibitory potency, our exploration was then focused on the synthetically easily accessible saturated analogues of (<i>S</i>)-<b>14c</b>. Therefore, a series of pyrrolydinyl analogues was examined in which ring unsaturation led to a heterocycloalkanyl core containing an additional stereogenic center. Both diastereomers featuring the pyrrolydinyl moiety ((<i>R</i>*,<i>S</i>**)-<b>18c</b>, (<i>S</i>*,<i>S</i>**)-<b>18c</b>) were endowed with higher potency than their corresponding aromatic analogue (<i>S</i>)-<b>14c</b>, irrespective of their stereochemistry (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). We then considered mono or bis substitutions at the <i>para</i> and <i>meta</i> position of the aryl sulfonyl ring. Concurrently, we prepared both diastereomers of the <i>meta</i>-dimethylamido derivative to further study the impact of stereochemistry on potency: (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>R</i>*,<i>S</i>**)-<b>18e</b>. They exerted similar potency in the cell-free test, but the <i>R</i> configuration at the heterocycloalkyl ring caused a 10-fold drop in the cell-based activity. This finding prompted us to select the stereochemical configuration of (<i>S</i>*,<i>S</i>**)-<b>18e</b> as the one able to provide the best inhibition of LPS-induced TNF-α release in the <i>in vitro</i> model of PBMCs. Preparation of (<i>S</i>*,<i>S</i>**)-<b>18d</b> and (<i>S</i>*,<i>S</i>**)-<b>19</b> allowed us to infer that, in this series, the <i>m</i>-dimethylaminocarbonyl substituent, coupled with <i>S,S</i> stereochemistry, is able to enhance by 10-fold the potency in PBMCs. Replacement of the phenyl ring with a methyl group in (<i>S</i>*,<i>S</i>**)-<b>18a</b> was detrimental, whereas compound (<i>S</i>*,<i>S</i>**)-<b>18b</b> with a longer methoxyethyl substituent showed interesting PDE4 inhibitory activity.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structure and Inhibitory Activity in Cell-Free and Cell-Based Assays of Pyrrolidinyl Esters Featuring a Substituent on the Nitrogen Atom<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a>,<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0015.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Data are the mean ± SD of three to four experiments performed in duplicate.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Data are presented as IC<sub>50</sub> values followed by their 95% confidence intervals obtained by nonlinear regression.</p></div></div><div></div></div><div class="NLM_p">The potent inhibitor (<i>S</i>*,<i>S</i>**)-<b>18e</b> was crystallized in the PDE4B catalytic site. Its binding mode is similar to that of roflumilast in the PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMU">1XMU</a> crystal structure. Indeed, the catecholic oxygens form two hydrogen bonds with the side chain of Gln443 residue in the hydrophobic pocket of the binding site, while the pyridine <i>N</i>-oxide ring is located in the metal region and forms a hydrogen bond with the backbone NH group of Met347 residue. The phenylsulfonyl-proline fragment is positioned in the solvent-exposed region of the catalytic site and the carbonyl group of the dimethylaminocarbonyl substituent interacts with a water molecule, which is indirectly linked to the water molecules coordinated to the metals (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). The high PDE4 inhibitory potency of compound (<i>S</i>*,<i>S</i>**)-<b>18b</b> may be related to its ability to undertake a hydrogen bond with the same water molecule bound to the amide substituent of (<i>S</i>*,<i>S</i>**)-<b>18e</b> (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). The wide surface of the solvent exposed region accommodates structurally different fragments, which in most cases are able to maintain high binding energy values.</div><figure id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0005.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Crystal structure of compound (<i>S</i>*,<i>S</i>**)-<b>18e</b> bound to the PDE4B catalytic binding site. Hydrogen bonds are represented as yellow dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0006.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Overlay of the docking binding pose for compound (<i>S</i>*,<i>S</i>**)-<b>18b</b> (magenta color) on the structure of (<i>S</i>*,<i>S</i>**)-<b>18e</b> (orange color) bound in the PDE4B catalytic site. Hydrogen bonds are represented as yellow dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further investigate the class of saturated heterocycles, we explored the SAR of a set of bioisosteric compounds where we incorporated the thiazolidinyl core thus replacing the pyrrolydinyl one (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). An aliphatic sulfonyl substituent was well accepted in (<i>S</i>*,<i>S</i>**)-<b>22b</b>, increasing the PBMC potency of this compound by 10-fold with respect to its pyrrolydinyl analogues (<i>S</i>*,<i>S</i>**)-<b>18a</b> and (<i>S</i>*,<i>S</i>**)-<b>18b</b>, whereas the aliphatic carboxamide in (<i>S</i>*,<i>S</i>**)-<b>24a</b> caused a drop in activity in the cell-based assay. Successively an in-depth examination of the role of the <i>N</i>-aryl-sulfonyl ring decorations was carried out. The unsubstitued benzensulfonylamide derivative (<i>S</i>*,<i>S</i>**)-<b>22c</b> served as a baseline compound and showed limited potency. The dimethoxy (<i>S</i>*,<i>S</i>**)-<b>22d</b> proved to be very active and, with the introduction of the amido groups, the inhibitory potency was slightly further enhanced ((<i>S</i>*,<i>S</i>**)-<b>22m</b>, (<i>S</i>*,<i>S</i>**)-<b>22e</b>). Replacement of the <i>N</i>-sulfonylamido with an <i>N</i>-carboxamido substituent as in (<i>S</i>*,<i>S</i>**)-<b>24b</b> is detrimental for cell-based activity, as already proved by the aliphatic derivative (<i>S</i>*,<i>S</i>**)-<b>24a</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structure and Inhibitory Activity in Cell Free and Cell Based Assays of Thiazolidinyl Esters Featuring a Substituent on the Nitrogen Atom<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a>,<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0016.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Data are the mean ± SD of three to four experiments performed in duplicate.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Data are presented as IC<sub>50</sub> values followed by their 95% confidence intervals obtained by nonlinear regression. Nd: not determined.</p></div></div><div></div></div><div class="NLM_p">(<i>S</i>*,<i>S</i>**)-<b>22e</b> emerged as one of the most potent compounds in the thiazolidinyl series and was chosen as reference compound to investigate the impact of the alkylation of the catecholic hydroxyl group on the inhibitory activity, as shown in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. The contribution of cyclopropylmethyl group was clearly evident in (<i>S</i>*,<i>S</i>**)-<b>28c</b>, where <i>O</i>-dealkylation led to a 3-fold less potent derivative in the cell-free assay and 100-fold less potent in the cell-based assay, likely because of limited cell penetration. Conversely, the alkyl moiety replacement in (<i>S</i>*,<i>S</i>**)-<b>28a</b> and (<i>S</i>*,<i>S</i>**)-<b>28b</b>, where methyl and cyclopentyl were chosen by analogy with rolipram and cilomilast, respectively, restores the inhibitory activity to the nanomolar range.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Structure and Inhibitory Activity in Cell Free and Cell Based Assays of (<i>S</i>*,<i>S</i>**)-<b>22e</b> Analogues Featuring Different R at the Phenolic Oxygen<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a>,<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0017.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Data are the mean ± SD of three to four experiments performed in duplicate.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">Data are presented as IC<sub>50</sub> values followed by their 95% confidence intervals obtained by nonlinear regression.</p></div></div><div></div></div><div class="NLM_p">We subsequently examined the effect of the stereochemical configuration in thiazolidinyl derivatives against activity (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). With this aim the three diastereoisomers of (<i>S</i>*,<i>S</i>**)-<b>22e</b> were synthesized. (<i>R</i>*,<i>S</i>**)-<b>22e</b> maintained comparable affinity and biological activity to the ones exerted by its epimer (<i>S</i>*,<i>S</i>**)-<b>22e</b>. Conversely, stereocenter inversion of the alcoholic portion ((<i>R</i>*,<i>R</i>**)-<b>22e</b>, (<i>S</i>*,<i>R</i>**)-<b>22e</b>) caused a remarkable loss of potency: (<i>R</i>*,<i>R</i>**)-<b>22e</b> and (<i>S</i>*,<i>R</i>**)-<b>22e</b> showed 50- and 150-fold drop of activity compared to their respective enantiomers, thus meaning that there is a stereochemical preference for the interaction with PDE4, confirming previous findings,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> while the configuration of the asymmetric carbon center on the thiazolidinyl core is not relevant for the interaction with PDE4. Accordingly in the thiazolidinyl series, the <i>R</i> configuration at the thiazolidine carbon seems to affect less PBMC potency than in the pyrrolidinyl series.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Structure and Inhibitory Activity in Cell Free and Cell Based Assays of the Four Diastereomer of (<i>S</i>*,<i>S</i>**)-<b>22e</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a>,<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0018.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>Table a</sup><p class="last">Data are the mean ± SD of three to four experiments performed in duplicate.</p></div><div class="footnote" id="t5fn2"><sup>Table b</sup><p class="last">Data are presented as IC<sub>50</sub> values followed by their 95% confidence intervals obtained by nonlinear regression. Nd: not determined.</p></div></div><div></div></div><div class="NLM_p">In the thiazolidinyl series the replacement of the terminal phenyl ring with a set of heteroaryl bioisosteres was considered, as shown in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>. The introduction of pyridine in (<i>S</i>*,<i>S</i>**)-<b>22g</b> and five-membered heteroaryls in (<i>S</i>*,<i>S</i>**)-<b>22h</b> and (<i>S</i>*,<i>S</i>**)-<b>22i</b> led to compounds endowed with higher potency than the naked phenyl (<i>S</i>*,<i>S</i>**)-<b>22c</b>. In contrast to what was observed for the <i>N</i>-phenylsulfonyl series, no further contribution to the potency was achieved by heteroaryl ring decoration in (<i>S</i>*,<i>S</i>**)-<b>22i</b>. The decrease of potency for thienyl derivative (<i>S</i>*,<i>S</i>**)-<b>22l</b> observed in both assays may be related to the steric hindrance exerted by the methyl groups.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Structure and Inhibitory Activity in Cell Free and Cell Based Assays of Thiazolidinyl Esters Featuring a Heteroarylsulfonyl Group on the Nitrogen Atom<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a>,<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0019.gif" alt="" id="fx10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>Table a</sup><p class="last">Data are the mean ± SD of three to four experiments performed in duplicate.</p></div><div class="footnote" id="t6fn2"><sup>Table b</sup><p class="last">Data are presented as IC<sub>50</sub> values followed by their 95% confidence intervals obtained by nonlinear regression.</p></div></div><div></div></div><div class="NLM_p">Finally, as part of our core scaffold modifications, we extended our investigations to additional saturated cyclic systems, which deserved a more extensive SAR analysis. We therefore performed a heterocycloalkyl swap introducing a small subset of 5- and 6-atoms cyclic bioisosteres while maintaining an almost unmodified <i>N</i>-arylsulfonyl group (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). No substantial changes in terms of potency were observed for the thioprolinyl analogue in (<i>R</i>*,<i>S</i>**)-<b>35</b> and piperidines (<i>S</i>*,<i>S</i>**)-<b>36a</b> and (<i>S</i>*,<i>S</i>**)-<b>36c</b>, suggesting that neither the absence nor the position of the sulfur atom seems to affect their biological activity. Preparation of (<i>S</i>*,<i>S</i>**)-<b>36d</b> confirmed that the contribution of the amide decoration on the phenyl ring is fundamental to achieve the wanted potency range, especially in the cellular system. Comparable activity to 2-substitued analogues is displayed by compounds (<i>R</i>*,<i>S</i>**)-<b>37</b> where the nitrogen was moved from position 2 to 3.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Structure and Inhibitory Activity in Cell Free and Cell Based Assays of Heterocycloalkyl Esters Featuring an Arylsulfonyl Substituent on the Nitrogen Atom<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a>,<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0020.gif" alt="" id="fx12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>Table a</sup><p class="last">Data are the mean ± SD of three to four experiments performed in duplicate.</p></div><div class="footnote" id="t7fn2"><sup>Table b</sup><p class="last">Data are presented as IC<sub>50</sub> values followed by their 95% confidence intervals obtained by nonlinear regression.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> <i>In Vitro</i> ADME Characterization</h3><div class="NLM_p">Through a funnel-like process, a subset of 10 compounds displaying excellent inhibitory activity on PDE4 and in the PBMC assay was chosen for further characterization, and their <i>in vitro</i> ADME profiles are captured in <a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>. The selection was based on the criteria that both IC<sub>50</sub> values on the free enzyme and in cell-based test should be less than or equal to 0.05 nM. Almost all compounds met the desired criteria to be progressed further as candidates for inhaled administration, showing (i) adequate metabolic stability in human lung S9 preparation, (ii) low <i>in vitro</i> permeability in the Caco2 assay, except for the piperidinyl derivatives (<i>S</i>*,<i>S</i>**)-<b>36a</b> and (<i>S</i>*,<i>S</i>**)-<b>36c</b> that were susceptible to high efflux, and (iii) human plasma protein binding values higher than 99%, excluding (<i>S</i>*,<i>S</i>**)-<b>22h</b>. The aforementioned ADME profile strongly reduces the likelihood that the free fraction in the systemic circulation, absorbed through the lung compartment or by the GI tract as a consequence of the swallowed fraction, could have an impact on arising unwanted side effects. Additionally, the selected compounds were stable in human plasma and showed favorable intrinsic clearance (CL<sub>int</sub>) values, allowing us to infer that such metabolic liability is likely to translate into the desired sustained hepatic turnover, thus furnishing the sought-after prerogatives for a minimized systemic exposure. A comparison between <i>in vitro</i> clearance data for the heterocycloalkyl series herein described and the benzoic ester series, whose values of clearance in hepatic microsomes for three representative compounds (<i>S</i>)-<b>32k</b>, (<i>S</i>)-<b>26p</b>, and (<i>S</i>)-<b>38e</b><a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> are listed in <a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>, clearly highlighted that we were able to reach the goal of obtaining effectively turned over compounds while maintaining potency.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. ADME Profile of Selected Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">CACO-2 permeability</th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">clearance</th><th class="rowsep1 colsep0" colspan="2" align="center">60 min remain. (%)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">AB (nm/s)</th><th class="colsep0 rowsep0" align="center">BA (nm/s)</th><th class="colsep0 rowsep0" align="center">Caco-2 perm. level<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">hPPB<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a> bound (%)</th><th class="colsep0 rowsep0" align="center">hepatic microsomes<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a> (μL/min/mg)</th><th class="colsep0 rowsep0" align="center">hepatocytes<a class="ref internalNav" href="#t8fn4" aria-label="d">d</a> (μL/min/10<sup>6</sup> cell)</th><th class="colsep0 rowsep0" align="center">hLung S9 stability</th><th class="colsep0 rowsep0" align="center">hPlasma stability</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>*,<i>S</i>**)-<b>18e</b></td><td class="colsep0 rowsep0" align="left">4.8</td><td class="colsep0 rowsep0" align="left">101.8</td><td class="colsep0 rowsep0" align="left">low</td><td class="colsep0 rowsep0" align="left">99.65</td><td class="colsep0 rowsep0" align="left">590.56</td><td class="colsep0 rowsep0" align="left">95.50</td><td class="colsep0 rowsep0" align="left">71.1</td><td class="colsep0 rowsep0" align="left">108.40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>*,<i>S</i>**)-<b>19</b></td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">124.9</td><td class="colsep0 rowsep0" align="left">low</td><td class="colsep0 rowsep0" align="left">99.68</td><td class="colsep0 rowsep0" align="left">365.35</td><td class="colsep0 rowsep0" align="left">56.67</td><td class="colsep0 rowsep0" align="left">71.6</td><td class="colsep0 rowsep0" align="left">101.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>*,<i>S</i>**)-<b>22m</b></td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">76.7</td><td class="colsep0 rowsep0" align="left">low</td><td class="colsep0 rowsep0" align="left">99.83</td><td class="colsep0 rowsep0" align="left">360.36</td><td class="colsep0 rowsep0" align="left">47.56</td><td class="colsep0 rowsep0" align="left">71.2</td><td class="colsep0 rowsep0" align="left">98.78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>*,<i>S</i>**)-<b>22e</b></td><td class="colsep0 rowsep0" align="left">4.2</td><td class="colsep0 rowsep0" align="left">31.8</td><td class="colsep0 rowsep0" align="left">low</td><td class="colsep0 rowsep0" align="left">99.79</td><td class="colsep0 rowsep0" align="left">287.41</td><td class="colsep0 rowsep0" align="left">82.45</td><td class="colsep0 rowsep0" align="left">70.2</td><td class="colsep0 rowsep0" align="left">97.96</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>*,<i>S</i>**)-<b>22d</b></td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">8.2</td><td class="colsep0 rowsep0" align="left">low</td><td class="colsep0 rowsep0" align="left">99.60</td><td class="colsep0 rowsep0" align="left">200.19</td><td class="colsep0 rowsep0" align="left">53.76</td><td class="colsep0 rowsep0" align="left">50.7</td><td class="colsep0 rowsep0" align="left">100.60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>*,<i>S</i>**)-<b>22i</b></td><td class="colsep0 rowsep0" align="left">12.6</td><td class="colsep0 rowsep0" align="left">182.7</td><td class="colsep0 rowsep0" align="left">low/medium</td><td class="colsep0 rowsep0" align="left">99.84</td><td class="colsep0 rowsep0" align="left">202.10</td><td class="colsep0 rowsep0" align="left">47.62</td><td class="colsep0 rowsep0" align="left">63.5</td><td class="colsep0 rowsep0" align="left">100.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>*,<i>S</i>**)-<b>22h</b></td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">39.5</td><td class="colsep0 rowsep0" align="left">low</td><td class="colsep0 rowsep0" align="left">98.50</td><td class="colsep0 rowsep0" align="left">281.17</td><td class="colsep0 rowsep0" align="left">66.86</td><td class="colsep0 rowsep0" align="left">77.7</td><td class="colsep0 rowsep0" align="left">101.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>R</i>*,<i>S</i>**)-<b>35</b></td><td class="colsep0 rowsep0" align="left">28.0</td><td class="colsep0 rowsep0" align="left">44.6</td><td class="colsep0 rowsep0" align="left">medium</td><td class="colsep0 rowsep0" align="left">99.83</td><td class="colsep0 rowsep0" align="left">267.87</td><td class="colsep0 rowsep0" align="left">25.91</td><td class="colsep0 rowsep0" align="left">52.1</td><td class="colsep0 rowsep0" align="left">93.99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>*,<i>S</i>**)-<b>36a</b></td><td class="colsep0 rowsep0" align="left">217.4</td><td class="colsep0 rowsep0" align="left">734</td><td class="colsep0 rowsep0" align="left">high</td><td class="colsep0 rowsep0" align="left">99.88</td><td class="colsep0 rowsep0" align="left">362.74</td><td class="colsep0 rowsep0" align="left">64.57</td><td class="colsep0 rowsep0" align="left">72.5</td><td class="colsep0 rowsep0" align="left">104.50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>*,<i>S</i>**)-<b>36c</b></td><td class="colsep0 rowsep0" align="left">131.8</td><td class="colsep0 rowsep0" align="left">684.3</td><td class="colsep0 rowsep0" align="left">high</td><td class="colsep0 rowsep0" align="left">99.77</td><td class="colsep0 rowsep0" align="left">243.50</td><td class="colsep0 rowsep0" align="left">33.16</td><td class="colsep0 rowsep0" align="left">59.7</td><td class="colsep0 rowsep0" align="left">88.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<b>32k</b><a class="ref internalNav" href="#t8fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">35.22</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<b>26p</b><a class="ref internalNav" href="#t8fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">50.94</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<b>38e</b><a class="ref internalNav" href="#t8fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">71.24</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td><td class="colsep0 rowsep0" align="left">nd</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">General absorption classification for permeability values: <10 nm/s, low level; 10–50 nm/s, medium level; >50 nm/s, high level.</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">hPPB = human plasma protein binding.</p></div><div class="footnote" id="t8fn3"><sup>c</sup><p class="last">Compounds were incubated with human liver microsomes at 1 μM for 60 min.</p></div><div class="footnote" id="t8fn4"><sup>d</sup><p class="last">Compounds were incubated with human hepatocytes at 1 μM for 90 min.</p></div><div class="footnote" id="t8fn5"><sup>e</sup><p class="last">Ref <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">23</a>. Nd = not determined.</p></div></div></div><div class="NLM_p">Since physicochemical properties are critical for an inhalation drug, the choice to progress compounds (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b> to further <i>in vivo</i> investigations relied on their ability to better perform in solid-state studies. In particular, highly crystalline, anhydrous, not hygroscopic forms were identified for both (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b> by means of proper crystallization screening and experiments (data not shown). Both compounds were successfully micronized by jet mill with acceptable yields, good physicochemical integrity, and allowing to obtain a particle size suitable for inhalation. They were then blended with lactose at strengths suitable for animal administration.</div><div id="sec2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>In Vitro</i> and <i>in Vivo</i> Characterization of Compounds (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b></h4><div class="NLM_p">(<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b>, administered as dry-powder formulation 2 h before the aerosolized ovalbumin (OVA) challenge, were screened in a dose–response study in Brown Norway rat OVA-induced airway inflammation model via intratracheal (IT) dosing (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). Both compounds displayed a dose-dependent pattern and markedly inhibited inflammatory cells infiltration in the bronchoalveolar lavage (BAL), exerting a 50% inhibition of eosinophils recruitment at 0.1 μmol/kg, while at 1 μmol/kg (<i>S</i>*,<i>S</i>**)-<b>22e</b> produced a higher efficacy in reducing cell infiltration than (<i>S</i>*,<i>S</i>**)-<b>18e</b>. Estimated values of ED<sub>50</sub> of 0.10 and 0.04 μmol/kg for (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b>, respectively, were calculated from the dose–response curves of inhibition of eosinophils recruitment.</div><figure id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0007.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Dose-dependent inhibition of OVA-induced recruitment of eosinophils in BALF (broncho alveolar lavage fluid) of rats treated with compound (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b>. The reference anti-inflammatory compound budesonide is reported for comparison.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The <i>in vitro</i> metabolite profiles of (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b> were studied using human hepatocytes, and the main metabolites detected are depicted in <a class="ref internalNav" href="#tbl9" aria-label="Table 9">Table 9</a>. For (<i>S</i>*,<i>S</i>**)-<b>18e</b>, two metabolites were identified in a percentage higher than 10% (<b>38</b> and <b>39</b>) and assessed in the PBMCs assay, exhibiting a 50000-fold and a 300-fold lower potency than the parent molecule, respectively. Considering that alcohol <b>38</b> stems from parent compound ester hydrolysis, the carboxylic acid fragment <b>40</b>, whose presence in vivo in an amount comparable to the alcoholic fragment can be arguably assumed, was prepared and tested as well, proving to be inactive with an IC<sub>50</sub> lower than 1 μM. Comparably to (<i>S</i>*,<i>S</i>**)-<b>22e</b>, compound (<i>S</i>*,<i>S</i>**)-<b>18e</b> generates a substantial amount of alcohol <b>38</b>. Its corresponding acid <b>41</b> showed to be unable to inhibit TNF-α release in our cellular model (IC<sub>50</sub> > 1 μM).</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Structure and Inhibitory Activity in Cell-Based Assay of Metabolites Obtained after 60 min Incubation of (<i>S</i>*,<i>S</i>**)-<b>22e</b> (Compounds <b>38–40</b>) and (<i>S</i>*,<i>S</i>**)-<b>18e</b> (Compounds <b>32</b> and <b>35</b>) with Human Hepatocytes at a Concentration of 10 μM</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0021.gif" alt="" id="fx14" /></img><div></div></div><div class="NLM_p">(<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b> exhibited ideal in vivo pharmacokinetic profiles for an inhaled agent. Lung levels, plasma levels, and pharmacokinetic parameters following IT treatment with (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b> in Sprague–Dawley rats are shown in <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>, <a class="ref internalNav" href="#tbl10" aria-label="Table 10">Table 10</a>, and <a class="ref internalNav" href="#tbl11" aria-label="Table 11">Table 11</a>. (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b> showed a lung half-life of around 5 h, which is in line with the corresponding mean residence time (MRT) (<a class="ref internalNav" href="#tbl10" aria-label="Table 10">Table 10</a>). Both compounds displayed prolonged lung retention (0.128 and 0.220 nmol/g concentration at 24 h, for (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b>, respectively), indicating that both molecules could deliver a long-lasting protective effect. Additionally, being optimized for inhalation, a key pharmacokinetic measure of success was having a high exposure ratio, at the same <i>T</i><sub>last</sub>, between lung and plasma. In fact, the exposures calculated until 8 h clearly indicated that (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b> were mainly distributed in lung compared to plasma (2261- and 5152-fold ratio for (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b>, respectively) (<a class="ref internalNav" href="#tbl10" aria-label="Tables 10">Tables 10</a> and <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a>).</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Pharmacokinetic Parameters of (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b> Determined from Lung Tissues Following IT Administration as Dry Powder in Rats at <b>1</b> μmol/kg</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">(<i>S</i>*,<i>S</i>**)-<b>22e</b></th><th class="colsep0 rowsep0" align="center">(<i>S</i>*,<i>S</i>**)-<b>18e</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (nmol/g)</td><td class="colsep0 rowsep0" align="left">16.06</td><td class="colsep0 rowsep0" align="left">16.24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.250</td><td class="colsep0 rowsep0" align="left">0.083</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>last</sub> (h)</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">4.39</td><td class="colsep0 rowsep0" align="left">5.18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>last</sub> (h·nmol/g)</td><td class="colsep0 rowsep0" align="left">65.27</td><td class="colsep0 rowsep0" align="left">49.65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT<sub>last</sub> (h)</td><td class="colsep0 rowsep0" align="left">5.56</td><td class="colsep0 rowsep0" align="left">4.52</td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. Pharmacokinetic Parameters of (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b> Determined from Plasma Following IT Administration as Dry Powder in Rats at <b>1</b> μmol/kg</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">(<i>S</i>*,<i>S</i>**)-<b>22e</b></th><th class="colsep0 rowsep0" align="center">(<i>S</i>*,<i>S</i>**)-<b>18e</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (pmol/g)</td><td class="colsep0 rowsep0" align="left">9.80</td><td class="colsep0 rowsep0" align="left">20.65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.083</td><td class="colsep0 rowsep0" align="left">0.083</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>last</sub> (h)</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">nc</td><td class="colsep0 rowsep0" align="left">nc</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>last</sub> (h·pmol/g)</td><td class="colsep0 rowsep0" align="left">10.38</td><td class="colsep0 rowsep0" align="left">33.27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT<sub>last</sub> (h)</td><td class="colsep0 rowsep0" align="left">1.33</td><td class="colsep0 rowsep0" align="left">1.08</td></tr></tbody></table></div></div><figure id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0008.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Lung levels (nmol/g) and plasma levels (pmol/mL) of (<i>S</i>*,<i>S</i>**)-<b>22e</b> (left) and (<i>S</i>*,<i>S</i>**)-<b>18e</b> (right) after IT administration as dry powder in Sprague–Dawley rats at 1 μmol/kg.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">(<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b> were subsequently evaluated in safety assessment studies. There was no evidence of inhibition of hERG potassium channels current at a concentration of 1 μM (data not shown). Both (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b> proved to be highly selective inhibitors for PDE4 (>10,000 versus PDE1, 3, 5, 7, 8, 10 and >100,000 vs PDE2, 6, 9, 11) (<a class="ref internalNav" href="#tbl12" aria-label="Table 12">Table 12</a>). The propensity of (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b> to bind biological target proteins unrelated to PDE family enzymes was evaluated by interrogating a panel of 400 key receptor, enzyme, and ion channel proteins at 1 μM concentration (Eurofins selectivity panels). The panel identified only three hits showing >50% binding at the concentration of 1 μM for (<i>S</i>*,<i>S</i>**)-<b>18e</b> (rat Acyl CoA-Cholesterol Acyltransferase (50%), human CYP3A4 (73%), and human monoamine oxidase A (76%)), and five hits showing >50% binding at the concentration of 1 μM for (<i>S</i>*,<i>S</i>**)-<b>22e</b> (human CYP2C19 (69%), human CYP3A4 (84%), human monoamine oxidase A (94%), and human UDP glucuronyltransferase 1A1 and rat imidazoline I2 receptor (60%)).</div><div class="NLM_table-wrap" id="tbl12"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 12. Isoform Selectivity Profile (in μM) of (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center">(<i>S</i>*,<i>S</i>**)-<b>18e</b><a class="ref internalNav" href="#t12fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">(<i>S</i>*,<i>S</i>**)-<b>22e</b><a class="ref internalNav" href="#t12fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hPDE1A</td><td class="colsep0 rowsep0" align="left">25.6</td><td class="colsep0 rowsep0" align="left">7.40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hPDE2A</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="left">>30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hPDE3A</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="left">6.21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hPDE4B</td><td class="colsep0 rowsep0" align="left">8.81 × 10<sup>–5</sup></td><td class="colsep0 rowsep0" align="left">2.78 × 10<sup>–5</sup></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hPDE5A</td><td class="colsep0 rowsep0" align="left">13.9</td><td class="colsep0 rowsep0" align="left">4.61</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Bov PDE6</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="left">5.78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hPDE7A</td><td class="colsep0 rowsep0" align="left">3.46</td><td class="colsep0 rowsep0" align="left">0.66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hPDE8A1</td><td class="colsep0 rowsep0" align="left">17.0</td><td class="colsep0 rowsep0" align="left">3.56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hPDE9A2</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="left">>30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hPDE10A2</td><td class="colsep0 rowsep0" align="left">4.03</td><td class="colsep0 rowsep0" align="left">0.81</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hPDE11A4</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="left">>30</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t12fn1"><div class="footnote" id="t12fn1"><sup>a</sup><p class="last">Data are given as mean IC<sub>50</sub> values (μmol/L) calculated from concentration–inhibition curves by nonlinear regression analysis from two independent experiments.</p></div></div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38143" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38143" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Following a structure-based design we identified a novel class of PDE4 inhibitors endowed with potent anti-inflammatory properties and suitable for topical pulmonary administration. Starting from a previously described series of benzoic esters, we explored the chemical space in the solvent-exposed region of the PDE4 catalytic pocket, focusing our efforts on new structural classes of <i>ortho</i>-substituted compounds. Our SAR efforts led to the discovery of pyrrolidinyl and thiazolidinyl esters as potent <i>in vitro</i> PDE4 inhibitors. The optimal <i>in vitro</i> ADME profiles (high plasma protein binding, high CL<sub>int</sub>, low Caco2 permeability level, high lung S9 stability) together with their ability to better perform in solid-state studies (highly crystalline, anhydrous, not hygroscopic) led to the selection of compounds (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b> for progression to in vivo preclinical studies. Both compounds effectively counteracted OVA-induced airway inflammation in rat upon IT administration as dry powders displaying a lung pharmacokinetic profile consistent with a long-lasting effect. For both compounds, the risk of potential systemic side-effects is minimized by the extensive liver metabolism to inactive metabolites, by their low plasmatic levels when administered intratracheally, and by the excellent selectivity profile when counterscreened toward more than 400 off-targets, including other human PDE isoforms. (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22</b> were therefore identified as compounds from these series having the potential to provide clinical benefits in conditions associated with pulmonary inflammation, including asthma and COPD.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45485" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45485" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Chemistry</h3><div class="NLM_p"><sup>1</sup>H NMR spectra were recorded on a Bruker ARX 300 (300 MHz) spectrometer or on a Varian AS400 (400 MHz) spectrometer, equipped with a self-shielded z-gradient coil 5 mm <sup>1</sup>H/<sup><i>n</i></sup>X broad band probehead for reverse detection, deuterium digital lock channel unit, and quadrature digital detection unit with transmitter offset frequency shift. Chemical shifts are reported as δ downfield in parts per million (ppm) and referenced to tetramethylsilane (TMS) as the internal standard in the <sup>1</sup>H measurements. Coupling constants (<i>J</i> values) are given in hertz (Hz) and multiplicities are reported using the following abbreviation (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, nd = not determined). The pulse programs were taken from the Varian and Bruker software libraries.</div><div class="NLM_p">UV purity and <i>m</i>/<i>z</i> of compounds were assessed by ESI+ LC–MS analysis, performed on an Alliance Waters HPLC Kinetex 2.6u C18 100A 100 × 4.6 mm column with Waters Quattro Micro API equipped with a UV detector set at 245 and 254 nm (Method A), on an Acquity Waters UPLC Kinetex 1.7u XB-C18 100A 100 × 2.1 mm (Phenomenex) column with Waters ZQ equipped with a UV detector set at 254 nm (Method B), on an Acquity Waters UPLC BEH C18 1.7 μm 50 × 2.1 mm column with Waters ZQ interfaced with 2996 PDA detector (Method C), or on an Acquity UPLC Kinetex C18 1.7 um 50 × 2.1 mm (Phenomenex) column with ZQ interfaced with 2996 PDA detector (Method D). All the compounds tested in biological assays have purity >95%.</div><div class="NLM_p">Specific rotation of compounds was measured with a Polarimeter PerkinElmer (model 241 or 341) at sodium D-line (589 nm), 25 °C, 1 dm path length.</div><div class="NLM_p">Diastereoisomeric ratio by LC/UV/MS, when indicated, is estimated to be affected by an experimental error of ±1%. Alternatively, diastereoisomeric ratio is determined by <sup>1</sup>H NMR, and it is estimated to be >95:5 when a single diastereoisomer was detected using NMR analysis.</div><div class="NLM_p">Preparative HPLC purifications were performed using the following methods:</div><div class="NLM_p">Method 1: Waters Corporation purification system equipped with a XTerra Prep MS C18 Column (5 μm, 19 × 150 mm, Waters), 11 min gradient of 0–100% solvent B, where solvent A is water/MeCN/HCOOH 95:5:0.05, and solvent B is water/MeCN/HCOOH 5:95:0.05.</div><div class="NLM_p">Method 2: Waters Corporation purification system equipped with a Waters Symmetry Prep C18 17um 19 × 300, 30 min gradient of 5–100% solvent B, where solvent A is 90% H<sub>2</sub>O, 10% acetonitrile, 0.05% TFA, and solvent B is 10% H<sub>2</sub>O, 90% acetonitrile, 0.05% TFA.</div><div class="NLM_p last">Reactions were monitored by TLC using 0.25 mm Merck silica gel plates (60 F254) or LC–MS analysis; column chromatography was performed on Merck silica gel 60 (0.063–0.2 mm). Anhydrous solvents were purchased from Aldrich and used as received. “Brine” refers to a saturated aqueous solution of NaCl. Unless otherwise specified, solutions of common inorganic salts used in workups are aqueous solutions.</div></div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (<i>S</i>)-4-(2-(3-Benzoylthiophene-2-carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-Oxide (<i>S</i>)-<b>14b</b></h3><div class="NLM_p last">(<i>S</i>)-3,5-Dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-hydroxyethyl)pyridine-1-oxide (<i>S</i>)-<b>12</b> (100 mg, 0.24 mmol), 5-benzoylthiophene-2-carboxylic acid (<b>13b</b>, 111 mg, 0.48 mmol), EDC (137 mg, 0.71 mmol), and DMAP (35 mg, 0.29 mmol) were dissolved in DMF (1.5 mL) at rt for 5 h; the reaction was quenched with H<sub>2</sub>O, the precipitate was filtered, washed with H<sub>2</sub>O, dissolved in ethyl acetate and washed with HCl 1 N, Na<sub>2</sub>CO<sub>3</sub> saturated solution, and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated under vacuum. The crude was purified by preparative HPLC (Method 1) conditions to give 80 mg of a beige solid (0.126 mmol, yield 53%). <i>m</i>/<i>z</i> 634.5 [MH]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.51 (s, 2 H), 8.12 (d, <i>J</i> = 4.9 Hz, 1 H), 7.64–7.61 (m, 3 H), 7.45–7.57 (m, 2 H), 7.33 (d, <i>J</i> = 1.0 Hz, 1 H), 7.08–7.14 (m, 1 H), 7.05 (t, <i>J</i> = 75.0 Hz, 1 H), 6.93–7.00 (m, 1 H), 6.74–6.81 (m, 1 H), 5.91–6.03 (m, 1 H), 3.86 (d, <i>J</i> = 7.1 Hz, 2 H), 3.26–3.31 (m, 1 H), 3.01–3.13 (m, 1 H), 1.14–1.29 (m, 1 H), 0.49–0.64 (m, 2 H), 0.24–0.41 (m, 2 H).</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (<i>S</i>)-3,5-Dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(1-(phenylsulfonyl)-1<i>H</i>-pyrrole-2-carbonyloxy)ethyl)pyridine 1-Oxide (<i>S</i>)-<b>14c</b></h3><div class="NLM_p last">A mixture of crude 1-(phenylsulfonyl)-1<i>H</i>-pyrrole-2-carboxylic acid (<b>13c</b>, 234 mg, purity 30%, approximately 0.28 mmol, obtained as described in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>), (<i>S</i>)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-hydroxyethyl)pyridine 1-oxide (<i>S</i>)-<b>12</b> (117 mg, 0.279 mmol), EDC (161 mg, 0.838 mmol), and DMAP (34.1 mg, 0.279 mmol) in DCM (15 mL) was stirred at rt for 5 h. The mixture was diluted with DCM and washed with 0.5 N HCl, sat. Na<sub>2</sub>CO<sub>3</sub>, and finally with brine; the organic phase was dried over sodium sulfate and the solvent removed under vacuum. The crude was purified by preparative HPLC (Method 2) to afford 45 mg of (<i>S</i>)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(1-(phenylsulfonyl)-1<i>H</i>-pyrrole-2-carbonyloxy)ethyl)pyridine 1-oxide (0.069 mmol, 25% yield). <i>m</i>/<i>z</i> 653.07 [MH]<sup>+</sup>, [α<sub>D</sub>] = −25.83 (c 0.6, DCM). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.47 (s, 2 H), 7.87 (dd, 1 H), 7.78–7.85 (m, 2 H), 7.68–7.78 (m, 1 H), 7.51–7.64 (m, 2 H), 7.28 (dd, 1 H), 7.16 (d, 1 H), 7.11 (d, 1 H), 6.98 (dd, 1 H), 7.06 (t, 1 H), 6.52 (t, 1 H), 6.01 (dd, 1 H), 3.89 (d, 2 H), 3.44 (dd, 1 H), 3.22 (dd, 1 H), 1.09–1.30 (m, 1 H), 0.47–0.63 (m, 2 H), 0.26–0.41 (m, 2 H).</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (<i>S</i>)-3,5-Dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(2-(phenylsulfonyl)benzoyloxy)ethyl)pyridine 1-Oxide (<i>S</i>)-<b>14d</b></h3><div class="NLM_p last">(<i>S</i>)-3,5-Dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-hydroxyethyl)pyridine 1-oxide (<i>S</i>)-<b>12</b> (456 mg, 1.086 mmol), 2-(phenylthio)benzoic acid (<b>13d</b>, 300 mg, 1.303 mmol, obtained as described in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>), EDC (312 mg, 1.628 mmol), and DMAP (265 mg, 2.171 mmol) were dissolved in dry DCM (12 mL), and the mixture was stirred at rt overnight. Thus, the mixture was treated with HCl 1 M (30 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (2× 100 mL). The organic phase was washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed under reduced pressure to give a crude residue (500 mg) that was purified by flash chromatography on silica gel eluting with DCM/MeOH from 100% DCM to 97/3 DCM/MeOH, obtaining (<i>S</i>)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(2-(phenylthio)benzoyloxy)ethyl)pyridine 1-oxide (380 mg, 0.601 mmol, 55.3% yield) as a white solid. <i>m</i>/<i>z</i> 632.02 [MH]<sup>+</sup>. (<i>S</i>)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(2-(phenylthio)benzoyloxy)ethyl)pyridine 1-oxide (340 mg, 0.538 mmol) was dissolved in dry DCM (8 mL). The solution was cooled at 0 °C, <i>m</i>CPBA (301 mg, 1.344 mmol) was added, and the mixture was kept at rt for 2 days. The mixture was washed several times with sat. NaHCO<sub>3</sub>, the organic phase was dried over sodium sulfate, and the solvent was removed to afford 326 mg of crude. This crude was purified by flash chromatography on silica gel eluting with DCM/MeOH 97/3 to afford 220 mg of the final compound (<i>S</i>)-<b>14d</b> (0.33 mmol, 62% yield). <i>m</i>/<i>z</i> 664.02 [MH]<sup>+</sup>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.54 (s, 2 H), 8.05–8.15 (m, 1 H), 7.73–7.89 (m, 4 H), 7.62–7.72 (m, 1 H), 7.49–7.62 (m, 3 H), 7.21 (d, 1 H), 7.19 (d, 1 H), 7.06 (dd, 1 H), 7.09 (t, 1 H), 6.22 (dd, 1 H), 3.92 (d, 2 H), 3.62 (dd, 1 H), 3.32 (dd, 1 H), 1.09–1.29 (m, 1 H), 0.48–0.64 (m, 2 H), 0.28–0.42 (m, 2 H).</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Procedure for the Preparation of Sulfonamides <b>18</b></h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((<i>S</i>)-1-(methylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>18a</b></h4><div class="NLM_p">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((<i>S</i>)-pyrrolidine-2-carbonyloxy)ethyl)-pyridine 1-oxide (<i>S</i>*,<i>S</i>**)-<b>16</b> (50 mg, 0.1 mmol) was dissolved in pyridine (0.5 mL) and DCM (2 mL); methanesulfonyl chloride <b>17a</b> (0.5 mL, 6.5 mmol) was added, and the reaction was stirred at rt for 2 h to achieve completion. The reaction mixture was diluted with aqueous HCl 1 N and extracted with ethyl acetate. The organic phase dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum to give 20 mg of (<i>S</i>*,<i>S</i>**)-<b>18a</b> as a white solid (0.03 mmol, 30% yield). <i>m</i>/<i>z</i> 596.44 [MH]<sup>+</sup>, <i>t</i><sub>R</sub> = 5.68, diastereomeric ratio = 85:15 (method A); <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ ppm 8.26 (s, 2 H), 7.14–7.28 (m, 2 H), 7.01–7.09 (m, 1 H), 6.92 (t, <i>J</i> = 75.0 Hz, 1 H), 6.13 (dd, <i>J</i> = 9.48, 4.63 Hz, 1 H), 4.38 (dd, <i>J</i> = 8.60, 3.75 Hz, 1 H), 3.99 (d, <i>J</i> = 6.62 Hz, 3 H), 3.45 (t, <i>J</i> = 6.39 Hz, 3 H), 3.29–3.38 (m, 1 H), 2.88 (s, 3 H), 2.27–2.41 (m, 1 H), 1.76–2.00 (m, 3 H), 1.29 (d, <i>J</i> = 6.62 Hz, 1 H), 0.61 (d, <i>J</i> = 6.62 Hz, 2 H), 0.39 (d, <i>J</i> = 3.97 Hz, 2 H).</div><div class="NLM_p last">Sulfonamides <b>18b</b>–<b>f</b> were prepared following the same procedure starting from the corresponding enantiomerically pure pyrrolidine <b>16</b> and sulfonyl chloride <b>17</b>.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((<i>S</i>)-1-(2-methoxyethylsulfonyl)pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>18b</b></h4><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((<i>S</i>)-pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (<i>S</i>*,<i>S</i>**)-<b>16</b> (200 mg, 0.361 mmol), pyridine (5 mL), 2-methoxyethanesulfonyl chloride <b>17b</b> (86 mg, 0.542 mmol), rt for 3 h, purification by preparative HPLC (Method 1), 37 mg of a pale yellow solid (0.06 mmol, 17% yield). <i>m</i>/<i>z</i> 639.14 [MH]<sup>+</sup>, <i>t</i><sub>R</sub> = 3.67 min, diastereomeric ratio ≥ 99:1 (method C); [α<sub>D</sub>] = −23.88 (c 0.5; DCM). <sup>1</sup>H NMR (300 MHz, acetone-<i>d</i><sub>6</sub>) δ ppm 8.54 (s, 2 H), 7.18 (d, 1 H), 7.12 (d, 1 H), 6.97 (dd, 1 H), 7.07 (t, 1 H), 5.99 (dd, 1 H), 4.30 (dd, 1 H), 3.92 (d, 2 H), 3.58–3.68 (m, 2 H), 3.31–3.50 (m, 5 H), 3.29 (s, 3 H), 3.24 (dd, 1 H), 2.07–2.25 (m, 1 H), 1.59–2.01 (m, 3 H), 1.05–1.36 (m, 1 H), 0.46–0.69 (m, 2 H), 0.21–0.46 (m, 2 H).</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-1-(phenylsulfonyl)pyrrolidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>18c</b></h4><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((<i>S</i>)-pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (<i>S</i>*,<i>S</i>**)-<b>16</b> (50 mg, 0.1 mmol), benzenesulfonyl chloride <b>17c</b> (28 mg, 0.16 mmol), pyridine (2 mL), rt for 4 h, 40 mg of the desired product (0.06 mmol, 63% yield). <i>m</i>/<i>z</i> 657.3 [MH]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.09 min, diastereomeric ratio = 2:98 (method B); <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ ppm 8.61 (s, 2 H), 7.69–7.82 (m, 3 H), 7.60–7.68 (m, 2 H), 7.19 (d, <i>J</i> = 7.9 Hz, 1 H), 7.14 (d, <i>J</i> = 1.8 Hz, 1 H), 7.08 (t, <i>J</i> = 75.0 Hz, 1 H), 6.98 (dd, <i>J</i> = 8.4, 1.8 Hz, 1 H), 6.02 (dd, <i>J</i> = 9.7, 4.4 Hz, 1 H), 4.13 (dd, <i>J</i> = 8.6, 4.2 Hz, 1 H), 3.92 (d, <i>J</i> = 6.6 Hz, 2 H), 3.47 (dd, <i>J</i> = 14.1, 9.7 Hz, 1 H), 3.33–3.41 (m, 1 H), 3.26 (dd, <i>J</i> = 14.1, 4.4 Hz, 1 H), 3.16 (ddd, <i>J</i> = 9.8, 6.8, 6.7 Hz, 1 H), 1.83–1.98 (m, 1 H), 1.58–1.74 (m, 2 H), 1.41–1.57 (m, 1 H), 1.14–1.27 (m, 1 H), 0.48–0.63 (m, 2 H), 0.26–0.40 (m, 2 H).</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>R</i>)-1-(phenylsulfonyl)pyrrolidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>R</i>*,<i>S</i>**)-<b>18c</b></h4><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>R</i>)-pyrrolidine-2-carbonyl)oxy)ethyl)pyridine 1-oxide (<i>R</i>*,<i>S</i>**)-<b>16</b> (150 mg, 0.29 mmol), pyridine (1.8 mL), benzenesulfonyl chloride <b>17c</b> (61.5 mg, 0.348 mmol), rt for 1 h, purification by preparative HPLC (method 1), 53 mg of the desired product (0.081 mmol, 27.8% yield). <i>m</i>/<i>z</i> 657.3 [MH]<sup>+</sup>, <i>t</i><sub>R</sub> = 4.03 min, diastereomeric ratio = 97:3 (method B); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.54 (s, 2 H), 7.74–7.83 (m, 2 H), 7.66–7.74 (m, 1 H), 7.57–7.65 (m, 2 H), 7.21 (d, <i>J</i> = 8.4 Hz, 1 H), 7.14 (d, <i>J</i>=l.86 Hz, 1 H), 7.09 (t, 1 = 75.0 Hz, 1 H), 7.00 (dd, <i>J</i> = 8.4, 1.8 Hz, 1 H), 5.98 (dd, <i>J</i> = 9.5, 4.6 Hz, 1 H), 4.14 (dd, <i>J</i> = 8.6, 4.6 Hz, 1 H), 3.86–4.01 (m, 2 H), 3.37–3.50 (m, 2 H), 3.27 (dd, <i>J</i>=l4.l, 4.4 Hz, 1 H), 3.14 (ddd, <i>J</i> = 9.8, 7.1, 6.9 Hz, 1 H), 1.45–1.98 (m, 4 H), 1.14–1.30 (m, 1 H), 0.48–0.63 (m, 2 H), 0.25–0.39 (m, 2 H).</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-1-((3,4-dimethoxyphenyl)sulfonyl)pyrrolidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>18d</b></h4><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((<i>S</i>)-pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (<i>S</i>*,<i>S</i>**)-<b>16</b> (84 mg, 0.16 mmol), 3,4-dimethoxybenzene-1-sulfonyl chloride <b>17d</b> (38.4 mg, 0.16 mmol), pyridine (1.5 mL), rt for 3 h, 20 mg of the desired product (0.028 mmol, 17% yield). <i>m</i>/<i>z</i> 717.2 [MH]<sup>+</sup>. <i>t</i><sub>R</sub> = 6.97 min, diastereomeric ratio = 99:1 (method A); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.30 (s, 2 H), 7.39–7.48 (m, 1 H), 7.25–7.35 (m, 2 H), 7.17 (dd, <i>J</i> = 14.8, 8.2 Hz, 2 H), 7.03–7.10 (m, 1 H), 6.93 (t, <i>J</i> = 75.0 Hz, 1 H), 6.10–6.19 (m, 1 H), 4.21–4.31 (m, 1 H), 4.00 (d, <i>J</i> = 7.1 Hz, 2 H), 3.91 and 3.92 (2s, 2CH<sub>3</sub>, 6 H), 3.54–3.65 (m, 1 H), 3.40–3.50 (m, 1 H), 3.22–3.38 (m, 2 H), 1.70–1.86 (m, 2 H), 1.55–1.71 (m, 1 H), 1.24–1.35 (m, 2 H), 0.53–0.66 (m, 2 H), 0.32–0.46 (m, 2 H).</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-1-((3- (dimethylcarbamoyl)phenyl)sulfonyl)pyrrolidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>18e</b></h4><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((<i>S</i>)-pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (<i>S</i>*,<i>S</i>**)-<b>16</b> (40 mg, 0.08 mmol), pyridine (2 mL), 3-(dimethylcarbamoyl)benzene-1-sulfonyl chloride <b>17e</b> (19 mg, 0.08 mmol), rt for 4 h, 20 mg of the desired product (0.03 mmol, 35.5% yield). <i>m</i>/<i>z</i> 728.1 [MH]<sup>+</sup>. <i>t</i><sub>R</sub> = 6.12 min, diastereomeric ratio = 99:1 (method A); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.60 (s, 2 H), 7.80–7.87 (m, 1 H), 7.68–7.80 (m, 3 H), 7.19 (d, <i>J</i> = 7.9 Hz, 1 H), 7.14 (d, <i>J</i> = 1.8 Hz, 1 H), 7.09 (t, <i>J</i> = 75.0 Hz, 1 H), 6.98 (dd, <i>J</i> = 8.4, 1.8 Hz, 1 H), 6.01 (dd, <i>J</i> = 9.7, 4.4 Hz, 1 H), 4.18 (dd, <i>J</i> = 8.6, 4.2 Hz, 1 H), 3.91 (d, <i>J</i> = 7.1 Hz, 2 H), 3.47 (dd, <i>J</i> = 14.3, 9.9 Hz, 1 H), 3.35–3.41 (m, 1 H), 3.26 (dd, <i>J</i> = 14.1, 4.4 Hz, 1 H), 3.18 (dt, <i>J</i> = 9.7, 6.8 Hz, 1 H), 3.02 (s, 3 H), 2.89 (s, 3 H), 1.88–2.02 (m, 1 H), 1.60–1.73 (m, 2 H), 1.47–1.60 (m, 1 H), 1.13–1.28 (m, 1 H), 0.51–0.60 (m, 2 H), 0.26–0.40 (m, 2 H).</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>R</i>)-1-((3-(dimethylcarbamoyl)phenyl)sulfonyl)pyrrolidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>R</i>*,<i>S</i>**)-<b>18e</b></h4><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>R</i>)-pyrrolidine-2-carbonyl)oxy)ethyl)pyridine 1-oxide (<i>R</i>*,<i>S</i>**)-<b>16</b> (50 mg, 0.1 mmol), 3-(dimethylcarbamoyl)benzene-1-sulfonyl chloride <b>17e</b> (31.1 mg, 0.13 mmol), pyridine (3 mL), rt for 4 h, purification by preparative HPLC (Method 1), 20 mg of the desired product (0.03 mmol, 30% yield). <i>m</i>/<i>z</i> 728.1 [MH]<sup>+</sup>. <i>t</i><sub>R</sub> = 6.20 min, diastereomeric ratio ≥ 99:1 (method A); [α<sub>D</sub>] = +39.02 (c 0.51; CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.54 (s, 2 H), 7.79–7.87 (m, 1 H), 7.70–7.76 (m, 2 H), 7.67 (d, <i>J</i> = 7.5 Hz, 1 H), 7.21 (d, <i>J</i> = 8.4 Hz, 1 H), 7.13 (d, <i>J</i> = 1.8 Hz, 1 H), 7.10 (t, <i>J</i> = 75.0 Hz, 1 H), 6.96–7.03 (m, 1 H), 5.94–6.01 (m, 1 H), 4.13–4.25 (m, 1 H), 3.85–3.97 (m, 2 H), 3.34–3.53 (m, 2 H), 3.23–3.30 (m, 1 H), 3.12–3.22 (m, 1 H), 3.00 (s, 3 H), 2.87 (s, 3 H), 1.86–2.01 (m, 1 H), 1.64–1.83 (m, 2 H), 1.52–1.63 (m, 1 H), 1.13–1.29 (m, 1 H), 0.56 (dd, <i>J</i> = 7.9, 1.3 Hz, 2 H), 0.25–0.41 (m, 2 H).</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-1-((3-(dimethylcarbamoyl)-4-methoxyphenyl)sulfonyl)pyrrolidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>19</b></h3><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((<i>S</i>)-pyrrolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (<i>S</i>*,<i>S</i>**)-<b>16</b> (40 mg, 0.08 mmol) was dissolved in pyridine (2 mL), and 5-(chlorosulfonyl)-2-methoxybenzoic acid <b>17f</b> (19 mg, 0.08 mmol) was added. The mixture was stirred at rt for 4 h, to achieve completion, diluted with aqueous HCl 1 N, and extracted with ethyl acetate. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum to give 50 mg of the desired product (<i>S</i>*,<i>S</i>**)-<b>18f</b> (0.07 mmol, 88% yield). <i>m</i>/<i>z</i> 731.1 [MH]<sup>+</sup>. (<i>S</i>*,<i>S</i>**)-<b>18f</b> (20 mg, 0.03 mmol) was dissolved in DCM (2 mL). CDI (4.4 mg, 0.03 mmol) and dimethylamine 2 M in THF (30 μL, 0.03 mmol) were added, and the mixture stirred for 2 days at rt. The reaction was concentrated under vacuum, diluted with EtOAc, and washed with HCl aq. 1 M. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum to yield the desired compound that was purified by preparative HPLC (method 1) (10 mg; 0.01 mmol, 48.2% yield). <i>m</i>/<i>z</i> 757.9 [MH]<sup>+</sup>; <i>t</i><sub>R</sub> = 3.56 min, diastereomeric ratio ≥ 99:1 (Method B); [α<sub>D</sub>] = −55.88 (c 0.48; CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.54 (s, 2 H), 7.80 (dd, <i>J</i> = 8.6, 2.4 Hz, 1 H), 7.56 (d, <i>J</i> = 2.7 Hz, 1 H), 7.32 (d, <i>J</i> = 8.8 Hz, 1 H), 7.10–7.21 (m, 2 H), 7.08 (t, <i>J</i> = 75.0 Hz, 1 H), 6.98 (dd, <i>J</i> = 8.4, 1.8 Hz, 1 H), 5.89–6.11 (m, 1 H), 4.04–4.20 (m, 1 H), 3.87–3.97 (m, 5 H), 3.46 (m, 1 H), 3.08–3.30 (m, 3 H), 2.99 (s, 3 H), 2.75 (s, 3 H), 1.60–1.75 (m, 2 H), 1.43–1.59 (m, 2 H), 0.80–0.89 (m, 1 H), 0.49–0.62 (m, 2 H), 0.33 (d, <i>J</i> = 4.4 Hz, 2 H).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Procedure for the Synthesis of Sulfonamides <b>22</b></h3><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((<i>S</i>)-3-(2-methoxyethylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>22b</b></h4><div class="NLM_p">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((<i>S</i>)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (<i>S</i>*,<i>S</i>**)-<b>21</b> (100 mg, 0.19 mmol) was dissolved in Py (1.5 mL, 18 mmol). 2-Methoxyethanesulfonyl chloride <b>17b</b> (39 mg, 0.24 mmol) was added, and the reaction was stirred at rt for 1 h to achieve completion. The reaction mixture was diluted with aqueous HCl 1 N and extracted with ethyl acetate. The organic phase was washed with aqueous HCl 1 N and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum. The rude product was purified by preparative HPLC (Method 1) to afford 67 mg of (<i>S</i>*,<i>S</i>**)-<b>22b</b> (0.10 mmol, 54% yield). <i>m</i>/<i>z</i> 657.2 [MH]<sup>+</sup>. LC–MS <i>t</i><sub>R</sub> 4.57 min, diastereomeric ratio = 98:2 (Method B); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.55 (s, 2 H), 7.15–7.21 (m, 1 H), 7.06–7.13 (m, 2 H), 6.93–7.00 (m, 1 H), 5.97–6.06 (m, 1 H), 5.44 (s, 1 H), 3.85–3.98 (m, 3 H), 3.50–3.70 (m, 4 H), 3.37–3.50 (m, 3 H), 3.20–3.28 (m, 3 H), 3.01–3.16 (m, 2 H), 1.23 (d, <i>J</i> = 5.3 Hz, 1 H), 0.51–0.63 (m, 2 H), 0.34 (q, <i>J</i> = 4.9 Hz, 2 H).</div><div class="NLM_p last">Sulfonamides <b>22c</b>–<b>l</b> were prepared following the same procedure starting from the corresponding enantiomerically pure thiazolidine <b>21</b> and sulfonyl chloride <b>17</b>.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-3-(phenylsulfonyl)thiazolidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>22c</b></h4><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((<i>S</i>)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (<i>S</i>*,<i>S</i>**)-<b>21</b> (1 g, 1.75 mmol), sulfonyl chloride <b>17c</b> (371 mg, 2.10 mmol), Py (4.5 mL, 1.75 mmol), rt, 20 min. The crude was purified by flash chromatography (579 mg, 0.86 mmol, yield 49%). <i>m</i>/<i>z</i> 675.2 [MH]<sup>+</sup>. LC–MS <i>t</i><sub>R</sub> 4.20 min, diastereomeric ratio = 97:3 (Method B); [α<sub>D</sub>] = −37.96 (c 0.56; CHCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.60 (s, 2 H), 7.87 (d, <i>J</i> = 7.5 Hz, 2 H), 7.75 (d, <i>J</i> = 7.5 Hz, 1 H), 7.61–7.70 (m, 2 H), 7.18 (d, <i>J</i> = 7.9 Hz, 1 H), 7.05–7.14 (m, 2 H), 6.96 (dd, <i>J</i> = 8.4, 1.8 Hz, 1 H), 6.01 (dd, <i>J</i> = 9.3, 4.9 Hz, 1 H), 5.43 (s, 1 H), 3.90 (d, <i>J</i> = 7.1 Hz, 2 H), 3.75–3.85 (m, 1 H), 3.59–3.68 (m, 1 H), 3.44 (d, <i>J</i> = 9.3 Hz, 1 H), 3.29 (m, 1 H), 2.91–3.00 (m, 1 H), 2.64 (d, <i>J</i> = 11.0 Hz, 1 H), 1.18 (d, <i>J</i> = 7.1 Hz, 1 H), 0.56 (dd, <i>J</i> = 7.9, 1.8 Hz, 2 H), 0.26–0.40 (m, 2 H).</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-3-((3,4-dimethoxyphenyl)sulfonyl)thiazolidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>22d</b></h4><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((<i>S</i>)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (<i>S</i>*,<i>S</i>**)-<b>21</b> (1.1 g, 1.92 mmol), sulfonyl chloride <b>17d</b> (546 mg, 2.31 mmol), Py (4.5 mL, 1.92 mmol), rt, 20 min. No purification needed (636 mg, 0.864 mmol, yield 45%). <i>m</i>/<i>z</i> 735.2 [MH]<sup>+</sup>. LC–MS <i>t</i><sub>R</sub> 4.12 min, diastereomeric ratio = 97:3 (Method B); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.59 (s, 2 H), 7.45 (dd, <i>J</i> = 8.4, 2.2 Hz, 1 H), 7.32 (d, <i>J</i> = 1.8 Hz, 1 H), 7.15–7.21 (m, 2 H), 7.11 (d, <i>J</i> = 1.8 Hz, 1 H), 7.08 (t, <i>J</i> = 75.0 Hz, 1 H), 6.95 (dd, <i>J</i> = 8.4, 1.8 Hz, 1 H), 6.01 (dd, <i>J</i> = 9.3, 4.9 Hz, 1 H), 5.51 (s, 1 H), 3.77–3.95 (m, 9 H), 3.54–3.66 (m, 1 H), 3.45 (dd, <i>J</i> = 14.1, 9.3 Hz, 1 H), 3.25–3.28 (m, 1 H), 2.87–3.00 (m, 1 H), 2.52–2.64 (m, 1 H), 1.19–1.28 (m, 1 H), 0.47–0.65 (m, 2 H), 0.27–0.39 (m, 2 H).</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((<i>S</i>)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>22e</b></h4><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((<i>S</i>)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (<i>S</i>*,<i>S</i>**)-<b>21</b> (300 mg, 0.525 mmol), sulfonyl chloride <b>17e</b> (156 mg, 0.630 mmol), Py (3 mL, 37.1 mmol), rt, 4 h. Flash chromatography (DCM/IsoPrOH 98/2) (250 mg, 0.334 mmol, 64% yield). <i>m</i>/<i>z</i> 746.2 [MH]<sup>+</sup>; [α<sub>D</sub>] = −43.30 (c 0.51; CHCl<sub>3</sub>), <i>t</i><sub>R</sub> = 3.66, diastereomeric ratio  ≥ 99/1 (Method A); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.58 (s, 2 H), 7.88–7.97 (m, 2 H), 7.68–7.82 (m, 2 H), 7.14–7.21 (m, 1 H), 7.09–7.13 (m, 1 H), 7.08 (t, <i>J</i> = 75.0 Hz, 1 H), 6.92–6.99 (m, 1 H), 5.91–6.10 (m, 1 H), 5.54 (s, 1 H), 3.79–3.94 (m, 3 H), 3.60–3.71 (m, 1 H), 3.41–3.51 (m, 1 H), 3.26–3.32 (m, 1 H), 3.02 (s, 3 H), 2.92–3.00 (m, 1 H), 2.89 (s, 3 H), 2.56–2.70 (m, 1 H), 1.20–1.27 (m, 1 H), 0.53–0.60 (m, 2 H), 0.29–0.36 (m, 2 H).</div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>R</i>)-3-((3-(dimethylcarbamoyl)phenyl)sulfonyl)thiazolidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>R</i>**)-<b>22e</b></h4><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>R</i>)-thiazolidine-2-carbonyl)oxy)ethyl)pyridine 1-oxide hydrochloride (<i>S</i>*,<i>R</i>**)-<b>21</b> (693 mg, 1.2 mmol), Py (7 mL, 1.2 mmol), 3-(dimethylcarbamoyl)benzene-1-sulfonyl chloride <b>17e</b> (780 mg, 3.36 mmol), rt, 4 h. Purified by <i>n</i>-Hex/DCM/IprOH/MeOH 45/50/4/1 (24 mg, 0.03 mmol, 2% yield). <i>m</i>/<i>z</i> 746.2 [MH]<sup>+</sup>; <i>t</i><sub>R</sub> = 3.57, diastereomeric ratio = 99:1(Method 2); <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.54 (s, 2 H), 7.93–8.00 (m, 2 H), 7.64–7.80 (m, 2 H), 7.22 (d, <i>J</i> = 8.4 Hz, 1 H), 7.11–7.15 (m, 1 H), 7.10 (t, <i>J</i> = 75.0 Hz, 1 H), 6.97–7.03 (m, 1 H), 5.89–6.03 (m, 1 H), 5.58 (s, 1 H), 3.93 (s, 2 H), 3.62–3.83 (m, 2 H), 3.41–3.53 (m, 1 H), 3.22–3.30 (m, 1 H), 2.95–3.07 (m, 4 H), 2.87 (s, 3 H), 2.61–2.73 (m, 1 H), 1.16–1.31 (m, 2 H), 0.48–0.64 (m, 2 H), 0.34 (d, <i>J</i> = 4.9 Hz, 2 H).</div></div><div id="sec4_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 3,5-Dichloro-4-((<i>R</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>R</i>)-3-((3-(dimethylcarbamoyl)phenyl)sulfonyl)thiazolidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>R</i>*,<i>R</i>**)-<b>22e</b></h4><div class="NLM_p last">3,5-Dichloro-4-((<i>R</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>R</i>)-thiazolidine-2-carbonyl)oxy)ethyl)pyridine 1-oxide hydrochloride (<i>R</i>*,<i>R</i>**)-<b>21</b> (350 mg, 0.612 mmol), Py (6.55 mL, 612 mmol), 3-(dimethylcarbamoyl)benzene-1-sulfonyl chloride <b>17e</b> (414 mg, 1.67 mmol), rt, 4 h. Purified by preparative HPLC (Method 1) (82 mg, 0.110 mmol, 18% yield). <i>m</i>/<i>z</i> 746.0 [MH] <sup>+</sup>, <i>t</i><sub>R</sub> = 3.63, diastereomeric ratio = 99:1 (Method B); <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.57 (s, 2 H), 7.86–8.00 (m, 2 H), 7.65–7.83 (m, 2 H), 7.18 (d, <i>J</i> = 7.9 Hz, 1 H), 7.11 (d, <i>J</i> = 1.3 Hz, 1 H), 7.08 (t, <i>J</i> = 75.0 Hz, 1 H), 6.86–6.96 (m, 1 H), 6.01 (dd, <i>J</i> = 9.0, 5.1 Hz, 1 H), 5.54 (s, 1 H), 3.80–3.98 (m, 3 H), 3.60–3.72 (m, 1 H), 3.46 (dd, <i>J</i> = 14.1, 9.3 Hz, 1 H), 3.30–3.35 (m, 1 H), 2.82–3.06 (m, 7 H), 2.63–2.73 (m, 1 H), 1.15–1.33 (m, 1 H), 0.47–0.65 (m, 2 H), 0.33 (q, <i>J</i> = 4.9 Hz, 2 H).</div></div><div id="sec4_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 3,5-Dichloro-4-((<i>R</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-3-((3-(dimethylcarbamoyl)phenyl)sulfonyl)thiazolidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>R</i>*,<i>S</i>**)-<b>22e</b></h4><div class="NLM_p last">3,5-Dichloro-4-((<i>R</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-thiazolidine-2-carbonyl)oxy)ethyl)pyridine 1-oxide hydrochloride (<i>R</i>*,<i>S</i>**)-<b>21</b> (140 mg, 0.245 mmol), Py (4.71 mL, 440 mmol), 3-(dimethylcarbamoyl)benzene-1-sulfonyl chloride <b>17e</b> (61 mg, 0.245 mmol), rt, 4 h. Purified by preparative HPLC (Method 1) (35 mg, 0.047 mmol, 19% yield). <i>m</i>/<i>z</i> 746.0 [MH]<sup>+</sup>; <i>t</i><sub>R</sub> = 3.57, 3.64, diastereomeric ratio = 84:16 (Method B); <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.54 (s, 2 H), 7.89–7.98 (m, 2 H), 7.63–7.80 (m, 2 H), 7.22 (d, <i>J</i> = 7.9 Hz, 1 H), 7.06–7.15 (m, 2 H), 7.00 (dd, <i>J</i> = 8.4, 1.3 Hz, 1 H), 5.97 (dd, <i>J</i> = 9.7, 4.4 Hz, 1 H), 5.57 (s, 1 H), 3.89–4.02 (m, 2 H), 3.57–3.86 (m, 2 H), 3.47 (dd, <i>J</i> = 14.1, 9.7 Hz, 1 H), 3.26 (d, <i>J</i> = 4.9 Hz, 1 H), 2.80–3.10 (m, 7 H), 2.61–2.74 (m, 1 H), 1.15–1.31 (m, 1 H), 0.50–0.64 (m, 2 H), 0.34 (q, <i>J</i> = 4.9 Hz, 2 H).</div></div><div id="sec4_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-3-(pyridin-3-ylsulfonyl)thiazolidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>22g</b></h4><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-thiazolidine-2-carbonyl)oxy)ethyl)pyridine 1-oxide hydrochloride (<i>S</i>*,<i>S</i>**)-<b>21</b> (540 mg, 0.944 mmol), Py (8 mL, 1 mmol), pyridine-3-sulfonyl chloride <b>17g</b> (252 mg, 1.42 mmol), rt, 1 h. Purified by preparative HPLC (Method 1) to afford 408 mg of (<i>S</i>*,<i>S</i>**)-<b>22g</b> (0.603 mmol, 60% yield). <i>m</i>/<i>z</i> 676.2 [MH]<sup>+</sup>; [α<sub>D</sub>] = −43.74 (c 0.53; CHCl<sub>3</sub>); <i>t</i><sub>R</sub> = 3.62, diastereomeric ratio = 99:1 (Method B); <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 9.05 (d, <i>J</i> = 2.2 Hz, 1 H), 8.91 (dd, <i>J</i> = 4.6, 1.5 Hz, 1 H), 8.58 (s, 2 H), 8.31 (ddd, <i>J</i> = 8.3, 1.9, 1.8 Hz, 1 H), 7.69 (dd, <i>J</i> = 8.4, 4.9 Hz, 1 H), 7.18 (d, <i>J</i> = 7.9 Hz, 1 H), 7.05–7.14 (m, 2 H), 6.95 (dd, <i>J</i> = 8.2, 1.5 Hz, 1 H), 6.01 (dd, <i>J</i> = 9.0, 5.1 Hz, 1 H), 5.63 (s, 1 H), 3.80–3.96 (m, 3 H), 3.61–3.72 (m, 1 H), 3.46 (dd, <i>J</i> = 14.1, 9.3 Hz, 1 H), 3.28–3.40 (m, 2 H), 2.91–3.04 (m, 1 H), 2.69 (ddd, <i>J</i> = 11.1, 6.4, 6.3 Hz, 1 H), 1.21 (ddd, <i>J</i> = 12.1, 7.5, 4.6 Hz, 1 H), 0.49–0.64 (m, 2 H), 0.26–0.41 (m, 2 H).</div></div><div id="sec4_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-3-((1-methyl-1<i>H</i>-imidazol-4-yl)sulfonyl)thiazolidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>22h</b></h4><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-thiazolidine-2-carbonyl)oxy)ethyl)pyridine 1-oxide hydrochloride (<i>S</i>*,<i>S</i>**)-<b>21</b> (100 mg, 0.175 mmol), Py (1.87 mL, 23.1 mmol), 1-methyl-1<i>H</i>-imidazole-4-sulfonyl chloride <b>17h</b> (39 mg, 0.21 mmol), rt, 2 h. Purified by preparative HPLC (Method 1) to afford 30 mg of (<i>S</i>*,<i>S</i>**)-<b>22h</b> (0.04 mmol, 25% yield). <i>m</i>/<i>z</i> 679.2 [MH]<sup>+</sup>; <i>t</i><sub>R</sub> = 3.28, diastereomeric ratio = 99:1 (Method B); <sup>1</sup>H NMR (400 MHz, DMSO<i>-d</i><sub>6</sub>) δ ppm 8.56 (s, 2 H), 7.93 (s, 1 H), 7.87 (s, 1 H), 7.17 (d, <i>J</i> = 8.4 Hz, 1 H), 7.10 (d, <i>J</i> = 9.7 Hz, 2 H), 6.92–6.98 (m, 1 H), 5.94–6.11 (m, 1 H), 5.35 (s, 1 H), 3.91 (d, <i>J</i> = 7.1 Hz, 2 H), 3.73–3.80 (m, 4 H), 3.61–3.71 (m, 1 H), 3.40–3.49 (m, 1 H), 3.23–3.30 (m, 1 H), 2.94–3.04 (m, 1 H), 2.76–2.88 (m, 1 H), 1.16–1.28 (m, 1 H), 0.56 (d, <i>J</i> = 7.9 Hz, 2 H), 0.34 (d, <i>J</i> = 4.4 Hz, 2 H).</div></div><div id="sec4_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-3-((1-methyl-5-(methylcarbamoyl)-1<i>H</i>-pyrrol-3-yl)sulfonyl)thiazolidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>22i</b></h4><div class="NLM_p last">From 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-thiazolidine-2-carbonyl)oxy)ethyl)pyridine 1-oxide hydrochloride (<i>S</i>*,<i>S</i>**)-<b>21</b>, (80 mg, 0.14 mmol), Py (1 mL, 12.4 mmol), 1-methyl-5-(methylcarbamoyl)-1<i>H</i>-pyrrole-3-sulfonyl chloride <b>17i</b> (40 mg, 0.168 mmol), rt, 2 h. Purified by preparative HPLC (Method 1) to afford 73 mg of (<i>S</i>*,<i>S</i>**)-<b>22i</b> (0.09 mmol, 66% yield). <i>m</i>/<i>z</i> 735.2 [MH]<sup>+</sup>; <i>t</i><sub>R</sub> = 3.47, diastereomeric ratio ≥ 99:1 (Method B); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 12.45–12.98 (bs, 1 H), 8.59 (s, 2 H), 8.27 (d, <i>J</i> = 4.9 Hz, 1 H), 7.67 (d, <i>J</i> = 1.8 Hz, 1 H), 7.18 (d, <i>J</i> = 8.4 Hz, 1 H), 7.06–7.13 (m, 3 H), 6.96 (dd, <i>J</i> = 8.4, 1.86 Hz, 1 H), 6.03 (dd, <i>J</i> = 9.3, 4.9 Hz, 1 H), 5.22 (s, 1 H), 3.84–3.96 (m, 5 H), 3.58–3.73 (m, 2 H), 3.45 (dd, <i>J</i> = 14.1, 9.3 Hz, 1 H), 3.28–3.30 (m, 1 H), 2.94–3.05 (m, 1 H), 2.75–2.84 (m, 1 H), 2.72 (d, <i>J</i> = 4.4 Hz, 3 H), 1.22 (d, <i>J</i> = 7.5 Hz, 1 H), 0.48–0.63 (m, 2 H), 0.33 (q, <i>J</i> = 4.9 Hz, 2 H).</div></div><div id="sec4_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-3-((2,5-dimethylthiophen-3-yl)sulfonyl)thiazolidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>22l</b></h4><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-thiazolidine-2-carbonyl)oxy)ethyl)pyridine 1-oxide hydrochloride (<i>S</i>*,<i>S</i>**)-<b>21</b> (150 mg, 0.26 mmol), Py (4 mL, 49.2 mmol), 2,5-dimethylthiophene-3-sulfonyl chloride <b>17l</b> (94 mg, 0.45 mmol), rt, 18 h. Purified by preparative HPLC (Method 2) to afford 160 mg of (<i>S</i>*,<i>S</i>**)-<b>22l</b> (0.22 mmol, 86% yield). <i>m</i>/<i>z</i> 709.02 [MH]<sup>+</sup>; [α<sub>D</sub>] = −50.27 (c 0.3, DCM), <i>t</i><sub>R</sub> = 4.41, diastereomeric ratio ≥ 95:5 (Method C); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.56 (s, 2 H), 7.19 (d, 1 H), 7.12 (d, 1 H), 6.98 (s, 1 H), 6.97 (dd, 1 H), 7.08 (t, 1 H), 6.02 (dd, 1 H), 5.40 (s, 1 H), 3.91 (d, 2 H), 3.78 (dt, 1 H), 3.62 (dt, 1 H), 3.45 (dd, 1 H), 3.30 (dd, 1 H), 3.03 (dt, 1 H), 2.80 (dt, 1 H), 2.57 (s, 3 H), 2.40 (s, 3 H), 1.11–1.34 (m, 1 H), 0.45–0.70 (m, 2 H), 0.24–0.45 (m, 2 H).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-3-((3-(dimethylcarbamoyl)-4-methoxyphenyl)sulfonyl)thiazolidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>S</i>*<i>,S</i>**)-<b>22m</b></h4><div class="NLM_p last">To a solution of 3,5-dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((<i>S</i>)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (<i>S</i>*,<i>S</i>**)-<b>21</b> (60 mg, 112 mmol) in Py (1 mL, 112 mmol), sulfonyl chloride <b>17f</b> (56 mg, 224 mmol) was added, and the reaction was stirred at rt for 1 h to achieve completion. The reaction mixture was diluted with aqueous HCl 1 N and extracted with ethyl acetate. The organic phase was washed with aqueous HCl 1 N and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum to give 70 mg of (<i>S</i>*,<i>S</i>**)-<b>22f</b>, no purification needed (0.093 mmol, yield 88%). <i>m</i>/<i>z</i> 749.1 [MH]<sup>+</sup>. LC–MS <i>t</i><sub>R</sub> = 3.44 min, diastereomeric ratio = 99:1 (Method B). 4-((<i>S</i>)-2-(((<i>S</i>)-3-((3-Carboxy-4-methoxyphenyl)sulfonyl)thiazolidine-2-carbonyl)oxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (<i>S</i>*,<i>S</i>**)-<b>22f</b> (70 mg, 0.093 mmol) was dissolved in DMF (1 mL). CDI (18 mg, 0.11 mmol) was added, and the mixture stirred for 30 min at rt. Then dimethylamine was added (200 μL, 0.6 mmol), and the mixture stirred at rt for 2 h. The reaction was quenched with water, and the product was extracted with AcOEt. The organic layer was washed with water (2×) and NaCl saturated solution, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated under vacuum. The crude product was purified by preparative HPLC (Method 1) conditions to give 70 mg of (<i>S</i>*,<i>S</i>**)-<b>22m</b> (0.09 mmol, yield 97%). <i>m</i>/<i>z</i> 776.2 [MH]<sup>+</sup>. LC–MS <i>t</i><sub>R</sub> 3.64 min, diastereomeric ratio = 97:3 (Method B); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.57 (s, 2 H), 7.81–7.97 (m, 1 H), 7.68–7.76 (m, 1 H), 7.32 (m, 1 H), 7.18 (d, <i>J</i> = 7.9 Hz, 1 H), 7.05–7.13 (m, 2 H), 6.91–6.98 (m, 1 H), 5.92–6.07 (m, 1 H), 5.57 (s, 1 H), 3.75–4.06 (m, 6 H), 3.55–3.68 (m, 1 H), 3.37–3.49 (m, 1 H), 3.25–3.35 (m, 1 H), 2.99 (s, 4 H), 2.75 (s, 3 H), 2.54–2.65 (m, 1 H), 1.14–1.29 (m, 1 H), 0.56 (dd, <i>J</i> = 7.9, 1.8 Hz, 2 H), 0.33 (d, <i>J</i> = 5.3 Hz, 2 H).</div></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-3-(3-methoxypropanoyl)thiazolidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>24a</b></h3><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((<i>S</i>)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (<i>S</i>*,<i>S</i>**)-<b>21</b> (150 mg, 0.262 mmol), 3-methoxypropanoic acid <b>23a</b> (14.84 μL, 0.157 mmol), DMAP (64 mg, 0.52 mmol), and EDC (50.3 mg, 0.262 mmol) were dissolved in dry DCM (6 mL), and the mixture was stirred at rt for 1 h. Thus, EDC (101 mg, 0.525 mmol), 3-methoxypropanoic acid (14.84 μL, 0.157 mmol), and DMAP (32.0 mg, 0.262 mmol) were added, and the mixture was stirred at rt overnight. The reaction mixture was washed with 1 N HCl (1 × 30 mL) and brine (1 × 30 mL). The solvent was removed <i>in vacuo</i> to give a residue that was purified by preparative HPLC (Method 2) to give 50 mg of (<i>S</i>*,<i>S</i>**)-<b>24a</b>: (0.08 mmol, 31% yield). <i>m</i>/<i>z</i> 607.05 [MH]<sup>+</sup>; <i>t</i><sub>R</sub> = 3.49, diastereomeric ratio = 77:23 (Method C); [α<sub>D</sub>] = −46.5 (c 0.49; DCM); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.54 (s, 2 H), 7.17 (d, 1 H), 7.07 (s, 1 H), 6.94 (dd, 1 H), 7.07 (t, 1 H), 5.81–6.02 (m, 1 H), 5.40 (s, 0.77 H) and 5.64 (s, 0.23 H), 4.11 (s, 2 H), 3.92 (d, 2 H), 3.72–3.85 (m, 2 H), 3.35–3.53 (m, 2 H), 3.12–3.26 (m, 1 H), 2.83–3.11 (m, 2 H), 1.12–1.35 (m, 1 H), 0.50–0.62 (m, 2 H), 0.20–0.42 (m, 2 H).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-3-(3-(dimethylcarbamoyl)benzoyl)thiazolidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>24b</b></h3><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((<i>S</i>)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (<i>S</i>*,<i>S</i>**)-<b>21</b> (100 mg; 0.175 mmol) was dissolved in DMF (1 mL). 3-(Dimethylcarbamoyl)benzoic acid <b>23b</b> (41 mg0.21 mmol) was added to the reaction solution followed by EDC (44 mg, 0.23 mmol) and DMAP (24 mg, 0.19 mmol). The reaction was stirred at rt for 4 h before to get to completion and quenched by adding 20 mL of aq HCl 1 M. The aqueous layer was extracted with EtOAc and washed with HCl 1 M (×3) and with aq K<sub>2</sub>CO<sub>3</sub> 5% (×3). The resulting organic extract was anhydrified with Na<sub>2</sub>SO<sub>4</sub>, filtered on a filter paper, and the solvent removed on a rotary evaporator under reduced pressure. The oil residue was purified by preparative HPLC (Method 1) to yield 45 mg of (<i>S</i>*,<i>S</i>**)-<b>24b</b> (0.063 mmol, yield 36%). <i>m</i>/<i>z</i> 710.2 [MH]<sup>+</sup>; <i>t</i><sub>R</sub> = 3.38, diastereomeric ratio = 3:97 (Method B); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.55 (s, 2 H), 7.40–7.65 (m, 4 H), 6.78–7.31 (m, 4 H), 5.85–6.14 (m, 1 H), 5.24 (s, 1 H), 3.69–4.02 (m, 4 H), 3.36–3.63 (m, 2 H), 3.09–3.21 (m, 1 H), 2.74–3.07 (m, 7 H), 1.12–1.28 (m, 1 H), 0.42–0.66 (m, 2 H), 0.18–0.39 (m, 2 H).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 3,5-Dichloro-4-((<i>S</i>)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((<i>S</i>)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>28a</b></h3><div class="NLM_p last">To a solution of 3,5-dichloro-4-((<i>S</i>)-2-(4-(difluoromethoxy)-3-methoxyphenyl)-2-((<i>S</i>)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide hydrochloride (<i>S</i>*,<i>S</i>**)-<b>27a</b> (350 mg, 0.658 mmol) in pyridine (6 mL) cooled at 0 °C, a solution of 3-(dimethylcarbamoyl)benzene-1-sulfonyl chloride (245 mg, 0.987 mmol) in DCM (3 mL) was added dropwise, and the reaction was stirred at 0 °C for 1 h. The mixture was diluted with DCM (30 mL) and washed twice with aqueous 1 N HCl; the organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed under vacuum. The residue was purified by preparative HPLC (Method 2) followed by flash chromatography on silica gel (DCM/MeOH = 97/3) to afford 147 mg of (<i>S</i>*,<i>S</i>**)-<b>28a</b> (0.208 mmol, 31.6% yield); <i>m</i>/<i>z</i> 705.97 [MH]<sup>+</sup>; <i>t</i><sub>R</sub> = 3.28 min, diastereomeric ratio = 95:5 (Method C); (<sup>1</sup>H NMR); [α<sub>D</sub>] = −43.1 (c 0.57, DCM); <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.57 (s, 2 H), 7.94 (dt, 1 H), 7.90 (t, 1 H), 7.77 (dt, 1 H), 7.71 (t, 1 H), 7.18 (d, 1 H), 7.15 (d, 1 H), 6.97 (dd, 1 H), 7.07 (t, 1 H), 6.04 (dd, 1 H), 5.54 (s, 1 H), 3.84 (s, 3 H), 3.75–3.94 (m, 1 H), 3.66 (dt, 1 H), 3.48 (dd, 1 H), 3.33 (dd, 1 H), 3.02 (br. s., 3 H), 2.98 (dd, 1 H), 2.90 (br. s., 3 H), 2.66 (dt, 1 H).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopentyloxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-3-((3-(dimethylcarbamoyl)phenyl)sulfonyl)thiazolidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>28b</b></h3><div class="NLM_p last">(<i>S</i>*,<i>S</i>**)-<b>28b</b> was prepared following an analogous procedure as for (<i>S</i>*,<i>S</i>**)-<b>28a</b> from (<i>S</i>*,<i>S</i>**)-<b>27b</b> (195 mg, 0.33 mmol), pyridine (4 mL), 3-(dimethylcarbamoyl)benzene-1-sulfonyl chloride (149 mg, 0.599 mmol), rt, 18 h. Purified by preparative HPLC (Method 2). Yield 94 mg of (<i>S</i>*,<i>S</i>**)-<b>28b</b> (0.122 mmol, 37% yield); <i>m</i>/<i>z</i> 760.17 [MH]<sup>+</sup>; <i>t</i><sub>R</sub> = 3.98 min, diastereomeric ratio = 95:5 (Method C); [α<sub>D</sub>] = −42.7 (c 0.50; DCM); <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.57 (s, 2 H), 7.95 (dt, 1 H), 7.91 (t, 1 H), 7.77 (dt, 1 H), 7.72 (td, 1 NH), 7.16 (d, 1 H), 7.08 (d, 1 H), 6.94 (dd, 1 H), 6.99 (t, 1 H), 6.02 (dd, 1 H), 5.57 (s, 1 H), 4.82–5.00 (m, 1 H), 3.87 (dt, 1 H), 3.65 (dt, 1 H), 3.46 (dd, 1 H), 3.32 (dd, 1 H), 3.03 (br. s., 3 H), 2.93–3.01 (m, 1 H), 2.90 (br. s., 3 H), 2.65 (dt, 1 H), 1.38–2.04 (m, 8 H).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 3,5-Dichloro-4-((<i>S</i>)-2-(4-(difluoromethoxy)-3-hydroxyphenyl)-2-((<i>S</i>)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>28c</b></h3><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((<i>S</i>)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)-thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide (<i>S</i>*,<i>S</i>**)-<b>22e</b> (200 mg, 0.268 mmol) was dissolved in 2,2,2-trifluoroacetic acid (2 mL, 0.268 mmol), and the solution stirred overnight at rt. The reaction mixture was diluted with DCM and concentrated under vacuum to give a crude, which was purified through preparative HPLC (Method 1) to give 90 mg of (<i>S</i>*,<i>S</i>**)-<b>28c</b> (0.131 mmol, 49% yield). <i>m</i>/<i>z</i> 661.3 [MH]<sup>+</sup>; <i>t</i><sub>R</sub> = 2.49 min, diastereomeric ratio = 99:1 (Method B); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 10.05 (s, 1 H), 8.58 (s, 2 H), 7.85–7.97 (m, 2 H), 7.67–7.80 (m, 2 H), 7.11 (d, <i>J</i> = 8.4 Hz, 1 H), 7.04 (t, <i>J</i> = 75.0 Hz, 1 H), 6.94 (d, <i>J</i> = 2.2 Hz, 1 H), 6.83–6.87 (m, 1 H), 5.86–6.02 (m, 1 H), 5.47 (s, 1 H), 3.78–3.92 (m, 1 H), 3.56–3.68 (m, 1 H), 3.37–3.49 (m, 1 H), 3.20–3.28 (m, 1 H), 2.93–3.09 (m, 4 H), 2.89 (s, 3 H), 2.59–2.69 (m 1 H).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Preparation of Compounds <b>35</b>, <b>36a–b</b>, <b>36d</b>, and <b>37</b></h3><div class="NLM_p">Compounds <b>35</b>, <b>36a–b</b>, <b>36d</b>, and <b>37</b> were synthesized following the same procedure described for the preparation of compounds (<i>S</i>*,<i>S</i>**)-<b>22b</b> starting from corresponding intermediates <b>32</b>, <b>33</b>, and <b>34</b> (whose preparation is described in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div><div id="sec4_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluo<b>ro</b>methoxy)phenyl)-2-(((<i>R</i>)-3-((3-(dimethylcarbamoyl)phenyl)sulfonyl)thiazolidine-4-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>R</i>*,<i>S</i>**)-<b>35</b></h4><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>R</i>)-thiazolidine-4-carbonyl)oxy)ethyl)pyridine 1-oxide (<i>R</i>*,<i>S</i>**)-<b>32</b> (75 mg, 0.14 mmol), sulfonyl chloride <b>17e</b> (42 mg, 0.17 mmol), Py (1.5 mL, 18.6 mmol), rt, 3 h. The crude was purified by preparative HPLC (Method 1), 40 mg solid (0.056 mmol, yield 41%). <i>m</i>/<i>z</i> 746.1 [MH]<sup>+</sup>. LC–MS <i>t</i><sub>R</sub> 6.30 min, diastereomeric ratio = 99:1 (Method A); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.59 (s, 2 H), 7.85–7.99 (m, 2 H), 7.65–7.79 (m, 2 H), 7.13–7.22 (m, 2 H), 7.09 (t, <i>J</i> = 75.0 Hz, 1 H), 6.98 (dd, <i>J</i> = 8.4, 1.86 Hz, 1 H), 6.00 (dd, <i>J</i> = 9.3, 4.4 Hz, 1 H), 4.89 (dd, <i>J</i> = 7.3, 4.6 Hz, 1 H), 4.73 (d, <i>J</i> = 10.6 Hz, 1 H), 4.32 (d, <i>J</i> = 10.6 Hz, 1 H), 3.92 (d, <i>J</i> = 7.1 Hz, 2 H), 3.46 (dd, <i>J</i> = 14.1, 9.7 Hz, 1 H), 3.23–3.30 (m, 1 H), 2.93–3.08 (m, 5 H), 2.88 (s, 3 H), 1.23 (d, <i>J</i> = 7.1 Hz, 1 H), 0.49–0.64 (m, 2 H), 0.33 (q, <i>J</i> = 4.9 Hz, 2 H).</div></div><div id="sec4_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-1-((3-(dimethylcarbamoyl)phenyl)sulfonyl)piperidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>36a</b></h4><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-piperidine-2-carbonyl)oxy)ethyl)pyridine 1-oxide (<i>S</i>*,<i>S</i>**)-<b>33</b> (900 mg, 1.70 mmol), sulfonyl chloride <b>17e</b> (634 mg, 2.56 mmol), Py (7 mL, 87 mmol), 0 °C, 4 h. The crude was purified by flash chromatography (DCM/IprOH 98/2), 80 mg solid (0.102 mmol, yield 6%). <i>m</i>/<i>z</i> 742.2 [MH]<sup>+</sup>. LC–MS <i>t</i><sub>R</sub> 3.85 min, diastereomeric ratio = 99:1 (Method B); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.50 (s, 2 H), 7.57–7.84 (m, 4 H), 7.08–7.17 (m, 1 H), 7.02–7.08 (m, 2 H), 6.83–6.93 (m, 1 H), 5.77–5.96 (m, 1 H), 4.56–4.73 (m, 1 H), 3.78–3.99 (m, 2 H), 3.56–3.74 (m, 1 H), 3.33–3.46 (m, 2 H), 3.17–3.26 (m, 1 H), 2.99 (s, 3 H), 2.86 (s, 3 H), 1.99–2.17 (m, 1 H), 1.43–1.69 (m, 3 H), 1.08–1.31 (m, 2 H), 0.71–0.99 (m, 1 H), 0.43–0.61 (m, 2 H), 0.25–0.38 (m, 2 H).</div></div><div id="sec4_11_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 4-((<i>S</i>)-2-(((<i>S</i>)-1-((3-Carboxy-4-methoxyphenyl)sulfonyl)piperidine-2-carbonyl)oxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>36b</b></h4><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-piperidine-2-carbonyl)oxy)ethyl)pyridine 1-oxide (<i>S</i>*,<i>S</i>**)-<b>33</b> (100 mg, 0.376 mmol), sulfonyl chloride <b>17f</b> (94 mg, 0.38 mmol), Py (1.5 mL, 18.6 mmol), rt, 8 h. The reaction mixture was diluted with HCl 1 N and extracted with AcOEt. The organic phase was washed with HCl 1 N and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum to give 60 mg of crude that was used without further purification. <i>m</i>/<i>z</i> 530.12 [MH]<sup>+</sup>.</div></div><div id="sec4_11_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-1-(phenylsulfonyl)piperidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>36d</b></h4><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-piperidine-2-carbonyl)oxy)ethyl)pyridine 1-oxide (<i>S</i>*,<i>S</i>**)-<b>33</b> (106 mg, 0.2 mmol), sulfonyl chloride <b>17c</b> (43 mg, 0.25 mmol), Py (1.5 mL, 18.6 mmol), rt, 2 h. The crude was purified by preparative HPLC (Method 1), 19 mg of solid (0.03 mmol, yield 15%). <i>m</i>/<i>z</i> 671.2 [MH]<sup>+</sup>. LC–MS <i>t</i><sub>R</sub> 4.44 min, diastereomeric ratio = 99:1 (Method B); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.64 (s, 2 H), 7.62–7.70 (m, 3 H), 7.57 (d, <i>J</i> = 7.5 Hz, 2 H), 7.15 (m, 1 H), 7.02–7.10 (m, 2 H), 6.89 (m, 1 H), 5.84–5.91 (m, 1 H), 4.56–4.66 (m, 1 H), 3.87 (m, 2 H), 3.57–3.67 (m, 1 H), 3.36–3.48 (m, 1 H), 3.16–3.27 (m, 1 H), 2.90–3.08 (m, 1 H), 1.98–2.12 (m, 1 H), 1.41–1.66 (m, 3 H), 1.10–1.30 (m, 2 H), 0.78–0.98 (m, 1 H), 0.57 (m, 2 H), 0.33 (dd, <i>J</i> = 4.9, 1.3 Hz, 2 H).</div></div><div id="sec4_11_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>R</i>)-1-((3-(dimethylcarbamoyl)phenyl)sulfonyl)piperidine-3-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>R</i>*,<i>S</i>**)-<b>37</b></h4><div class="NLM_p last">3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>R</i>)-piperidine-3-carbonyl)oxy)ethyl)pyridine 1-oxide (<i>R</i>*,<i>S</i>**)-<b>34</b> (248 mg, 0.47 mmol), sulfonyl chloride <b>17e</b> (138 mg, 0.56 mmol), Py (4 mL, 50 mmol), rt, 18 h. The crude was purified by flash chromatography on silica gel (DCM/MeOH = 99/1 to 98/2), 60 mg (0.146 mmol, yield 31%). <i>m</i>/<i>z</i> 742.1 [MH]<sup>+</sup>. LC–MS <i>t</i><sub>R</sub> 3.78 min, diastereomeric ratio = 95:5 (Method C); [α<sub>D</sub>] = +2.018 (c 0.565, MeOH). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.55 (s, 2 H), 7.72–7.84 (m, 3 H), 7.70 (t, 1 H), 7.18 (d, 1 H), 7.10 (d, 1 H), 6.96 (dd, 1 H), 7.07 (t, 1 H), 5.94 (dd, 1 H), 3.92 (d, 2 H), 3.47–3.59 (m, 1 H), 3.45 (dd, 1 H), 3.32–3.39 (m, 1 H), 3.21 (dd, 1 H), 3.02 (br. s., 3 H), 2.90 (br. s., 3 H), 2.55–2.69 (m, 2 H), 1.03–1.96 (m, 6 H), 0.47–0.69 (m, 2 H), 0.20–0.47 (m, 2 H).</div></div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Synthesis of 3,5-Dichloro-4-((<i>S</i>)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((<i>S</i>)-1-((3-(dimethylcarbamoyl)-4-methoxyphenyl)sulfonyl)piperidine-2-carbonyl)oxy)ethyl)pyridine 1-Oxide (<i>S</i>*,<i>S</i>**)-<b>36c</b></h3><div class="NLM_p last">4-((<i>S</i>)-2-(((<i>S</i>)-1-((3-Carboxy-4-methoxyphenyl)sulfonyl)piperidine-2-carbonyl)oxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide (<i>S</i>*,<i>S</i>**)-<b>36b</b> (60 mg, 0.08 mmol) was dissolved in DMF (1.5 mL). CDI (26 mg, 0.16 mmol) was added, and the mixture stirred for 30 min at rt. Then dimethylamine 2 M in THF was added (402 μL, 0.81 mmol), and the mixture stirred at rt for 18 h. The reaction was quenched with water, and the product was extracted with AcOEt. The organic layer was washed with water (2×) and NaCl saturated solution, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated under vacuum. The crude product was purified by preparative HPLC (Method 1) to give 25 mg of (<i>S</i>*,<i>S</i>**)-<b>36c</b> (0.064 mmol, yield 40%). <i>m</i>/<i>z</i> 772.3 [MH]<sup>+</sup>. LC–MS <i>t</i><sub>R</sub> 3.84 min, diastereomeric ratio = 99:1 (Method B); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 8.62 (s, 2 H), 7.59–7.77 (m, 1 H), 7.45–7.56 (m, 1 H), 7.18–7.22 (m, 1 H), 7.13–7.17 (m, 1 H), 7.03–7.09 (m, 2 H), 6.79–6.95 (m, 1 H), 5.83–5.94 (m, 1 H), 4.53–4.72 (m, 1 H), 3.81–3.96 (m, 5 H), 3.60 (d, <i>J</i> = 11.9 Hz, 1 H), 3.40 (d, <i>J</i> = 10.6 Hz, 1 H), 3.28–3.29 (m, 1 H), 3.23 (dd, <i>J</i> = 14.1, 5.3 Hz, 1 H), 2.98 (s, 3 H), 2.74 (s, 3 H), 2.06 (d, <i>J</i> = 12.8 Hz, 1 H), 1.43–1.61 (m, 3 H), 1.12–1.31 (m, 2 H), 0.88 (d, <i>J</i> = 12.8 Hz, 1 H), 0.52–0.61 (m, 2 H), 0.29–0.36 (m, 2 H).</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Biology and ADME</h3><div class="NLM_p last">Determination of inhibition of PDE4 enzymatic activity in the cell free assay, see ref <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">23</a>. <i>In vitro</i> determination of anti-inflammatory activity in the PBMCs assay, see ref <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">23</a>. Human lung S9 stability, see ref <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">23</a>. Plasma protein binding, see ref <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">23</a>. Caco-2 membrane permeability assay, see ref <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">23</a>. Plasma stability, see ref <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">23</a>.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Human Hepatocyte Stability</h3><div class="NLM_p last">Test compounds were incubated, in duplicate, at a concentration of 1 μM with hepatocytes (1 million cells/mL) in Leibovitz L-15 Medium, at 37 °C. At 0, 10, 20, 30, 60, and 90 min, 50 μL aliquots of the incubates were taken, added with 80 μL of ice-cold acetonitrile and 20 μL of 1 μM warfarin in acetonitrile (injection check), and samples centrifuged. The supernatants were analyzed for unchanged compound by LC–MS/MS. 7-Ethoxycoumarin (1 μM) and 7-hydroxycoumarin (30 μM), positive controls, respectively, of phase I and phase II activities of hepatocytes, as well as control incubations with test compounds incubated in the absence of hepatocytes (medium only) for 0 and 90 min, were included. Control samples were processed as test compound samples.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Human Microsomes Stability</h3><div class="NLM_p last">Test compounds were incubated, in duplicate, at the concentration of 1 μM with liver microsomes (0.8 mg protein/mL) in Dulbecco’s buffer (pH 7.4) at 37 °C in the presence of 1 mM NADPH. At different time points (0, 5, 10, 20, 30, and 60 min), 50 μL aliquots of the incubates were taken, added with 80 μL of ice-cold acetonitrile, and 20 μL of 1 μM warfarin in acetonitrile (injection check) to stop the reaction, and samples were centrifuged. The supernatants were analyzed by LC–MS/MS for unchanged compounds. Test compounds were incubated with liver microsomes in Dulbecco’s buffer in the absence of NADPH for 0 and 60 min, as control. Midazolam at the concentration of 1 μM, was incubated with microsomes as positive control for phase I activity of microsomes. Control samples were processed as test compound samples.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> <i>In Vitro</i> Metabolite Profile</h3><div class="NLM_p last">Commercially available cryopreserved hepatocytes of pooled mixed sex humans were used. Test compounds were incubated, in duplicate, at the concentration of 10 μM with human liver hepatocytes (1 mL/1 million cells) in Leibovitz L-15 medium, at 37 °C. At <i>t</i> = 0, 60 min samples aliquots of the incubates were taken. The sample workup included evaporation of protein-free supernatant under nitrogen and reconstitution of the residue in mobile phase for HPLC analysis. Control incubations were performed with test compounds incubated in the absence of hepatocytes (medium only) for 60 min. Control samples were processed as test compound samples. Samples were analyzed by LC–MS/MS.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> PDEs Enzyme Assays</h3><div class="NLM_p last">All the PDE isoenzymes were prepared as human recombinant proteins from insect Sf9 cells, with the exception of PDE6, purified from bovine retina.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The radiometric assay method is a modification of the two-step method of Thompson and Appleman.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Compounds (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b> were tested against PDEs at five concentrations (1% final DMSO concentration) in duplicate with a starting concentration of 30 μM and a 1:10 serial dilution. All the PDEs enzymatic assays were performed at Eurofins (Taiwan).</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> <i>In Vivo</i> Pharmacology</h3><div id="sec4_18_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> ED<sub>50</sub> Determination of Inhibition of Ovalbumin-Induced Lung Eosinophilia in Rats</h4><div class="NLM_p">Adult male Brown–Norway rats (Charles River Laboratories Italy, Calco, Italy) were sensitized by intraperitoneal injection of a suspension containing ovalbumin (OVA; 1 mg/rat) and Al(OH)<sub>3</sub> (100 mg/rat) in 1 mL of saline for 3 consecutive days. Then, 2 to 3 weeks later, the animals were exposed to an aerosol of OVA solution (1% in saline) by a nose-only apparatus system for 30 min to trigger an influx of inflammatory cells into the airways. Vehicle-control treated animals were exposed to an aerosol of saline using the same general conditions. For the determination of inhibitory potency, test compounds were administered intratracheally 2 h before and 6 h after the antigen (OVA) aerosol. For the intratracheal administration of test compounds or vehicle, animals were anesthetized with isoflurane (4% in oxygen), and a laryngoscope was moved forward into the mouth to visualize the trachea and guide the insertion of a fine-tipped dry powder insufflator (PennCentury, Philadelphia, PA) directly into the trachea and located 1–2 mm above the bifurcation. Dry powder formulations were prepared by blending coarse respiratory grade lactose and the micronized test compound to achieve 10 mg/kg body weight total particulate powder. Dry powders were blown into the airways during the spontaneous phase inspiration in an air volume of 3 mL. The difference in weight of the needle before and after the administration was used to calculate the dose administered. Control animals received 10 mg/kg of lactose. At 24 h after exposure either to OVA or saline aerosol, animals were sacrificed by an overdose of anesthetic. Bronchoalveolar lavage (BAL) fluid was obtained by gently washing the lungs with three aliquots (4 mL each) of solution A (10× Hanks’ balanced salt solution, 100 mL; EDTA 100 mM, 100 mL; HEPES 1 mM, 10 mL; distilled water, 790 mL). Routine recovery of BAL fluids did not significantly differ among animals with ∼80% of instilled volume recovered (9.5–10.5 mL). The resulting BAL fluid was centrifuged at 800<i>g</i> for 10 min at 4 °C, and the supernatants were removed and discharged. The pellets were resuspended in a volume of 1.5 mL, and total and differential cell counts were performed within 2 h using an automated cell counter (Sysmex, Dasit, Cornaredo, Italy). A dose–response curve was constructed for the inhibition of Ova-induced lung eosinophilia at 2 h predosing, and half-maximal effect doses (ED<sub>50</sub>) were estimated from the fitted curve.</div><div class="NLM_p last">All the experimental procedures and conditions were reviewed and approved by the local ethics committees and were performed in full compliance with the international European ethics standards (86/609-EEC), the Italian legislative decree 116/1992, the French National Committee (décret 87/848) for the care and use of laboratory animals, and the Animals (Scientific Procedures) Act of 1986.</div></div><div id="sec100" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Pharmacokinetics of (<i>S</i>*,<i>S</i>**)-18e and (<i>S</i>*,<i>S</i>**)-22e in Rats</h4><div class="NLM_p last">(<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b> were administered to Sprague–Dawley rats (250–400 g; Charles River Laboratories Italy) by the intratracheal route as micronized powder as described previously. At the time of sacrifice, blood samples were collected in heparinized tubes. The samples were immediately separated by centrifugation at 1200<i>g</i> for 15 min. Lung samples were collected at 0.25, 1, 2, 4, 8, 16, and 24 h after the administration of the test compounds (with <i>n</i> = 3 for each sampling time). Animals were sacrificed by overdose of anesthetic (4% isoflurane in 100% O<sub>2</sub>). At the time of sacrifice, the lungs were excised and washed with saline three times. A portion of lung tissue was homogenized into polypropylene tubes in three volumes of a acetonitrile/saline solution (50%/50%; v/v) using an Ultra-Turrax homogenizer (IKA-Werke GmbH, Staufen, Germany) at 3000 rpm for 30 s at room temperature. All biologic samples were then transferred into polypropylene tubes and put in the freezer at −80 °C until analysis by electrospray liquid chromatography–tandem mass spectrometry using an Alliance Waters high-pressure liquid chromatography (Waters Corporation, Milford, MA) coupled to a ABI-Sciex API2000 (AB Sciex, Framingham, MA) operated in positive ion mode.</div></div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Molecular Modeling</h3><div class="NLM_p last">PDE4B protein structures in complex with ligands were prepared using the default settings of the Protein Preparation Wizard in Maestro.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Only the water molecules that are coordinated to the metal ions or are relevant for binding in the solvent-exposed region were retained for docking. Three-dimensional structures for all ligands were generated with LigPrep,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> using Epik<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> for the determination of ligand ionization and tautomeric states. Preliminary binding poses of compound (<i>S</i>)-<b>14a</b> and (<i>S</i>*,<i>S</i>**)-<b>18b</b> in the PDE4B catalytic site were obtained with the Glide<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> standard precision (SP) mode giving the possibility to generate up to five distinct poses, which were then optimized applying the Glide XP refinement method. A visual analysis of the docked poses allowed the selection of the most relevant binding mode.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Expression, Purification, and Crystallization</h3><div class="NLM_p last">The DNA sequence encoding the human PDE4B cat-UCR2 (241–659) sequence was cloned into pFastbac1 (Life Technologies) using BamH1 and EcoR1 restriction sites. Recombinant bacmid DNA was produced according to the Bac-to-Bac baculovirus expression method. The resulting recombinant baculovirus was used to infect 1 L of suspension cultures of Sf-9 cells. Following 72 h of incubation at 27 °C, the supernatant was harvested, pelleted, and stored at −80 °C prior to purification. The pellets were resuspended in lysis buffer and mechanically broken using a continuous cell disrupter (Constant Systems) at a pressure of 20 kpsi. All purifications were subsequently carried out eluting the protein with a buffer (50 mM Tris HCl pH 8.0, 300 mM NaCl, 350 mM imidazole, 1 mM DL-dithiothreitol) directly onto a G-25 desalt column pre-equilibrated in desalt buffer (50 mM Tris HCl pH 8.0, 50 mM NaCl, 1 mM <span class="smallcaps smallerCapital">dl</span>-dithiothreitol). The elution was loaded onto a Q-sepharose HP column (GE Healthcare) and eluted with a gradient of Q Buffer B (50 mM Tris HCl pH 8.0, 500 mM NaCl, 10 mM imidazole, 1 mM <span class="smallcaps smallerCapital">dl</span>-dithiothreitol). Fractions containing PDE4B cat-UCR2 were subsequently purified by size exclusion chromatography (Superdex S100; 10 mM HEPES, 100 mM NaCl, 1 mM <span class="smallcaps smallerCapital">dl</span>-dithiothreitol). Crystals of human PDE4B cat-UCR domain (10 mg/mL) were grown at 20 °C by hanging drop vapor diffusion. Drops comprised 2 μL of protein solution mixed with a reservoir buffer consisting of 100 mM sodium acetate pH 4.5, 14% PEG400, and 50 mM calcium acetate. Crystals, up to 100 μm in the largest dimension, grew from precipitate after 1–2 weeks. Crystals were transferred to a cryoprotectant solution (100 mM sodium acetate pH 4.5, 14% PEG400, 50 mM calcium acetate, and 20% glycerol) and then flash-frozen prior to X-ray data collection.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Structure Determination</h3><div class="NLM_p last">Data were collected at the DIAMOND synchrotron on a Pilatus P2M detector on beamline I04.1 with a wavelength of 0.92 Å. Crystals of the PDE4B/(<i>S</i>*,<i>S</i>**)-<b>18e</b> complex diffracted at 1.65 Å and belonged to the <i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub> space group, with cell parameters <i>a</i> = 55.27 Å, <i>b</i> = 55.73 Å, <i>c</i> = 225.56 Å. Phasing was performed with PHASER,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and refinement was done with REFMAC.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The final model obtained an <i>R</i><sub>work</sub> of 18.4% and an <i>R</i><sub>free</sub> of 21.1%.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i76"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01044">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36040" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36040" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the ACS Publications Web site: . The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01044" class="ext-link">10.1021/acs.jmedchem.7b01044</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings and biological data (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01044/suppl_file/jm7b01044_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Synthesis and characterization of noncommercially available acids <b>13c</b> and <b>13d</b> and preparation of intermediates <b>15</b>, <b>16</b>, <b>20</b>, <b>21</b>, <b>25</b>, <b>26</b>, <b>27</b>, <b>29</b>, <b>30</b>, <b>31</b>, <b>32</b>, <b>33</b>, and <b>34</b>. Summary of crystallographic data of the hPDE4Bcat-UCR in complex with the inhibitor (<i>S</i>*,<i>S</i>**)-<b>18e</b> and refinement statistics (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01044/suppl_file/jm7b01044_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01044/suppl_file/jm7b01044_si_001.csv">jm7b01044_si_001.csv (5.96 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01044/suppl_file/jm7b01044_si_002.pdf">jm7b01044_si_002.pdf (769.27 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB code of compound (<i>S*</i>,<i>S**</i>)-<b>18e</b>: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OHJ">5OHJ</a> (see <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>).</p><div class="testing" data-doi="10.1021/acs.jmedchem.7b01044" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47760" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47760" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laura Carzaniga</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2426-1526" title="Orcid link">http://orcid.org/0000-0002-2426-1526</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b4d89ad7d5c6ced5daddd3d5f4d7dcddd1c7dd9ad7dbd9"><span class="__cf_email__" data-cfemail="d9b5f7bab8aba3b8b7b0beb899bab1b0bcaab0f7bab6b4">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elisabetta Armani</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#87e2a9e6f5eae6e9eec7e4efeee2f4eea9e4e8ea"><span class="__cf_email__" data-cfemail="690c47081b04080700290a01000c1a00470a0604">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gabriele Amari</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea Rizzi</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carmelida Capaldi</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Renato De Fanti</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eleonora Ghidini</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gino Villetti</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chiara Carnini</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nadia Moretto</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fabrizio Facchinetti</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paola Caruso</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gessica Marchini</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Loredana Battipaglia</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Riccardo Patacchini</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Valentina Cenacchi</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roberta Volta</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francesco Amadei</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alice Pappani</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Silvia Capacchi</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Valentina Bagnacani</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maurizio Delcanale</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paola Puccini</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Silvia Catinella</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maurizio Civelli</span> - <span class="hlFld-Affiliation affiliation">§Chemistry
Research and Drug Design, ∥Pharmacology and Toxicology, ‡Pharmacokinetics
Biochemistry and Metabolism, †Analytics and Early Formulations, #Project Leader Corporate
Drug Development, and ⊥Corporate Pre-Clinical R&D Director, Chiesi Farmaceutici S.p.A, Nuovo Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d81e7001-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i78">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11508" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11508" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Prof. Silvia Rivara for helpful discussion and critical reading of this manuscript and Dr. Doriano Lamba for his excellent contribution with the analysis of the crystallographic results. We acknowledge the significant technical support provided by Pier Tonino Bolzoni and Marco Bergamaschi. The crystal structure determination was handled externally at Cangenix Ltd. (Ingram Building, Park Wood Road, Canterbury, Kent, United Kingdom). The authors would like to thank the Diamond Light Source for beamtime and the staff of the I04-1 beamline for assistance with crystal testing and data collection.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i79" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i79"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i80" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i80"> Abbreviations Used</h2><tr><td class="NLM_term">ACN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">AcOH</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">AMP</td><td class="NLM_def"><p class="first last">adenosine monophosphate</p></td></tr><tr><td class="NLM_term">BOC</td><td class="NLM_def"><p class="first last"><i>tert</i>-butoxycarbonyl</p></td></tr><tr><td class="NLM_term">Boc<sub>2</sub>O</td><td class="NLM_def"><p class="first last">di-<i>tert</i>-butyl dicarbonate</p></td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">cyclic adenosine monophosphate</p></td></tr><tr><td class="NLM_term">cGMP</td><td class="NLM_def"><p class="first last">cyclic guanosine monophosphate</p></td></tr><tr><td class="NLM_term">compd</td><td class="NLM_def"><p class="first last">compound</p></td></tr><tr><td class="NLM_term">COPD</td><td class="NLM_def"><p class="first last">chronic obstructive pulmonary disease</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">DMEM</td><td class="NLM_def"><p class="first last">Dulbecco’s modified Eagle’s medium</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">EDC</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide)</p></td></tr><tr><td class="NLM_term">ESI</td><td class="NLM_def"><p class="first last">electrospray ionization</p></td></tr><tr><td class="NLM_term">Et<sub>2</sub>O</td><td class="NLM_def"><p class="first last">diethyl ether</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethyl alcohol</p></td></tr><tr><td class="NLM_term">FBS</td><td class="NLM_def"><p class="first last">fetal bovine serum</p></td></tr><tr><td class="NLM_term">FCS</td><td class="NLM_def"><p class="first last">fetal calf serum</p></td></tr><tr><td class="NLM_term">FEV1</td><td class="NLM_def"><p class="first last">forced expiratory volume</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">iPr<sub>2</sub>NH</td><td class="NLM_def"><p class="first last">diisopropylamine</p></td></tr><tr><td class="NLM_term">iPrO<sub>2</sub></td><td class="NLM_def"><p class="first last">diisopropyl ether</p></td></tr><tr><td class="NLM_term">iPrOH</td><td class="NLM_def"><p class="first last">isopropyl alcohol</p></td></tr><tr><td class="NLM_term">LARBS</td><td class="NLM_def"><p class="first last">low-affinity rolipram binding site</p></td></tr><tr><td class="NLM_term">LC–MS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">LPS</td><td class="NLM_def"><p class="first last">lipopolysaccharides</p></td></tr><tr><td class="NLM_term"><i>m</i>CPBA</td><td class="NLM_def"><p class="first last"><i>meta</i>-chloroperoxybenzoic acid</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methyl alcohol</p></td></tr><tr><td class="NLM_term">MRT</td><td class="NLM_def"><p class="first last">mean residence time</p></td></tr><tr><td class="NLM_term">NADPH</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide phosphate reduced form</p></td></tr><tr><td class="NLM_term">NEAA</td><td class="NLM_def"><p class="first last">nonesssential amino acids</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood mononuclear cell</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate buffer saline</p></td></tr><tr><td class="NLM_term">PDE4</td><td class="NLM_def"><p class="first last">phosphodiesterase-4</p></td></tr><tr><td class="NLM_term">Pgp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">PPB</td><td class="NLM_def"><p class="first last">plasma protein binding</p></td></tr><tr><td class="NLM_term">RPMI</td><td class="NLM_def"><p class="first last">Roswell Park Memorial Institute</p></td></tr><tr><td class="NLM_term">tR</td><td class="NLM_def"><p class="first last">retention time</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin layer chromatography</p></td></tr><tr><td class="NLM_term">TNF-α</td><td class="NLM_def"><p class="first last">tumor necrosis factor-alpha</p></td></tr><tr><td class="NLM_term">TWC</td><td class="NLM_def"><p class="first last">total white cells</p></td></tr><tr><td class="NLM_term">UCR2</td><td class="NLM_def"><p class="first last">upstream conserved region 2</p></td></tr><tr><td class="NLM_term">XRD</td><td class="NLM_def"><p class="first last">X-ray diffraction</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i81">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17633" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17633" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 32 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Francis, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houslay, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conti, M.</span><span> </span><span class="NLM_article-title">Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action</span> <span class="citation_source-journal">Handb. Exp. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">204</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span><span class="refDoi"> DOI: 10.1007/978-3-642-17969-3_2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1007%2F978-3-642-17969-3_2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=21695635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFChsLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2011&pages=47-84&author=S.+H.+Francisauthor=M.+D.+Houslayauthor=M.+Conti&title=Phosphodiesterase+inhibitors%3A+factors+that+influence+potency%2C+selectivity%2C+and+action&doi=10.1007%2F978-3-642-17969-3_2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action</span></div><div class="casAuthors">Francis, Sharron H.; Houslay, Miles D.; Conti, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">Phosphodiesterases as Drug Targets</span>),
    <span class="NLM_cas:pages">47-84</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotide phosphodiesterases (PDEs) are promising targets for pharmacol. intervention.  The presence of multiple PDE genes, diversity of the isoforms produced from each gene, selective tissue and cellular expression of the isoforms, compartmentation within cells, and an array of conformations of PDE proteins are some of the properties that challenge the development of drugs that target these enzymes.  Nevertheless, many of the characteristics of PDEs are also viewed as unique opportunities to increase specificity and selectivity when designing novel compds. for certain therapeutic indications.  This chapter provides a summary of the major concepts related to the design and use of PDE inhibitors.  The overall structure and properties of the catalytic domain and conformations of PDEs are summarized in light of the most recent X-ray crystal structures.  The distinctive properties of catalytic domains of different families as well as the tech. challenges assocd. with probing PDE properties and their interactions with small mols. are discussed.  The effect of posttranslational modifications and protein-protein interactions are addnl. factors to be considered when designing PDE inhibitors.  PDE inhibitor interaction with other proteins needs to be taken into account and is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcHpr3Mz9BKbVg90H21EOLACvtfcHk0lg25SRsgQYnrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFChsLnP&md5=f0d9d5b89ecdd7a7fafad766ef5295c8</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-17969-3_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-17969-3_2%26sid%3Dliteratum%253Aachs%26aulast%3DFrancis%26aufirst%3DS.%2BH.%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26aulast%3DConti%26aufirst%3DM.%26atitle%3DPhosphodiesterase%2520inhibitors%253A%2520factors%2520that%2520influence%2520potency%252C%2520selectivity%252C%2520and%2520action%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2011%26volume%3D204%26spage%3D47%26epage%3D84%26doi%3D10.1007%2F978-3-642-17969-3_2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Hatzelmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morcillo, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lungarella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnot, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanjar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beume, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schudt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenor, H.</span><span> </span><span class="NLM_article-title">The preclinical pharmacology of roflumilast – a selective oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Pulm. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span><span class="refDoi"> DOI: 10.1016/j.pupt.2010.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1016%2Fj.pupt.2010.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=20381629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlWqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=235-256&author=A.+Hatzelmannauthor=E.+J.+Morcilloauthor=G.+Lungarellaauthor=S.+Adnotauthor=S.+Sanjarauthor=R.+Beumeauthor=C.+Schudtauthor=H.+Tenor&title=The+preclinical+pharmacology+of+roflumilast+%E2%80%93+a+selective+oral+phosphodiesterase+4+inhibitor+in+development+for+chronic+obstructive+pulmonary+disease&doi=10.1016%2Fj.pupt.2010.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The preclinical pharmacology of roflumilast - A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Hatzelmann, Armin; Morcillo, Esteban J.; Lungarella, Giuseppe; Adnot, Serge; Sanjar, Shahin; Beume, Rolf; Schudt, Christian; Tenor, Hermann</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-256</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  After more than two decades of research into phosphodiesterase 4 (PDE4) inhibitors, roflumilast (3-cyclopropylmethoxy-4-difluoromethoxy-N-[3,5-di-chloropyrid-4-yl]-benzamide) may become the first agent in this class to be approved for patient treatment worldwide.  Within the PDE family of 11 known isoenzymes, roflumilast is selective for PDE4, showing balanced selectivity for subtypes A-D, and is of high subnanomolar potency.  The active principle of roflumilast in man is its dichloropyridyl N-oxide metabolite, which has similar potency as a PDE4 inhibitor as the parent compd.  The long half-life and high potency of this metabolite allows for once-daily, oral administration of a single, 500-μg tablet of roflumilast.  The mol. mode of action of roflumilast - PDE4 inhibition and subsequent enhancement of cAMP levels - is well established.  To further understand its functional mode of action in chronic obstructive pulmonary disease (COPD), for which roflumilast is being developed, a series of in vitro and in vivo preclin. studies has been performed.  COPD is a progressive, devastating condition of the lung assocd. with an abnormal inflammatory response to noxious particles and gases, particularly tobacco smoke.  In addn., according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), significant extrapulmonary effects, including comorbidities, may add to the severity of the disease in individual patients, and which may be addressed preferentially by orally administered remedies.  COPD shows an increasing prevalence and mortality, and its treatment remains a high, unmet medical need.  In vivo, roflumilast mitigates key COPD-related disease mechanisms such as tobacco smoke-induced lung inflammation, mucociliary malfunction, lung fibrotic and emphysematous remodelling, oxidative stress, pulmonary vascular remodelling and pulmonary hypertension.  In vitro, roflumilast N-oxide has been demonstrated to affect the functions of many cell types, including neutrophils, monocytes/macrophages, CD4+ and CD8+ T-cells, endothelial cells, epithelial cells, smooth muscle cells and fibroblasts.  These cellular effects are thought to be responsible for the beneficial effects of roflumilast on the disease mechanisms of COPD, which translate into reduced exacerbations and improved lung function.  As a multicomponent disease, COPD requires a broad therapeutic approach that might be achieved by PDE4 inhibition.  However, as a PDE4 inhibitor, roflumilast is not a direct bronchodilator.  In summary, roflumilast may be the first-in-class PDE4 inhibitor for COPD therapy.  In addn. to being a non-steroid, anti-inflammatory drug designed to target pulmonary inflammation, the preclin. pharmacol. described in this review points to a broad functional mode of action of roflumilast that putatively addresses addnl. COPD mechanisms.  This enables roflumilast to offer effective, oral maintenance treatment for COPD, with an acceptable tolerability profile and the potential to favorably affect the extrapulmonary effects of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDAicMKzimBbVg90H21EOLACvtfcHk0lheHmnNFiB4Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlWqur8%253D&md5=ada4424630713054cefe9a6f5c98121b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2010.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2010.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DHatzelmann%26aufirst%3DA.%26aulast%3DMorcillo%26aufirst%3DE.%2BJ.%26aulast%3DLungarella%26aufirst%3DG.%26aulast%3DAdnot%26aufirst%3DS.%26aulast%3DSanjar%26aufirst%3DS.%26aulast%3DBeume%26aufirst%3DR.%26aulast%3DSchudt%26aufirst%3DC.%26aulast%3DTenor%26aufirst%3DH.%26atitle%3DThe%2520preclinical%2520pharmacology%2520of%2520roflumilast%2520%25E2%2580%2593%2520a%2520selective%2520oral%2520phosphodiesterase%25204%2520inhibitor%2520in%2520development%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2010%26volume%3D23%26spage%3D235%26epage%3D256%26doi%3D10.1016%2Fj.pupt.2010.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Parikh, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakraborti, A. K.</span><span> </span><span class="NLM_article-title">Phosphodiesterase 4 (PDE4) inhibitors in the treatment of COPD: promising drug candidates and future directions</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span><span class="refDoi"> DOI: 10.2174/0929867323666151117121334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.2174%2F0929867323666151117121334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=26572614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Oiu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=129-141&issue=2&author=N.+Parikhauthor=A.+K.+Chakraborti&title=Phosphodiesterase+4+%28PDE4%29+inhibitors+in+the+treatment+of+COPD%3A+promising+drug+candidates+and+future+directions&doi=10.2174%2F0929867323666151117121334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 4 (PDE4) Inhibitors in the Treatment of COPD: Promising Drug Candidates and Future Directions</span></div><div class="casAuthors">Parikh, Naisargee; Chakraborti, Asit K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The PDE4 enzyme has been proven to be a versatile drug target for therapeutics to treat diverse disease conditions such as asthma, COPD, diabetes, Huntington's disease, and various other inflammatory disorders.  The treatment of COPD is the most studied utility for PDE4 inhibitors due to their ability to inhibit inflammatory cell responses.  Roflumilast is the only approved drug belonging to this class to treat COPD and has shown significant results in the treatment of asthmatic patients.  This perspective highlights the pharmacol. details of roflumilast and cilomilast.  Moreover, efforts have been made to justify the superiority of roflumilast over cilomilast by detailed comparison of their pharmacol., pharmacokinetic, pharmacodynamic properties and structural features.  Several other mols., with promising PDE4 inhibitory activity have also been highlighted.  Commonly assocd. side effects with this class of compds., their management, and future direction towards the development of PDE4 inhibitors with improved therapeutic index are the focus of this perspective.  More emphasis has been given towards the future development strategies to limit the side effects such as emesis and to achieve better benefit to risk ratio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHRuuoQ7II8rVg90H21EOLACvtfcHk0lheHmnNFiB4Bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Oiu70%253D&md5=b7901858db904fcd9a714b2b5d9ec9ef</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F0929867323666151117121334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867323666151117121334%26sid%3Dliteratum%253Aachs%26aulast%3DParikh%26aufirst%3DN.%26aulast%3DChakraborti%26aufirst%3DA.%2BK.%26atitle%3DPhosphodiesterase%25204%2520%2528PDE4%2529%2520inhibitors%2520in%2520the%2520treatment%2520of%2520COPD%253A%2520promising%2520drug%2520candidates%2520and%2520future%2520directions%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2016%26volume%3D23%26issue%3D2%26spage%3D129%26epage%3D141%26doi%3D10.2174%2F0929867323666151117121334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Giembycz, M. A.</span><span> </span><span class="NLM_article-title">Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimizm or wishful thinking?</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">155</span><span class="NLM_x">, </span> <span class="NLM_fpage">288</span><span class="NLM_x">–</span> <span class="NLM_lpage">290</span><span class="refDoi"> DOI: 10.1038/bjp.2008.297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1038%2Fbjp.2008.297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=18660832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFKkurbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2008&pages=288-290&author=M.+A.+Giembycz&title=Can+the+anti-inflammatory+potential+of+PDE4+inhibitors+be+realized%3A+guarded+optimizm+or+wishful+thinking%3F&doi=10.1038%2Fbjp.2008.297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?</span></div><div class="casAuthors">Giembycz, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">288-290</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  PDE4 inhibitors have been in development as a novel anti-inflammatory therapy since the 1980s with asthma and chronic obstructive pulmonary disease (COPD) being primary indications.  Despite initial optimism, none have yet reached the market.  In most cases, the development of PDE4 inhibitors of various structural classes, including cilomilast, filaminast, lirimilast, piclamilast, tofimilast, AWD-12-281 (aka GSK 842470), CDP840, CI-1018, D-4418, IC485, L-826,141, SCH 351391 and V11294A has been discontinued due to lack of efficacy.  A primary problem is the low therapeutic ratio of these compds., which severely limits the dose that can be given.  Indeed, for many of these compds. it is likely that the max. tolerated dose is either sub-therapeutic or at the very bottom of the efficacy dose-response curve.  Therefore, the challenge is to overcome this limitation.  It is, therefore, encouraging that many new(er)' PDE4 inhibitors in development are reported to have an improved therapeutic window including tetomilast, oglemilast, apremilast, ONO 6126, IPL-512602 and IPL-455903 (aka HT-0712), although the basis for their superior tolerability has not been disclosed.  In addn., other approaches are possible that may allow the anti-inflammatory activity of PDE inhibitors to be realized.  Accordingly, this Commentary endorses the view of Spina (2008), published in the current issue of the British Journal of Pharmacol., that the therapeutic utility of PDE4 inhibitors to suppress inflammation still remains a viable concept.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV0IqM4s41YrVg90H21EOLACvtfcHk0ljOs1qVYewxgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFKkurbP&md5=b7209db766a51ebbdf0bf9752635540a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.297%26sid%3Dliteratum%253Aachs%26aulast%3DGiembycz%26aufirst%3DM.%2BA.%26atitle%3DCan%2520the%2520anti-inflammatory%2520potential%2520of%2520PDE4%2520inhibitors%2520be%2520realized%253A%2520guarded%2520optimizm%2520or%2520wishful%2520thinking%253F%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D155%26spage%3D288%26epage%3D290%26doi%3D10.1038%2Fbjp.2008.297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Giembycz, M. A.</span><span> </span><span class="NLM_article-title">An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">138</span><span class="NLM_x">–</span> <span class="NLM_lpage">152</span><span class="refDoi"> DOI: 10.1111/j.1365-2125.2006.02640.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1111%2Fj.1365-2125.2006.02640.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=16842388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVersr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=138-152&issue=2&author=M.+A.+Giembycz&title=An+update+and+appraisal+of+the+cilomilast+Phase+III+clinical+development+programme+for+chronic+obstructive+pulmonary+disease&doi=10.1111%2Fj.1365-2125.2006.02640.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Giembycz, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">138-152</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Cilomilast (Ariflo, SB 207499) is an orally active, second-generation phosphodiesterase (PDE) 4 inhibitor that is being developed by GlaxoSmithkline for the treatment of chronic obstructive pulmonary disease (COPD).  The results of Phase I and Phase II studies have demonstrated that cilomilast significantly improves lung function and quality of life to a clin. meaningful extent, which has led to a comprehensive Phase III program of research evaluating efficacy, safety and mechanism of action.  However, the results of those Phase III studies are unremarkable and disappointing, raising doubt over the future of cilomilast as a novel therapy for COPD.  This review summarizes data obtained from the Phase III clin. development program, highlights some of the potential concerns both specific to cilomilast and to PDE4 inhibitors in general and assesses the likelihood that cilomilast will reach the market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG3j4h3elSNrVg90H21EOLACvtfcHk0ljOs1qVYewxgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVersr8%253D&md5=0d8f4c3833a446ed6a43cc9b355a2c46</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2006.02640.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2006.02640.x%26sid%3Dliteratum%253Aachs%26aulast%3DGiembycz%26aufirst%3DM.%2BA.%26atitle%3DAn%2520update%2520and%2520appraisal%2520of%2520the%2520cilomilast%2520Phase%2520III%2520clinical%2520development%2520programme%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2006%26volume%3D62%26issue%3D2%26spage%3D138%26epage%3D152%26doi%3D10.1111%2Fj.1365-2125.2006.02640.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Giembycz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Field, S. K.</span><span> </span><span class="NLM_article-title">Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD</span> <span class="citation_source-journal">Drug Des., Dev. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">158</span><span class="refDoi"> DOI: 10.2147/DDDT.S7667</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.2147%2FDDDT.S7667" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=20689641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlGrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=147-158&author=M.+A.+Giembyczauthor=S.+K.+Field&title=Roflumilast%3A+first+phosphodiesterase+4+inhibitor+approved+for+treatment+of+COPD&doi=10.2147%2FDDDT.S7667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD</span></div><div class="casAuthors">Giembycz, Mark A.; Field, Stephen K.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">147-158</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  In Apr. 2010, the European Medicines Agency Committee for Medicinal Products for Human Use recommended approval of roflumilast, a selective phosphodiesterase 4 inhibitor, for the "maintenance treatment of severe chronic obstructive pulmonary disease (COPD, FEV1 postbronchodilator less than 50% predicted) assocd. with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment".  This decision was based, in part, on the results of several large, international, multicenter, randomized, placebo-controlled trials of either six or 12 mo' duration that had been undertaken in COPD patients.  Roflumilast 500 μg daily improved lung function and reduced exacerbations in patients with more severe COPD, esp. those with chronic bronchitis, frequent exacerbations, or who required frequent rescue inhaler therapy in the placebo-controlled trials.  It also improved lung function and reduced exacerbations in patients with moderately severe COPD treated with salmeterol or tiotropium.  Advantages of roflumilast over inhaler therapy are that it is an oral tablet and only needs to be taken once daily.  While taking roflumilast, the most common adverse effects patients experienced were gastrointestinal upset and headache.  Wt. loss, averaging 2.2 kg, occurred in patients treated with roflumilast.  Patients taking roflumilast were more likely to drop out of the trials than patients in the control groups.  Patients who discontinued therapy usually did so during the first few weeks and were more likely to have experienced gastrointestinal side effects.  Roflumilast is the first selective phosphodiesterase 4 inhibitor and will offer physicians another treatment option for patients with more severe COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSnapbPDMvA7Vg90H21EOLACvtfcHk0ljOs1qVYewxgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlGrtLY%253D&md5=d60f2905011c4ff5706f31f789520784</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S7667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S7667%26sid%3Dliteratum%253Aachs%26aulast%3DGiembycz%26aufirst%3DM.%2BA.%26aulast%3DField%26aufirst%3DS.%2BK.%26atitle%3DRoflumilast%253A%2520first%2520phosphodiesterase%25204%2520inhibitor%2520approved%2520for%2520treatment%2520of%2520COPD%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2010%26volume%3D4%26spage%3D147%26epage%3D158%26doi%3D10.2147%2FDDDT.S7667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Schett, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloan, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schafer, P.</span><span> </span><span class="NLM_article-title">Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases</span> <span class="citation_source-journal">Ther. Adv. Musculoskeletal Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">278</span><span class="refDoi"> DOI: 10.1177/1759720X10381432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1177%2F1759720X10381432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=22870453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1WgtbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=271-278&issue=5&author=G.+Schettauthor=V.+S.+Sloanauthor=R.+M.+Stevensauthor=P.+Schafer&title=Apremilast%3A+a+novel+PDE4+inhibitor+in+the+treatment+of+autoimmune+and+inflammatory+diseases&doi=10.1177%2F1759720X10381432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases</span></div><div class="casAuthors">Schett, Georg; Stoan, Victor S.; Stevens, Randall M.; Schafer, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Musculoskeletal Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">271-278</span>CODEN:
                <span class="NLM_cas:coden">TAMDDB</span>;
        ISSN:<span class="NLM_cas:issn">1759-720X</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterase k (PDEA) is a key enzyme in the degrdn. of cyclic adenosine monophosphate and is centrally involved in the cytokine prodn. of inflammatory cells, angiogenesis, and the functional properties of other cell types such as keratinocytes.  In this review article, apremilast, a novel small mol. inhibitor of PDE4, is introduced.  Apremilast has profound anti-inflammatory properties in animal models of inflammatory disease, as well as human chronic inflammatory diseases such as psoriasis and psoriatic arthritis.  Apremilast blocks the synthesis of several pro-inflammatory cytokines and chemokines, such as tumor necrosis factor alpha, interleukin 23, CXCL9, and CXCL10 in multiple cell types.  In contrast to the biologics, which neutralize pro-inflammatory mediators at the protein level, apremilast modulates prodn. of these mediators at the level of mRNA expression.  Apremilast also interferes with the prodn. of leukotriene B4, inducible nitric oxide synthase, and matrix metalloproteinase and reduces complex inflammatory processes, such as dendritic cell infiltration, epidermal skin thickening, and joint destruction.  As this novel PDE4 inhibitor interferes with several key processes of inflammation, it may emerge as a promising new drug for the treatment of chronic inflammatory diseases such as those of the skin and the joints.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYW_Pi4RaIhrVg90H21EOLACvtfcHk0ljOs1qVYewxgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1WgtbjF&md5=be31ae98aafeedb881815c8c1c9f22fc</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1177%2F1759720X10381432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1759720X10381432%26sid%3Dliteratum%253Aachs%26aulast%3DSchett%26aufirst%3DG.%26aulast%3DSloan%26aufirst%3DV.%2BS.%26aulast%3DStevens%26aufirst%3DR.%2BM.%26aulast%3DSchafer%26aufirst%3DP.%26atitle%3DApremilast%253A%2520a%2520novel%2520PDE4%2520inhibitor%2520in%2520the%2520treatment%2520of%2520autoimmune%2520and%2520inflammatory%2520diseases%26jtitle%3DTher.%2520Adv.%2520Musculoskeletal%2520Dis.%26date%3D2010%26volume%3D2%26issue%3D5%26spage%3D271%26epage%3D278%26doi%3D10.1177%2F1759720X10381432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Kroegel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foerster, M.</span><span> </span><span class="NLM_article-title">Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span><span class="refDoi"> DOI: 10.1517/13543784.16.1.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1517%2F13543784.16.1.109" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=109-24&issue=1&author=C.+Kroegelauthor=M.+Foerster&title=Phosphodiesterase-4+inhibitors+as+a+novel+approach+for+the+treatment+of+respiratory+disease%3A+cilomilast&doi=10.1517%2F13543784.16.1.109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1517%2F13543784.16.1.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.16.1.109%26sid%3Dliteratum%253Aachs%26aulast%3DKroegel%26aufirst%3DC.%26aulast%3DFoerster%26aufirst%3DM.%26atitle%3DPhosphodiesterase-4%2520inhibitors%2520as%2520a%2520novel%2520approach%2520for%2520the%2520treatment%2520of%2520respiratory%2520disease%253A%2520cilomilast%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D16%26issue%3D1%26spage%3D109%26epage%3D24%26doi%3D10.1517%2F13543784.16.1.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Robichaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savoie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamatiou, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachance, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolicoeur, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasori, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, C. C.</span><span> </span><span class="NLM_article-title">Assessing the emetic potential of PDE4 inhibitors in rats</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">135</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span><span class="refDoi"> DOI: 10.1038/sj.bjp.0704457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1038%2Fsj.bjp.0704457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=11786486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVegug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2002&pages=113-118&issue=1&author=A.+Robichaudauthor=C.+Savoieauthor=P.+B.+Stamatiouauthor=N.+Lachanceauthor=P.+Jolicoeurauthor=R.+Rasoriauthor=C.+C.+Chan&title=Assessing+the+emetic+potential+of+PDE4+inhibitors+in+rats&doi=10.1038%2Fsj.bjp.0704457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing the emetic potential of PDE4 inhibitors in rats</span></div><div class="casAuthors">Robichaud, A.; Savoie, C.; Stamatiou, P. B.; Lachance, N.; Jolicoeur, P.; Rasori, R.; Chan, C. C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-118</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Type 4 phosphodiesterase (PDE4) inhibitors mimic the pharmacol. actions of alpha2-adrenoceptor antagonists.  This has been postulated as the mechanism by which PDE4 inhibitors induce emesis and was also demonstrated by their ability to reverse xylazine/ketamine-induced anesthesia.  We further characterized this latter effect since it appears to reflect the emetic potential of PDE4 inhibitors.  Selective inhibitors of PDE 1, 2, 3, 4 and 5 were studied in rats, on the duration of anesthesia induced by the combination of xylazine (10 mg kg-1, i.m.) and ketamine (10 mg kg-1, i.m.).  PMNPQ ((i.e. 6-(4-pyridylmethyl)-8-(3-nitrophenyl)quinoline) - PDE4 inhibitor 0.01-3 mg kg-1), like MK-912 (alpha2-adrenoceptor antagonist: 0.01-3 mg kg-1), dose-dependently reduced the duration of anesthesia.  In contrast, vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor), milrinone (PDE3 inhibitor) and zaprinast (PDE5 inhibitor) had no significant effect at the doses tested (1-10 mg kg-1).  Anal. of plasma and cerebrospinal fluid (CSF) of treated animals confirmed the absorption and distribution to the brain of the inactive inhibitors.  Neither MK-912 (3 mg kg-1) nor PMNPQ (0.1-1 mg kg-1) altered the duration of anesthesia induced via a non-alpha2-adrenoceptor pathway (sodium pentobarbitone 50 mg kg-1, i.p.).  Central NK1 receptors are involved in PDE4 inhibitor-induced emesis.  Consistently, [sar9, Met(O2)11]-substance P (NK1 receptor agonist, 6 μg i.c.v.) reduced the duration of anesthesia induced by xylazine/ketamine.  In summary, this model is functionally coupled to PDE4, specific to alpha2-adrenoceptors and relevant to PDE4 inhibitor-induced emesis.  It therefore provides a novel way of evaluating the emetic potential of PDE4 inhibitors in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhFBpxwaft4bVg90H21EOLACvtfcHk0lg2B3oxLMeuiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVegug%253D%253D&md5=ce6141bb9867f3b9e469bc72393d33e7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0704457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0704457%26sid%3Dliteratum%253Aachs%26aulast%3DRobichaud%26aufirst%3DA.%26aulast%3DSavoie%26aufirst%3DC.%26aulast%3DStamatiou%26aufirst%3DP.%2BB.%26aulast%3DLachance%26aufirst%3DN.%26aulast%3DJolicoeur%26aufirst%3DP.%26aulast%3DRasori%26aufirst%3DR.%26aulast%3DChan%26aufirst%3DC.%2BC.%26atitle%3DAssessing%2520the%2520emetic%2520potential%2520of%2520PDE4%2520inhibitors%2520in%2520rats%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D135%26issue%3D1%26spage%3D113%26epage%3D118%26doi%3D10.1038%2Fsj.bjp.0704457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Wedzicha, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calverley, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabe, K. F.</span><span> </span><span class="NLM_article-title">Roflumilast: a review of its use in the treatment of COPD</span> <span class="citation_source-journal">Int. J. Chronic Obstruct. Pulm. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span><span class="refDoi"> DOI: 10.2147/COPD.S89849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.2147%2FCOPD.S89849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=26792988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmt1elsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=81-90&author=J.+A.+Wedzichaauthor=P.+M.+Calverleyauthor=K.+F.+Rabe&title=Roflumilast%3A+a+review+of+its+use+in+the+treatment+of+COPD&doi=10.2147%2FCOPD.S89849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Roflumilast: a review of its use in the treatment of COPD</span></div><div class="casAuthors">Wedzicha, Jadwiga A.; Calverley, Peter M. A.; Rabe, Klaus F.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Chronic Obstructive Pulmonary Disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-90</span>CODEN:
                <span class="NLM_cas:coden">IJCOC3</span>;
        ISSN:<span class="NLM_cas:issn">1178-2005</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">COPD is a progressive condition involving chronic inflammation and parenchymal destruction with resulting airflow limitation.  COPD is assocd. with worsening airflow limitation over time and increased frequency of COPD exacerbations, leading to increased mortality and morbidity.  The effects of COPD extend beyond the lungs, as multiple comorbidities may occur with COPD, including cardiovascular disease, diabetes mellitus, osteoporosis, depression, and pneumonia.  COPD exacerbations are assocd. with a rapid worsening of baseline symptoms that requires prompt management and may necessitate hospitalization in the case of a severe episode.  Patients with COPD exacerbations require urgent management of symptoms to prevent further worsening, and preventative steps may be taken to help reduce the no. and frequency of future exacerbations.  Roflumilast is a potent and selective inhibitor of the enzyme phosphodiesterase-4 that targets the systemic inflammation assocd. with COPD.  Roflumilast has a variety of anti-inflammatory effects including decreasing inflammatory mediators and the expression of cell surface markers and inhibition of apoptosis.  Several clin. trials evaluating roflumilast in the treatment of COPD have demonstrated significant improvements from baseline vs. placebo in lung function, including increases in mean pre- and postbronchodilator forced expiratory vol. in 1 s and forced vital capacity.  Data suggest that roflumilast reduces moderate to severe exacerbations with the benefit most well established in patients with severe disease.  Given this evidence, roflumilast, as part of a combination regimen with long-acting bronchodilators, appears to be a reasonable treatment option for patients with severe to very severe COPD assocd. with chronic bronchitis and a history of exacerbations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTmDAT45ELHrVg90H21EOLACvtfcHk0lg2B3oxLMeuiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmt1elsL0%253D&md5=82f632fd0c400d17ca28e10688997904</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S89849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S89849%26sid%3Dliteratum%253Aachs%26aulast%3DWedzicha%26aufirst%3DJ.%2BA.%26aulast%3DCalverley%26aufirst%3DP.%2BM.%26aulast%3DRabe%26aufirst%3DK.%2BF.%26atitle%3DRoflumilast%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520the%2520treatment%2520of%2520COPD%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2016%26volume%3D11%26spage%3D81%26epage%3D90%26doi%3D10.2147%2FCOPD.S89849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Matera, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogliani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calzetta, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cazzola, M.</span><span> </span><span class="NLM_article-title">Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold?</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1983</span><span class="NLM_x">–</span> <span class="NLM_lpage">1992</span><span class="refDoi"> DOI: 10.1007/s40265-014-0303-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1007%2Fs40265-014-0303-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1983-1992&author=M.+G.+Materaauthor=P.+Roglianiauthor=L.+Calzettaauthor=M.+Cazzola&title=Phosphodiesterase+inhibitors+for+chronic+obstructive+pulmonary+disease%3A+what+does+the+future+hold%3F&doi=10.1007%2Fs40265-014-0303-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0303-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0303-8%26sid%3Dliteratum%253Aachs%26aulast%3DMatera%26aufirst%3DM.%2BG.%26aulast%3DRogliani%26aufirst%3DP.%26aulast%3DCalzetta%26aufirst%3DL.%26aulast%3DCazzola%26aufirst%3DM.%26atitle%3DPhosphodiesterase%2520inhibitors%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520what%2520does%2520the%2520future%2520hold%253F%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D1983%26epage%3D1992%26doi%3D10.1007%2Fs40265-014-0303-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Pinner, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, A.</span><span> </span><span class="NLM_article-title">Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">66</span><span class="refDoi"> DOI: 10.1016/j.clinthera.2011.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1016%2Fj.clinthera.2011.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=22284994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVektb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2012&pages=56-66&issue=1&author=N.+A.+Pinnerauthor=L.+A.+Hamiltonauthor=A.+Hughes&title=Roflumilast%3A+a+phosphodiesterase-4+inhibitor+for+the+treatment+of+severe+chronic+obstructive+pulmonary+disease&doi=10.1016%2Fj.clinthera.2011.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Roflumilast: A Phosphodiesterase-4 Inhibitor for the Treatment of Severe Chronic Obstructive Pulmonary Disease</span></div><div class="casAuthors">Pinner, Nathan A.; Hamilton, Leslie A.; Hughes, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-66</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background: Roflumilast is a newly approved phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease (COPD) assocd. with chronic bronchitis and a history of exacerbations.  Objective: The objective of this article is to review the pharmacol., clin. efficacy, and tolerability of roflumilast in the treatment of COPD.  Methods: Articles were identified using MEDLINE (1966-August 1, 2011) and EMBASE (1947-August 1, 2011).  Searches were conducted using the terms roflumilast and COPD.  Included in the search were all English-language clin. trials that were randomized, had durations of >6 wk, and studied the effects of roflumilast on the forced expiratory vol. in 1 s (FEV1) or rates of exacerbations in patients with COPD.  Abstrs. from the annual meetings of the American Thoracic Society, American College of Chest Physicians, and European Respiratory Society were also searched to identify relevant publications.  In addn., all pertinent studies evaluating the pharmacokinetics and pharmacodynamics of roflumilast were included.  Results: A total of 6 clin. trials (4 publications) evaluating the efficacy of roflumilast were identified and included.  For the treatment of COPD, roflumilast was assocd. with a significant improvement in lung function (increase in FEV1 of 36-88 mL) when compared with placebo.  Roflumilast also reduced the rate of exacerbations in subsets of patients with chronic cough and a history of exacerbations.  Overall, health-related quality of life was not significantly affected.  Adverse effects were common in clin. trials, with 9% to 16% of patients discontinuing therapy as a result.  The most frequently reported adverse effects were gastrointestinal issues, headache, and wt. loss.  Suicide-related adverse effects have occurred in 5 patients receiving roflumilast and 1 patient receiving placebo.  Conclusion: Roflumilast significantly improved FEV1 in clin. trials but had inconsistent redns. in the rates of exacerbations.  Comparative studies with recommended therapies for COPD, particularly inhaled corticosteroids, are needed to better assess the role of roflumilast in the management of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAquCjqobFO7Vg90H21EOLACvtfcHk0lhnM4i3SH22cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVektb0%253D&md5=32cdf18496bb91887c4dfe5774b101da</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2011.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2011.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DPinner%26aufirst%3DN.%2BA.%26aulast%3DHamilton%26aufirst%3DL.%2BA.%26aulast%3DHughes%26aufirst%3DA.%26atitle%3DRoflumilast%253A%2520a%2520phosphodiesterase-4%2520inhibitor%2520for%2520the%2520treatment%2520of%2520severe%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DClin.%2520Ther.%26date%3D2012%26volume%3D34%26issue%3D1%26spage%3D56%26epage%3D66%26doi%3D10.1016%2Fj.clinthera.2011.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Gutke, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guse, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khobzaoui, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renukappa-Gutke, T.</span><span> </span><span class="NLM_article-title">Burnet, M. AWD-12–281 (inhaled) (elbion/GlaxoSmithKline)</span> <span class="citation_source-journal">Curr. Opin. Investig. Drugs.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1149</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=1149-58&author=H.+J.+Gutkeauthor=J.+H.+Guseauthor=M.+Khobzaouiauthor=T.+Renukappa-Gutke&title=Burnet%2C+M.+AWD-12%E2%80%93281+%28inhaled%29+%28elbion%2FGlaxoSmithKline%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGutke%26aufirst%3DH.%2BJ.%26aulast%3DGuse%26aufirst%3DJ.%2BH.%26aulast%3DKhobzaoui%26aufirst%3DM.%26aulast%3DRenukappa-Gutke%26aufirst%3DT.%26atitle%3DBurnet%252C%2520M.%2520AWD-12%25E2%2580%2593281%2520%2528inhaled%2529%2520%2528elbion%252FGlaxoSmithKline%2529%26jtitle%3DCurr.%2520Opin.%2520Investig.%2520Drugs.%26date%3D2005%26volume%3D6%26spage%3D1149%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Danto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, J.</span><span> </span><span class="NLM_article-title">A randomized, double-blind, placebocontrolled, parallel group, six-week study of the efficacy and safety of tofimilast dry powder for inhalation (DPI) in adults with COPD</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">A131</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2007&pages=A131&author=S.+Dantoauthor=G.+C.+Weiauthor=J.+Gill&title=A+randomized%2C+double-blind%2C+placebocontrolled%2C+parallel+group%2C+six-week+study+of+the+efficacy+and+safety+of+tofimilast+dry+powder+for+inhalation+%28DPI%29+in+adults+with+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDanto%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DG.%2BC.%26aulast%3DGill%26aufirst%3DJ.%26atitle%3DA%2520randomized%252C%2520double-blind%252C%2520placebocontrolled%252C%2520parallel%2520group%252C%2520six-week%2520study%2520of%2520the%2520efficacy%2520and%2520safety%2520of%2520tofimilast%2520dry%2520powder%2520for%2520inhalation%2520%2528DPI%2529%2520in%2520adults%2520with%2520COPD%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2007%26volume%3D175%26spage%3DA131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Vestbo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkinson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, J.</span><span> </span><span class="NLM_article-title">A controlled trial of 6-weeks’ treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1044</span><span class="refDoi"> DOI: 10.1183/09031936.00068908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1183%2F09031936.00068908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=19213793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtFahtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2009&pages=1039-1044&author=J.+Vestboauthor=L.+Tanauthor=G.+Atkinsonauthor=J.+Ward&title=A+controlled+trial+of+6-weeks%E2%80%99+treatment+with+a+novel+inhaled+phosphodiesterase+type-4+inhibitor+in+COPD&doi=10.1183%2F09031936.00068908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD</span></div><div class="casAuthors">Vestbo, J.; Tan, L.; Atkinson, G.; Ward, J.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1039-1044</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Anti-inflammatory drugs are lacking in chronic obstructive pulmonary disease (COPD) and inhibitors of the phosphodiesterase type-4 (PDE4) enzyme have been suggested to be an interesting class of drugs to treat inflammation in COPD.  The present authors report the findings of a phase II trial of a novel inhaled PDE4 inhibitor.  Three doses, 0.1, 0.4 and 1.0 mg b.i.d., of the compd. UK-500,001 were tested in a double-blind, placebo-controlled, 6-wk trial in 209 patients with moderate-to-severe COPD.  The primary efficacy parameter was trough forced expiratory vol. in one second after 6 wk of treatment, and secondary end-points included other lung function end-points and symptom scores assessed at 2-wk intervals.  The present study was stopped following a planned interim anal. for futility.  No effect on the primary efficacy parameter, other measures of lung function or symptom scores was obsd. at any dose of UK-500,001 after 6 wk of treatment.  However, after the first 2 wk of treatment, an improvement in a no. of outcome measures in the 1.0 mg b.i.d. dose group was obsd. compared with placebo.  The drug was well tolerated, although PDE4 inhibitor-related side-effects were obsd., esp. in the highest dose group.  The findings of the present study question the role of inhaled phosphodiesterase type-4 inhibitors in chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqfiD54uWV9bVg90H21EOLACvtfcHk0lhnM4i3SH22cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtFahtb4%253D&md5=73ac7894ef11b2cdd9f95fcd95b52286</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1183%2F09031936.00068908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00068908%26sid%3Dliteratum%253Aachs%26aulast%3DVestbo%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DAtkinson%26aufirst%3DG.%26aulast%3DWard%26aufirst%3DJ.%26atitle%3DA%2520controlled%2520trial%2520of%25206-weeks%25E2%2580%2599%2520treatment%2520with%2520a%2520novel%2520inhaled%2520phosphodiesterase%2520type-4%2520inhibitor%2520in%2520COPD%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2009%26volume%3D33%26spage%3D1039%26epage%3D1044%26doi%3D10.1183%2F09031936.00068908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Tralau-Stewart, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williamson, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nials, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoigne, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angell, A. D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solanke, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiseman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranshaw, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knowles, R. G.</span><span> </span><span class="NLM_article-title">GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">337</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span><span class="refDoi"> DOI: 10.1124/jpet.110.173690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1124%2Fjpet.110.173690" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=21205923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGquro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2011&pages=145-154&author=C.+J.+Tralau-Stewartauthor=R.+A.+Williamsonauthor=A.+T.+Nialsauthor=M.+Gascoigneauthor=J.+Dawsonauthor=G.+J.+Hartauthor=A.+D.+R.+Angellauthor=Y.+E.+Solankeauthor=F.+S.+Lucasauthor=J.+Wisemanauthor=P.+Wardauthor=L.+E.+Ranshawauthor=R.+G.+Knowles&title=GSK256066%2C+an+exceptionally+high-affinity+and+selective+inhibitor+of+phosphodiesterase+4+suitable+for+administration+by+inhalation%3A+in+vitro%2C+kinetic%2C+and+in+vivo+characterization&doi=10.1124%2Fjpet.110.173690"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization</span></div><div class="casAuthors">Tralau-Stewart, Cathy J.; Williamson, Richard A.; Nials, Anthony T.; Gascoigne, Michele; Dawson, John; Hart, Graham J.; Angell, Anthony D. R.; Solanke, Yemisi E.; Lucas, Fiona S.; Wiseman, Joanne; Ward, Peter; Ranshaw, Lisa E.; Knowles, Richard G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">145-154</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Oral phosphodiesterase 4 (PDE4) inhibitors such as roflumilast have established the potential of PDE4 inhibition for the treatment of respiratory diseases.  However, PDE4 inhibitor efficacy is limited by mechanism-related side effects such as emesis and nausea.  Delivering the inhibitor by the inhaled route may improve therapeutic index, and the authors describe 6-({3-[(dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-4-{[3-methyloxy] phenylamino}-3-quinolinecarboxamide (GSK256066), an exceptionally high-affinity inhibitor of PDE4 designed for inhaled administration.  GSK256066 is a slow and tight binding inhibitor of PDE4B (apparent IC50 3.2 pM; steady-state IC50 <0.5 pM), which is more potent than any previously documented compd., for example, roflumilast (IC50 390 pM), tofimilast (IC50 1.6 nM), and cilomilast (IC50 74 nM).  Consistent with this, GSK256066 inhibited tumor necrosis factor α prodn. by lipopolysaccharide (LPS)-stimulated human peripheral blood monocytes with 0.01 nM IC50 (compared with IC50 values of 5, 22, and 389 nM for roflumilast, tofimilast, and cilomilast, resp.) and by LPS-stimulated whole blood with 126 pM IC50.  GSK256066 was highly selective for PDE4 (>380,000-fold vs. PDE1, PDE2, PDE3, PDE5, and PDE6 and >2500-fold against PDE7), inhibited PDE4 isoforms A-D with equal affinity, and had a substantial high-affinity rolipram binding site ratio (>17).  When administered intratracheally to rats, GSK256066 inhibited LPS-induced pulmonary neutrophilia with ED50 values of 1.1 μg/kg (aq. suspension) and 2.9 μg/kg (dry powder formulation) and was more potent than an aq. suspension of the corticosteroid fluticasone propionate (ED50 9.3 μg/kg).  Thus, GSK256066 was demonstrated to have exceptional potency in vitro and in vivo and is being clin. investigated as a treatment for chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRV6i1BfsW87Vg90H21EOLACvtfcHk0ljiJlP4TBL2hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGquro%253D&md5=1a4747eadf3541433b9abc043782a0ca</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.173690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.173690%26sid%3Dliteratum%253Aachs%26aulast%3DTralau-Stewart%26aufirst%3DC.%2BJ.%26aulast%3DWilliamson%26aufirst%3DR.%2BA.%26aulast%3DNials%26aufirst%3DA.%2BT.%26aulast%3DGascoigne%26aufirst%3DM.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DHart%26aufirst%3DG.%2BJ.%26aulast%3DAngell%26aufirst%3DA.%2BD.%2BR.%26aulast%3DSolanke%26aufirst%3DY.%2BE.%26aulast%3DLucas%26aufirst%3DF.%2BS.%26aulast%3DWiseman%26aufirst%3DJ.%26aulast%3DWard%26aufirst%3DP.%26aulast%3DRanshaw%26aufirst%3DL.%2BE.%26aulast%3DKnowles%26aufirst%3DR.%2BG.%26atitle%3DGSK256066%252C%2520an%2520exceptionally%2520high-affinity%2520and%2520selective%2520inhibitor%2520of%2520phosphodiesterase%25204%2520suitable%2520for%2520administration%2520by%2520inhalation%253A%2520in%2520vitro%252C%2520kinetic%252C%2520and%2520in%2520vivo%2520characterization%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D337%26spage%3D145%26epage%3D154%26doi%3D10.1124%2Fjpet.110.173690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Nials, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tralau-Stewart, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoigne, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranshaw, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knowles, R. G.</span><span> </span><span class="NLM_article-title">In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">568</span><span class="NLM_x">–</span> <span class="NLM_lpage">578</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=25576073" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=568-578&author=A.+T.+Nialsauthor=C.+J.+Tralau-Stewartauthor=M.+H.+Gascoigneauthor=D.+I.+Ballauthor=L.+E.+Ranshawauthor=R.+G.+Knowles&title=In+vivo+characterization+of+GSK256066%2C+a+high-affinity+inhaled+phosphodiesterase+4+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNials%26aufirst%3DA.%2BT.%26aulast%3DTralau-Stewart%26aufirst%3DC.%2BJ.%26aulast%3DGascoigne%26aufirst%3DM.%2BH.%26aulast%3DBall%26aufirst%3DD.%2BI.%26aulast%3DRanshaw%26aufirst%3DL.%2BE.%26aulast%3DKnowles%26aufirst%3DR.%2BG.%26atitle%3DIn%2520vivo%2520characterization%2520of%2520GSK256066%252C%2520a%2520high-affinity%2520inhaled%2520phosphodiesterase%25204%2520inhibitor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D568%26epage%3D578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Moretto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caruso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastore, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghidini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Fanti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capaldi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carzaniga, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buccellati, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sala, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patacchini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delcanale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villetti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Facchinetti, F.</span><span> </span><span class="NLM_article-title">CHF6001 I: A novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">189</span><span class="NLM_x">, </span> <span class="NLM_fpage">A6725</span><span class="refDoi"> DOI: 10.1124/jpet.114.220541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1124%2Fjpet.114.220541" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2014&pages=A6725&author=N.+Morettoauthor=P.+Carusoauthor=R.+Boscoauthor=G.+Marchiniauthor=F.+Pastoreauthor=E.+Armaniauthor=G.+Amariauthor=A.+Rizziauthor=E.+Ghidiniauthor=R.+De+Fantiauthor=C.+Capaldiauthor=L.+Carzanigaauthor=E.+Hirschauthor=C.+Buccellatiauthor=A.+Salaauthor=C.+Carniniauthor=R.+Patacchiniauthor=M.+Delcanaleauthor=M.+Civelliauthor=G.+Villettiauthor=F.+Facchinetti&title=CHF6001+I%3A+A+novel+highly+potent+and+selective+phosphodiesterase+4+inhibitor+with+robust+anti-inflammatory+activity+and+suitable+for+topical+pulmonary+administration&doi=10.1124%2Fjpet.114.220541"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220541%26sid%3Dliteratum%253Aachs%26aulast%3DMoretto%26aufirst%3DN.%26aulast%3DCaruso%26aufirst%3DP.%26aulast%3DBosco%26aufirst%3DR.%26aulast%3DMarchini%26aufirst%3DG.%26aulast%3DPastore%26aufirst%3DF.%26aulast%3DArmani%26aufirst%3DE.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DGhidini%26aufirst%3DE.%26aulast%3DDe%2BFanti%26aufirst%3DR.%26aulast%3DCapaldi%26aufirst%3DC.%26aulast%3DCarzaniga%26aufirst%3DL.%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DBuccellati%26aufirst%3DC.%26aulast%3DSala%26aufirst%3DA.%26aulast%3DCarnini%26aufirst%3DC.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DCivelli%26aufirst%3DM.%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DFacchinetti%26aufirst%3DF.%26atitle%3DCHF6001%2520I%253A%2520A%2520novel%2520highly%2520potent%2520and%2520selective%2520phosphodiesterase%25204%2520inhibitor%2520with%2520robust%2520anti-inflammatory%2520activity%2520and%2520suitable%2520for%2520topical%2520pulmonary%2520administration%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D189%26spage%3DA6725%26doi%3D10.1124%2Fjpet.114.220541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Villetti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battipaglia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preynat, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolzoni, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caruso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergamaschi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pisano, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puviani, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stellari, F. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cenacchi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertacche, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mileo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagnacani, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moretti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puccini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catinella, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Facchinetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sala, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civelli, M.</span><span> </span><span class="NLM_article-title">CHF6001 II: A novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">568</span><span class="NLM_x">–</span> <span class="NLM_lpage">578</span><span class="refDoi"> DOI: 10.1124/jpet.114.220558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1124%2Fjpet.114.220558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=25576073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Olsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=568-578&author=G.+Villettiauthor=C.+Carniniauthor=L.+Battipagliaauthor=L.+Preynatauthor=P.+T.+Bolzoniauthor=F.+Bassaniauthor=P.+Carusoauthor=M.+Bergamaschiauthor=A.+R.+Pisanoauthor=V.+Puvianiauthor=F.+F.+Stellariauthor=V.+Cenacchiauthor=R.+Voltaauthor=V.+Bertaccheauthor=V.+Mileoauthor=V.+Bagnacaniauthor=E.+Morettiauthor=P.+Pucciniauthor=S.+Catinellaauthor=F.+Facchinettiauthor=A.+Salaauthor=M.+Civelli&title=CHF6001+II%3A+A+novel+phosphodiesterase+4+inhibitor%2C+suitable+for+topical+pulmonary+administration%2D%2Din+vivo+preclinical+pharmacology+profile+defines+a+potent+anti-inflammatory+compound+with+a+wide+therapeutic+window&doi=10.1124%2Fjpet.114.220558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration-in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window</span></div><div class="casAuthors">Villetti, Gino; Carnini, Chiara; Battipaglia, Loredana; Preynat, Laurent; Bolzoni, Pier Tonino; Bassani, Franco; Caruso, Paola; Bergamaschi, Marco; Pisano, Anna Rita; Puviani, Veronica; Stellari, Fabio Franco; Cenacchi, Valentina; Volta, Roberta; Bertacche, Vittorio; Mileo, Valentina; Bagnacani, Valentina; Moretti, Elisa; Puccini, Paola; Catinella, Silvia; Facchinetti, Fabrizio; Sala, Angelo; Civelli, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">568-578, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">CHF6001 [(S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoyloxy)ethyl)pyridine 1-oxide] is a novel phosphodiesterase 4 (PDE4) inhibitor designed for use in pulmonary diseases by inhaled administration.  Intratracheal administration of CHF6001 to ovalbumin-sensitized Brown-Norway rats suppressed the antigen-induced decline of lung functions (ED50 = 0.1 μmol/kg) and antigen-induced eosinophilia (ED50 = 0.03 μmol/kg) when administered (0.09 μmol/kg) up to 24 h before antigen challenge, in agreement with CHF6001-sustained lung concns. up to 72 h after intratracheal treatment (mean residence time 26 h).  Intranasal, once daily administration of CHF6001 inhibited neutrophil infiltration obsd. after 11 days of tobacco smoke exposure in mice, both upon prophylactic (0.15-0.45 μmol/kg per day) or interventional (0.045-0.45 μmol/kg per day) treatment.  CHF6001 was ineffective in reversing ketamine/xylazine-induced anesthesia (a surrogate of emesis in rat) up to 5 μmol/kg administered intratracheally, a dose 50- to 150-fold higher than anti-inflammatory ED50 obsd. in rats.  When given topically to ferrets, no emesis and nausea were evident up to 10 to 20 μmol/kg, resp., whereas the PDE4 inhibitor GSK-256066 (6-[3-(dimethylcarbamoyl)phenyl]sulfonyl-4-(3-methoxyanilino)-8-methylquinoline-3-carboxamide) induced nausea at 1 μmol/kg intratracheally.  A 14-day inhalation toxicol. study in rats showed a no-obsd.-adverse-effect level dose of 4.4 μmol/kg per day for CHF6001, lower than the 0.015 μmol/kg per day for GSK-256066.  CHF6001 was found effective and extremely well tolerated upon topical administration in relevant animal models, and may represent a step forward in PDE4 inhibition for the treatment of asthma and chronic obstructive respiratory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc2BkhFCksErVg90H21EOLACvtfcHk0lh74Zv7XUxvnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Olsb0%253D&md5=58c3c206d5429d8be54923731d5811ff</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220558%26sid%3Dliteratum%253Aachs%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DCarnini%26aufirst%3DC.%26aulast%3DBattipaglia%26aufirst%3DL.%26aulast%3DPreynat%26aufirst%3DL.%26aulast%3DBolzoni%26aufirst%3DP.%2BT.%26aulast%3DBassani%26aufirst%3DF.%26aulast%3DCaruso%26aufirst%3DP.%26aulast%3DBergamaschi%26aufirst%3DM.%26aulast%3DPisano%26aufirst%3DA.%2BR.%26aulast%3DPuviani%26aufirst%3DV.%26aulast%3DStellari%26aufirst%3DF.%2BF.%26aulast%3DCenacchi%26aufirst%3DV.%26aulast%3DVolta%26aufirst%3DR.%26aulast%3DBertacche%26aufirst%3DV.%26aulast%3DMileo%26aufirst%3DV.%26aulast%3DBagnacani%26aufirst%3DV.%26aulast%3DMoretti%26aufirst%3DE.%26aulast%3DPuccini%26aufirst%3DP.%26aulast%3DCatinella%26aufirst%3DS.%26aulast%3DFacchinetti%26aufirst%3DF.%26aulast%3DSala%26aufirst%3DA.%26aulast%3DCivelli%26aufirst%3DM.%26atitle%3DCHF6001%2520II%253A%2520A%2520novel%2520phosphodiesterase%25204%2520inhibitor%252C%2520suitable%2520for%2520topical%2520pulmonary%2520administration--in%2520vivo%2520preclinical%2520pharmacology%2520profile%2520defines%2520a%2520potent%2520anti-inflammatory%2520compound%2520with%2520a%2520wide%2520therapeutic%2520window%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D568%26epage%3D578%26doi%3D10.1124%2Fjpet.114.220558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Singh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leaker, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyce, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nandeuil, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collarini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients</span> <span class="citation_source-journal">Pulm. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span><span class="refDoi"> DOI: 10.1016/j.pupt.2016.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1016%2Fj.pupt.2016.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=27373438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1eisLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2016&pages=1-6&author=D.+Singhauthor=B.+Leakerauthor=M.+Boyceauthor=M.+A.+Nandeuilauthor=S.+Collariniauthor=F.+Mariottiauthor=D.+Santoroauthor=P.+J.+Barnes&title=A+novel+inhaled+phosphodiesterase+4+inhibitor+%28CHF6001%29+reduces+the+allergen+challenge+response+in+asthmatic+patients&doi=10.1016%2Fj.pupt.2016.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients</span></div><div class="casAuthors">Singh, D.; Leaker, B.; Boyce, M.; Nandeuil, M. A.; Collarini, S.; Mariotti, F.; Santoro, D.; Barnes, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">CHF6001 is an inhaled phosphodiesterase 4 (PDE4) inhibitor in development for the treatment of obstructive lung diseases.  The efficacy and safety of CHF6001 were investigated in a double blind, placebo controlled, 3-way cross-over study using the allergen challenge model.  Thirty-six atopic asthmatics who were not taking inhaled corticosteroids and who demonstrated a late asthmatic response (LAR) to inhaled allergen at screening were randomized to receive CHF6001 400 μg or 1200 μg or placebo administered once a day using a dry powder inhaler.  The three treatment periods were 9 days; allergen challenges were performed on day 9 and induced sputum was obtained after 10 h from challenge.  Washout periods between treatments were up to 5 wk.  Both CHF6001 doses significantly attenuated the LAR; the primary endpoint anal. showed that CHF6001 400 μg and 1200 μg caused redns. of 19.7% (p = 0.015) and 28.2% (p < 0.001) resp. of the weighted FEV1 AUC4-10h compared with placebo.  The difference between the CHF6001 doses was not statistically significant (p = 0.223).  Compared with placebo, CHF6001 caused greater redn. in sputum eosinophil counts, although these changes were not statistically significant.  CHF6001 was well tolerated, with similar nos. of adverse events in each treatment period.  This inhaled PDE4 inhibitor has the potential to provide clin. benefits in patients with atopic asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFxltgVfb-QrVg90H21EOLACvtfcHk0lh74Zv7XUxvnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1eisLzI&md5=cb8064827c2d80be4ae9b9d5f591c514</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2016.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2016.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DLeaker%26aufirst%3DB.%26aulast%3DBoyce%26aufirst%3DM.%26aulast%3DNandeuil%26aufirst%3DM.%2BA.%26aulast%3DCollarini%26aufirst%3DS.%26aulast%3DMariotti%26aufirst%3DF.%26aulast%3DSantoro%26aufirst%3DD.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DA%2520novel%2520inhaled%2520phosphodiesterase%25204%2520inhibitor%2520%2528CHF6001%2529%2520reduces%2520the%2520allergen%2520challenge%2520response%2520in%2520asthmatic%2520patients%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2016%26volume%3D40%26spage%3D1%26epage%3D6%26doi%3D10.1016%2Fj.pupt.2016.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">De Savi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickinson, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonough, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrill, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmour, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dearman, M. S.</span><span> </span><span class="NLM_article-title">Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4661</span><span class="NLM_x">–</span> <span class="NLM_lpage">4676</span><span class="refDoi"> DOI: 10.1021/jm5001216</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5001216" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4661-4676&author=C.+De+Saviauthor=R.+J.+Coxauthor=D.+J.+Warnerauthor=A.+R.+Cookauthor=M.+R.+Dickinsonauthor=A.+McDonoughauthor=L.+C.+Morrillauthor=B.+Parkerauthor=B.+Andrewsauthor=S.+S.+Youngauthor=P.+S.+Gilmourauthor=R.+Rileyauthor=M.+S.+Dearman&title=Efficacious+inhaled+PDE4+inhibitors+with+low+emetic+potential+and+long+duration+of+action+for+the+treatment+of+COPD&doi=10.1021%2Fjm5001216"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm5001216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5001216%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DCox%26aufirst%3DR.%2BJ.%26aulast%3DWarner%26aufirst%3DD.%2BJ.%26aulast%3DCook%26aufirst%3DA.%2BR.%26aulast%3DDickinson%26aufirst%3DM.%2BR.%26aulast%3DMcDonough%26aufirst%3DA.%26aulast%3DMorrill%26aufirst%3DL.%2BC.%26aulast%3DParker%26aufirst%3DB.%26aulast%3DAndrews%26aufirst%3DB.%26aulast%3DYoung%26aufirst%3DS.%2BS.%26aulast%3DGilmour%26aufirst%3DP.%2BS.%26aulast%3DRiley%26aufirst%3DR.%26aulast%3DDearman%26aufirst%3DM.%2BS.%26atitle%3DEfficacious%2520inhaled%2520PDE4%2520inhibitors%2520with%2520low%2520emetic%2520potential%2520and%2520long%2520duration%2520of%2520action%2520for%2520the%2520treatment%2520of%2520COPD%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4661%26epage%3D4676%26doi%3D10.1021%2Fjm5001216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Ting, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aslanian, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, K. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prelusky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamca, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">House, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celly, C. S.</span><span> </span><span class="NLM_article-title">Discovery of oral and inhaled PDE4 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5528</span><span class="NLM_x">–</span> <span class="NLM_lpage">5532</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.08.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1016%2Fj.bmcl.2013.08.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=24018187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSku7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5528-5532&author=P.+C.+Tingauthor=J.+F.+Leeauthor=R.+Kuangauthor=J.+Caoauthor=D.+Guauthor=Y.+Huangauthor=Z.+Liuauthor=R.+G.+Aslanianauthor=K.+I.+Fengauthor=D.+Preluskyauthor=J.+Lamcaauthor=A.+Houseauthor=J.+E.+Phillipsauthor=P.+Wangauthor=+Wuauthor=D.+Lundellauthor=R.+W.+Chapmanauthor=C.+S.+Celly&title=Discovery+of+oral+and+inhaled+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2013.08.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of oral and inhaled PDE4 inhibitors</span></div><div class="casAuthors">Ting, Pauline C.; Lee, Joe F.; Kuang, Rongze; Cao, Jianhua; Gu, Danlin; Huang, Ying; Liu, Zhidan; Aslanian, Robert G.; Feng, Kung-I.; Prelusky, Daniel; Lamca, James; House, Aileen; Phillips, Jonathan E.; Wang, Peng; Wu, Ping; Lundell, Daniel; Chapman, Richard W.; Celly, Chander S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5528-5532</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The optimization of oxazole-based PDE4 inhibitor 1 has led to the identification of both oral (compd. 16) and inhaled (compd. 34) PDE4 inhibitors.  Selectivity against PDE10/PDE11, off target screening, and in vivo activity in the rat are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWC60jYiR9G7Vg90H21EOLACvtfcHk0lhIRm6Kfwc6KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSku7fJ&md5=5b76d198abe24df922d239e48d8813be</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.056%26sid%3Dliteratum%253Aachs%26aulast%3DTing%26aufirst%3DP.%2BC.%26aulast%3DLee%26aufirst%3DJ.%2BF.%26aulast%3DKuang%26aufirst%3DR.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DGu%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DAslanian%26aufirst%3DR.%2BG.%26aulast%3DFeng%26aufirst%3DK.%2BI.%26aulast%3DPrelusky%26aufirst%3DD.%26aulast%3DLamca%26aufirst%3DJ.%26aulast%3DHouse%26aufirst%3DA.%26aulast%3DPhillips%26aufirst%3DJ.%2BE.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWu%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DChapman%26aufirst%3DR.%2BW.%26aulast%3DCelly%26aufirst%3DC.%2BS.%26atitle%3DDiscovery%2520of%2520oral%2520and%2520inhaled%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5528%26epage%3D5532%26doi%3D10.1016%2Fj.bmcl.2013.08.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Armani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Fanti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghidini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capaldi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carzaniga, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caruso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peretto, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Porta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolzoni, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Facchinetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moretto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patacchini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cenacchi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amadei, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capacchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delcanale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puccini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catinella, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villetti, G.</span><span> </span><span class="NLM_article-title">Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">793</span><span class="NLM_x">–</span> <span class="NLM_lpage">816</span><span class="refDoi"> DOI: 10.1021/jm401549m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401549m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=793-816&issue=3&author=E.+Armaniauthor=G.+Amariauthor=A.+Rizziauthor=R.+De+Fantiauthor=E.+Ghidiniauthor=C.+Capaldiauthor=L.+Carzanigaauthor=P.+Carusoauthor=M.+Gualaauthor=I.+Perettoauthor=E.+La+Portaauthor=P.+T.+Bolzoniauthor=F.+Facchinettiauthor=C.+Carniniauthor=N.+Morettoauthor=R.+Patacchiniauthor=F.+Bassaniauthor=V.+Cenacchiauthor=R.+Voltaauthor=F.+Amadeiauthor=S.+Capacchiauthor=M.+Delcanaleauthor=P.+Pucciniauthor=S.+Catinellaauthor=M.+Civelliauthor=G.+Villetti&title=Novel+class+of+benzoic+acid+ester+derivatives+as+potent+PDE4+inhibitors+for+inhaled+administration+in+the+treatment+of+respiratory+diseases&doi=10.1021%2Fjm401549m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm401549m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401549m%26sid%3Dliteratum%253Aachs%26aulast%3DArmani%26aufirst%3DE.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DDe%2BFanti%26aufirst%3DR.%26aulast%3DGhidini%26aufirst%3DE.%26aulast%3DCapaldi%26aufirst%3DC.%26aulast%3DCarzaniga%26aufirst%3DL.%26aulast%3DCaruso%26aufirst%3DP.%26aulast%3DGuala%26aufirst%3DM.%26aulast%3DPeretto%26aufirst%3DI.%26aulast%3DLa%2BPorta%26aufirst%3DE.%26aulast%3DBolzoni%26aufirst%3DP.%2BT.%26aulast%3DFacchinetti%26aufirst%3DF.%26aulast%3DCarnini%26aufirst%3DC.%26aulast%3DMoretto%26aufirst%3DN.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DBassani%26aufirst%3DF.%26aulast%3DCenacchi%26aufirst%3DV.%26aulast%3DVolta%26aufirst%3DR.%26aulast%3DAmadei%26aufirst%3DF.%26aulast%3DCapacchi%26aufirst%3DS.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DPuccini%26aufirst%3DP.%26aulast%3DCatinella%26aufirst%3DS.%26aulast%3DCivelli%26aufirst%3DM.%26aulast%3DVilletti%26aufirst%3DG.%26atitle%3DNovel%2520class%2520of%2520benzoic%2520acid%2520ester%2520derivatives%2520as%2520potent%2520PDE4%2520inhibitors%2520for%2520inhaled%2520administration%2520in%2520the%2520treatment%2520of%2520respiratory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D3%26spage%3D793%26epage%3D816%26doi%3D10.1021%2Fjm401549m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Card, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">England, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabrizizad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillette, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milburn, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y. J.</span><span> </span><span class="NLM_article-title">Structural basis for the activity of drugs that inhibit phosphodiesterases</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2233</span><span class="NLM_x">–</span> <span class="NLM_lpage">2247</span><span class="refDoi"> DOI: 10.1016/j.str.2004.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1016%2Fj.str.2004.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=15576036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVClur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=2233-2247&author=G.+L.+Cardauthor=B.+P.+Englandauthor=Y.+Suzukiauthor=D.+Fongauthor=B.+Powellauthor=B.+Leeauthor=C.+Luuauthor=M.+Tabrizizadauthor=S.+Gilletteauthor=P.+N.+Ibrahimauthor=D.+R.+Artisauthor=G.+Bollagauthor=M.+V.+Milburnauthor=S.+H.+Kimauthor=J.+Schlessingerauthor=K.+Y.+J.+Zhang&title=Structural+basis+for+the+activity+of+drugs+that+inhibit+phosphodiesterases&doi=10.1016%2Fj.str.2004.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases</span></div><div class="casAuthors">Card, Graeme L.; England, Bruce P.; Suzuki, Yoshihisa; Fong, Daniel; Powell, Ben; Lee, Byunghun; Luu, Catherine; Tabrizizad, Maryam; Gillette, Sam; Ibrahim, Prabha N.; Artis, Dean R.; Bollag, Gideon; Milburn, Michael V.; Kim, Sung-Hou; Schlessinger, Joseph; Zhang, Kam Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2233-2247</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) comprise a large family of enzymes that catalyze the hydrolysis of cAMP or cGMP and are implicated in various diseases.  The authors describe the high-resoln. crystal structures of the catalytic domains of PDE4B, PDE4D, and PDE5A with ten different inhibitors, including the drug candidates cilomilast and roflumilast, for respiratory diseases.  These cocrystal structures reveal a common scheme of inhibitor binding to the PDEs: (i) a hydrophobic clamp formed by highly conserved hydrophobic residues that sandwich the inhibitor in the active site; (ii) hydrogen bonding to an invariant glutamine that controls the orientation of inhibitor binding.  A scaffold can be readily identified for any given inhibitor based on the formation of these two types of conserved interactions.  These structural insights will enable the design of isoform-selective inhibitors with improved binding affinity and should facilitate the discovery of more potent and selective PDE inhibitors for the treatment of a variety of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8l4KWCohSy7Vg90H21EOLACvtfcHk0lhIRm6Kfwc6KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVClur3K&md5=0fa91e4b9047e3df3946c526592be396</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2004.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2004.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DCard%26aufirst%3DG.%2BL.%26aulast%3DEngland%26aufirst%3DB.%2BP.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DTabrizizad%26aufirst%3DM.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26atitle%3DStructural%2520basis%2520for%2520the%2520activity%2520of%2520drugs%2520that%2520inhibit%2520phosphodiesterases%26jtitle%3DStructure%26date%3D2004%26volume%3D12%26spage%3D2233%26epage%3D2247%26doi%3D10.1016%2Fj.str.2004.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Baehr, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devlin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Applebury, M. L.</span><span> </span><span class="NLM_article-title">Isolation and characterization of cGMP phosphodiesterase from bovine rod outer segments</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">254</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">11669</span><span class="NLM_x">–</span> <span class="NLM_lpage">11677</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=1979&pages=11669-11677&issue=22&author=W.+Baehrauthor=M.+J.+Devlinauthor=M.+L.+Applebury&title=Isolation+and+characterization+of+cGMP+phosphodiesterase+from+bovine+rod+outer+segments"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaehr%26aufirst%3DW.%26aulast%3DDevlin%26aufirst%3DM.%2BJ.%26aulast%3DApplebury%26aufirst%3DM.%2BL.%26atitle%3DIsolation%2520and%2520characterization%2520of%2520cGMP%2520phosphodiesterase%2520from%2520bovine%2520rod%2520outer%2520segments%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1979%26volume%3D254%26issue%3D22%26spage%3D11669%26epage%3D11677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Thompson, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleman, M. M.</span><span> </span><span class="NLM_article-title">Multiple cyclic nucleotide phosphodiesterase activities from rat brain</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1971</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">311</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span><span class="refDoi"> DOI: 10.1021/bi00778a018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00778a018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1971&pages=311-6&issue=2&author=W.+J.+Thompsonauthor=M.+M.+Appleman&title=Multiple+cyclic+nucleotide+phosphodiesterase+activities+from+rat+brain&doi=10.1021%2Fbi00778a018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fbi00778a018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00778a018%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DW.%2BJ.%26aulast%3DAppleman%26aufirst%3DM.%2BM.%26atitle%3DMultiple%2520cyclic%2520nucleotide%2520phosphodiesterase%2520activities%2520from%2520rat%2520brain%26jtitle%3DBiochemistry%26date%3D1971%26volume%3D10%26issue%3D2%26spage%3D311%26epage%3D6%26doi%3D10.1021%2Fbi00778a018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span> <span class="citation_source-book">Maestro</span>, version 9.2; <span class="NLM_publisher-name">Scrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Maestro%2C+version+9.2%3B+Scr%C3%B6dinger%2C+LLC%3A+New+York%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DMaestro%26pub%3DScr%25C3%25B6dinger%252C%2520LLC%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span> <span class="citation_source-book">LigPrep</span>, version 3.4; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=LigPrep%2C+version+3.4%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DLigPrep%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Shelley, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cholleti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenwood, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timlin, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchimaya, M.</span><span> </span><span class="NLM_article-title">Epik: A software program for pk a prediction and protonation state generation for drug-like molecules</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">681</span><span class="NLM_x">–</span> <span class="NLM_lpage">691</span><span class="refDoi"> DOI: 10.1007/s10822-007-9133-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1007%2Fs10822-007-9133-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=17899391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVKrtbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=681-691&author=J.+C.+Shelleyauthor=A.+Cholletiauthor=L.+L.+Fryeauthor=J.+R.+Greenwoodauthor=M.+R.+Timlinauthor=M.+Uchimaya&title=Epik%3A+A+software+program+for+pk+a+prediction+and+protonation+state+generation+for+drug-like+molecules&doi=10.1007%2Fs10822-007-9133-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Epik: a software program for pKa prediction and protonation state generation for drug-like molecules</span></div><div class="casAuthors">Shelley, John C.; Cholleti, Anuradha; Frye, Leah L.; Greenwood, Jeremy R.; Timlin, Mathew R.; Uchimaya, Makoto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">681-691</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Epik is a computer program for predicting pKa values for drug-like mols.  Epik can use this capability in combination with technol. for tautomerization to adjust the protonation state of small drug-like mols. to automatically generate one or more of the most probable forms for use in further mol. modeling studies.  Many medicinal chems. can exchange protons with their environment, resulting in various ionization and tautomeric states, collectively known as protonation states.  The protonation state of a drug can affect its soly. and membrane permeability.  In modeling, the protonation state of a ligand will also affect which conformations are predicted for the mol., as well as predictions for binding modes and ligand affinities based upon protein-ligand interactions.  Despite the importance of the protonation state, many databases of candidate mols. used in drug development do not store reliable information on the most probable protonation states.  Epik is sufficiently rapid and accurate to process large databases of drug-like mols. to provide this information.  Several new technologies are employed.  Extensions to the well-established Hammett and Taft approaches are used for pKa prediction, namely, mesomer standardization, charge cancellation, and charge spreading to make the predicted results reflect the nature of the mol. itself rather just for the particular Lewis structure used on input.  In addn., a new iterative technol. for generating, ranking and culling the generated protonation states is employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC6PRLT1xT8LVg90H21EOLACvtfcHk0ljPZR5avQlvdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVKrtbzP&md5=f4f429ea3894e1ad2519cdf3333a5645</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs10822-007-9133-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-007-9133-z%26sid%3Dliteratum%253Aachs%26aulast%3DShelley%26aufirst%3DJ.%2BC.%26aulast%3DCholleti%26aufirst%3DA.%26aulast%3DFrye%26aufirst%3DL.%2BL.%26aulast%3DGreenwood%26aufirst%3DJ.%2BR.%26aulast%3DTimlin%26aufirst%3DM.%2BR.%26aulast%3DUchimaya%26aufirst%3DM.%26atitle%3DEpik%253A%2520A%2520software%2520program%2520for%2520pk%2520a%2520prediction%2520and%2520protonation%2520state%2520generation%2520for%2520drug-like%2520molecules%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2007%26volume%3D21%26spage%3D681%26epage%3D691%26doi%3D10.1007%2Fs10822-007-9133-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span> <span class="citation_source-book">Glide</span>, version 5.7; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Glide%2C+version+5.7%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGlide%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winn, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storoni, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span> </span><span class="NLM_article-title">Phaser crystallographic software</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">658</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span><span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0lgEJCFy6ZSF_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodson, E. J.</span><span> </span><span class="NLM_article-title">Refinement of macromolecular structures by the maximum-likelihood method</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span><span class="refDoi"> DOI: 10.1107/S0907444996012255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=15299926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+macromolecular+structures+by+the+maximum-likelihood+method&doi=10.1107%2FS0907444996012255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0lgEJCFy6ZSF_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520macromolecular%2520structures%2520by%2520the%2520maximum-likelihood%2520method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26spage%3D240%26epage%3D255%26doi%3D10.1107%2FS0907444996012255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 9 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yong-Jin Wu, <span class="NLM_string-name hlFld-ContribAuthor">Nicholas A. Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (14)
                                     , 9786-9874. <a href="https://doi.org/10.1021/acs.jmedchem.1c00790" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00790</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00790%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DGeminal%252BDiheteroatomic%252BMotifs%25253A%252BSome%252BApplications%252Bof%252BAcetals%25252C%252BKetals%25252C%252Band%252BTheir%252BSulfur%252Band%252BNitrogen%252BHomologues%252Bin%252BMedicinal%252BChemistry%252Band%252BDrug%252BDesign%26aulast%3DWu%26aufirst%3DYong-Jin%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D30042021%26date%3D02072021%26volume%3D64%26issue%3D14%26spage%3D9786%26epage%3D9874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chao-Ming Hsieh, Chun-Yi Chen, Ji-Wang Chern, <span class="NLM_string-name hlFld-ContribAuthor">Nei-Li Chan</span>. </span><span class="cited-content_cbyCitation_article-title">Structure of Human Phosphodiesterase 5A1 Complexed with Avanafil Reveals Molecular Basis of Isoform Selectivity and Guidelines for Targeting α-Helix Backbone Oxygen by Halogen Bonding. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (15)
                                     , 8485-8494. <a href="https://doi.org/10.1021/acs.jmedchem.0c00853" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00853</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00853%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%252Bof%252BHuman%252BPhosphodiesterase%252B5A1%252BComplexed%252Bwith%252BAvanafil%252BReveals%252BMolecular%252BBasis%252Bof%252BIsoform%252BSelectivity%252Band%252BGuidelines%252Bfor%252BTargeting%252B%2525CE%2525B1-Helix%252BBackbone%252BOxygen%252Bby%252BHalogen%252BBonding%26aulast%3DHsieh%26aufirst%3DChao-Ming%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D20052020%26date%3D27072020%26date%3D14072020%26volume%3D63%26issue%3D15%26spage%3D8485%26epage%3D8494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Huihui Ti, Yang Zhou, Xue Liang, Runfeng Li, Ke Ding, <span class="NLM_string-name hlFld-ContribAuthor">Xin Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (13)
                                     , 5944-5978. <a href="https://doi.org/10.1021/acs.jmedchem.8b01520" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01520</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01520%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeted%252BTreatments%252Bfor%252BChronic%252BObstructive%252BPulmonary%252BDisease%252B%252528COPD%252529%252BUsing%252BLow-Molecular-Weight%252BDrugs%252B%252528LMWDs%252529%26aulast%3DTi%26aufirst%3DHuihui%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D30092018%26date%3D12022019%26date%3D25012019%26volume%3D62%26issue%3D13%26spage%3D5944%26epage%3D5978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Allie
Y. Chen, Rebecca N. Adamek, Benjamin L. Dick, Cy V. Credille, Christine N. Morrison, <span class="NLM_string-name hlFld-ContribAuthor">Seth M. Cohen</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Metalloenzymes for Therapeutic Intervention. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2019,</strong> <em>119 </em>
                                    (2)
                                     , 1323-1455. <a href="https://doi.org/10.1021/acs.chemrev.8b00201" title="DOI URL">https://doi.org/10.1021/acs.chemrev.8b00201</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.8b00201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.8b00201%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DTargeting%252BMetalloenzymes%252Bfor%252BTherapeutic%252BIntervention%26aulast%3DChen%26aufirst%3DAllie%2BY.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D29032018%26date%3D07092018%26volume%3D119%26issue%3D2%26spage%3D1323%26epage%3D1455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tommaso Prosdocimi, Luca Mollica, Stefano Donini, Marta S. Semrau, Anna Paola Lucarelli, Egidio Aiolfi, Andrea Cavalli, Paola Storici, Silvana Alfei, Chiara Brullo, Olga Bruno, <span class="NLM_string-name hlFld-ContribAuthor">Emilio Parisini</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Bases of PDE4D Inhibition by Memory-Enhancing GEBR Library Compounds. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2018,</strong> <em>57 </em>
                                    (19)
                                     , 2876-2888. <a href="https://doi.org/10.1021/acs.biochem.8b00288" title="DOI URL">https://doi.org/10.1021/acs.biochem.8b00288</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.8b00288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.8b00288%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%26atitle%3DMolecular%252BBases%252Bof%252BPDE4D%252BInhibition%252Bby%252BMemory-Enhancing%252BGEBR%252BLibrary%252BCompounds%26aulast%3DProsdocimi%26aufirst%3DTommaso%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D08032018%26date%3D04042018%26date%3D01052018%26date%3D13042018%26volume%3D57%26issue%3D19%26spage%3D2876%26epage%3D2888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nusrat  Sahiba</span>, <span class="hlFld-ContribAuthor ">Ayushi  Sethiya</span>, <span class="hlFld-ContribAuthor ">Jay  Soni</span>, <span class="hlFld-ContribAuthor ">Dinesh K.  Agarwal</span>, <span class="hlFld-ContribAuthor ">Shikha  Agarwal</span>. </span><span class="cited-content_cbyCitation_article-title">Saturated Five-Membered Thiazolidines and Their Derivatives: From Synthesis to Biological Applications. </span><span class="cited-content_cbyCitation_journal-name">Topics in Current Chemistry</span><span> <strong>2020,</strong> <em>378 </em>
                                    (2)
                                     <a href="https://doi.org/10.1007/s41061-020-0298-4" title="DOI URL">https://doi.org/10.1007/s41061-020-0298-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s41061-020-0298-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs41061-020-0298-4%26sid%3Dliteratum%253Aachs%26jtitle%3DTopics%2520in%2520Current%2520Chemistry%26atitle%3DSaturated%252BFive-Membered%252BThiazolidines%252Band%252BTheir%252BDerivatives%25253A%252BFrom%252BSynthesis%252Bto%252BBiological%252BApplications%26aulast%3DSahiba%26aufirst%3DNusrat%26date%3D2020%26date%3D2020%26volume%3D378%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jonathan E.  Phillips</span>. </span><span class="cited-content_cbyCitation_article-title">Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2020,</strong> <em>11 </em><a href="https://doi.org/10.3389/fphar.2020.00259" title="DOI URL">https://doi.org/10.3389/fphar.2020.00259</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2020.00259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2020.00259%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DInhaled%252BPhosphodiesterase%252B4%252B%252528PDE4%252529%252BInhibitors%252Bfor%252BInflammatory%252BRespiratory%252BDiseases%26aulast%3DPhillips%26aufirst%3DJonathan%2BE.%26date%3D2020%26date%3D2020%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design opportunities presented by solvent‐exposed regions of target proteins. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2194-2238. <a href="https://doi.org/10.1002/med.21581" title="DOI URL">https://doi.org/10.1002/med.21581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21581%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMolecular%252Bdesign%252Bopportunities%252Bpresented%252Bby%252Bsolvent%2525E2%252580%252590exposed%252Bregions%252Bof%252Btarget%252Bproteins%26aulast%3DJiang%26aufirst%3DXiangyi%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2194%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Valentin S.  Dorokhov</span>, <span class="hlFld-ContribAuthor ">Ivan S.  Golovanov</span>, <span class="hlFld-ContribAuthor ">Vladimir A.  Tartakovsky</span>, <span class="hlFld-ContribAuthor ">Alexey Yu.  Sukhorukov</span>, <span class="hlFld-ContribAuthor ">Sema L.  Ioffe</span>. </span><span class="cited-content_cbyCitation_article-title">Diastereoselective synthesis and profiling of bicyclic imidazolidinone derivatives bearing a difluoromethylated catechol unit as potent phosphodiesterase 4 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (38)
                                     , 6900-6908. <a href="https://doi.org/10.1039/C8OB01039K" title="DOI URL">https://doi.org/10.1039/C8OB01039K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB01039K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB01039K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DDiastereoselective%252Bsynthesis%252Band%252Bprofiling%252Bof%252Bbicyclic%252Bimidazolidinone%252Bderivatives%252Bbearing%252Ba%252Bdifluoromethylated%252Bcatechol%252Bunit%252Bas%252Bpotent%252Bphosphodiesterase%252B4%252Binhibitors%26aulast%3DDorokhov%26aufirst%3DValentin%2BS.%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D38%26spage%3D6900%26epage%3D6908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0022.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0001.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of oral PDE4 inhibitors: cilomilast (<b>1</b>), roflumilast (<b>2</b>), apremilast (<b>3</b>), and tetomilast (<b>4</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of representative inhaled PDE4 inhibitors in clinical development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures of Astra Zeneca (<b>10</b>) and Merck (<b>11</b>) inhaled PDE4 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Docking pose of (<i>S</i>)-<b>14a</b> in the catalytic site of the PDE4B crystal structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMU">1XMU</a>). A pocket for the insertion of substituents on the phenyl ring of the ligand is available in the solvent exposed region of the catalytic binding site (magenta).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Compounds <b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) EDC, DMAP, DCM or DMF, rt; (b) mCPBA, DCM, rt, 48h.</p></p></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Compounds <b>18</b> and <b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (<i>S</i>)-1-(<i>tert</i>-butoxycarbonyl)pyrrolidine-2-carboxylic acid or (<i>R</i>)-1-(<i>tert</i>-butoxycarbonyl)pyrrolidine-2-carboxylic acid, EDC, DMAP, DMF, rt, 48 h; (b) HCl/dioxane 4 M, rt, 8 h; (c) Py or Py/DCM, rt; (d) dimethylamine 2 M in THF, CDI, DMF, rt.</p></p></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Compounds <b>22</b> and <b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (<i>S</i>)-3-(<i>tert</i>-butoxycarbonyl)thiazolidine-2-carboxylic acid or (<i>R</i>)-3-(<i>tert</i>-butoxycarbonyl)thiazolidine-2-carboxylic acid, EDC, DMAP, DMF, rt; (b) HCl/AcOEt 5 M, rt; (c) Py, rt; (d) EDC, DMAP, DCM or DMF, rt; (e) alkylamine, CDI, DMF, rt.</p></p></figure><figure data-id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Compounds <b>28</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (<i>S</i>)-3-(<i>tert</i>-butoxycarbonyl)thiazolidine-2-carboxylic acid, EDC, DMAP, DCM, rt; (b) HCl/AcOEt 4 M, rt; (c) Py, DCM, rt; (d) TFA, rt, overnight.</p></p></figure><figure data-id="sch5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0013.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Preparation of Compounds <b>35</b>, <b>36</b>, and <b>37</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (<i>R</i>)-3-(<i>tert</i>-butoxycarbonyl)thiazolidine-4-carboxylic acid or (<i>R</i>)-1-(<i>tert</i>-butoxycarbonyl)piperidine-3-carboxylic acid or (<i>S</i>)-1-(<i>tert</i>-butoxycarbonyl)piperidine-2-carboxylic acid, EDC, DMAP, DMF, rt; (b) HCl/dioxane 4 M, rt; (c) Py, rt; (d) dimethylamine 2 M in THF, CDI, DMF, rt.</p></p></figure><figure data-id="fig5" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0005.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Crystal structure of compound (<i>S</i>*,<i>S</i>**)-<b>18e</b> bound to the PDE4B catalytic binding site. Hydrogen bonds are represented as yellow dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0006.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Overlay of the docking binding pose for compound (<i>S</i>*,<i>S</i>**)-<b>18b</b> (magenta color) on the structure of (<i>S</i>*,<i>S</i>**)-<b>18e</b> (orange color) bound in the PDE4B catalytic site. Hydrogen bonds are represented as yellow dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0007.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Dose-dependent inhibition of OVA-induced recruitment of eosinophils in BALF (broncho alveolar lavage fluid) of rats treated with compound (<i>S</i>*,<i>S</i>**)-<b>18e</b> and (<i>S</i>*,<i>S</i>**)-<b>22e</b>. The reference anti-inflammatory compound budesonide is reported for comparison.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/medium/jm-2017-01044t_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0008.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Lung levels (nmol/g) and plasma levels (pmol/mL) of (<i>S</i>*,<i>S</i>**)-<b>22e</b> (left) and (<i>S</i>*,<i>S</i>**)-<b>18e</b> (right) after IT administration as dry powder in Sprague–Dawley rats at 1 μmol/kg.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-24/acs.jmedchem.7b01044/20171221/images/large/jm-2017-01044t_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01044&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i81">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62446" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62446" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 32 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Francis, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houslay, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conti, M.</span><span> </span><span class="NLM_article-title">Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action</span> <span class="citation_source-journal">Handb. Exp. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">204</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span><span class="refDoi"> DOI: 10.1007/978-3-642-17969-3_2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1007%2F978-3-642-17969-3_2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=21695635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFChsLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2011&pages=47-84&author=S.+H.+Francisauthor=M.+D.+Houslayauthor=M.+Conti&title=Phosphodiesterase+inhibitors%3A+factors+that+influence+potency%2C+selectivity%2C+and+action&doi=10.1007%2F978-3-642-17969-3_2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase inhibitors: factors that influence potency, selectivity, and action</span></div><div class="casAuthors">Francis, Sharron H.; Houslay, Miles D.; Conti, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">Phosphodiesterases as Drug Targets</span>),
    <span class="NLM_cas:pages">47-84</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">0171-2004</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotide phosphodiesterases (PDEs) are promising targets for pharmacol. intervention.  The presence of multiple PDE genes, diversity of the isoforms produced from each gene, selective tissue and cellular expression of the isoforms, compartmentation within cells, and an array of conformations of PDE proteins are some of the properties that challenge the development of drugs that target these enzymes.  Nevertheless, many of the characteristics of PDEs are also viewed as unique opportunities to increase specificity and selectivity when designing novel compds. for certain therapeutic indications.  This chapter provides a summary of the major concepts related to the design and use of PDE inhibitors.  The overall structure and properties of the catalytic domain and conformations of PDEs are summarized in light of the most recent X-ray crystal structures.  The distinctive properties of catalytic domains of different families as well as the tech. challenges assocd. with probing PDE properties and their interactions with small mols. are discussed.  The effect of posttranslational modifications and protein-protein interactions are addnl. factors to be considered when designing PDE inhibitors.  PDE inhibitor interaction with other proteins needs to be taken into account and is also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcHpr3Mz9BKbVg90H21EOLACvtfcHk0li_SdAjBlYS4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFChsLnP&md5=f0d9d5b89ecdd7a7fafad766ef5295c8</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1007%2F978-3-642-17969-3_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-642-17969-3_2%26sid%3Dliteratum%253Aachs%26aulast%3DFrancis%26aufirst%3DS.%2BH.%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26aulast%3DConti%26aufirst%3DM.%26atitle%3DPhosphodiesterase%2520inhibitors%253A%2520factors%2520that%2520influence%2520potency%252C%2520selectivity%252C%2520and%2520action%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2011%26volume%3D204%26spage%3D47%26epage%3D84%26doi%3D10.1007%2F978-3-642-17969-3_2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Hatzelmann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morcillo, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lungarella, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnot, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanjar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beume, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schudt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenor, H.</span><span> </span><span class="NLM_article-title">The preclinical pharmacology of roflumilast – a selective oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Pulm. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span><span class="refDoi"> DOI: 10.1016/j.pupt.2010.03.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1016%2Fj.pupt.2010.03.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=20381629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlWqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2010&pages=235-256&author=A.+Hatzelmannauthor=E.+J.+Morcilloauthor=G.+Lungarellaauthor=S.+Adnotauthor=S.+Sanjarauthor=R.+Beumeauthor=C.+Schudtauthor=H.+Tenor&title=The+preclinical+pharmacology+of+roflumilast+%E2%80%93+a+selective+oral+phosphodiesterase+4+inhibitor+in+development+for+chronic+obstructive+pulmonary+disease&doi=10.1016%2Fj.pupt.2010.03.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The preclinical pharmacology of roflumilast - A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Hatzelmann, Armin; Morcillo, Esteban J.; Lungarella, Giuseppe; Adnot, Serge; Sanjar, Shahin; Beume, Rolf; Schudt, Christian; Tenor, Hermann</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-256</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  After more than two decades of research into phosphodiesterase 4 (PDE4) inhibitors, roflumilast (3-cyclopropylmethoxy-4-difluoromethoxy-N-[3,5-di-chloropyrid-4-yl]-benzamide) may become the first agent in this class to be approved for patient treatment worldwide.  Within the PDE family of 11 known isoenzymes, roflumilast is selective for PDE4, showing balanced selectivity for subtypes A-D, and is of high subnanomolar potency.  The active principle of roflumilast in man is its dichloropyridyl N-oxide metabolite, which has similar potency as a PDE4 inhibitor as the parent compd.  The long half-life and high potency of this metabolite allows for once-daily, oral administration of a single, 500-μg tablet of roflumilast.  The mol. mode of action of roflumilast - PDE4 inhibition and subsequent enhancement of cAMP levels - is well established.  To further understand its functional mode of action in chronic obstructive pulmonary disease (COPD), for which roflumilast is being developed, a series of in vitro and in vivo preclin. studies has been performed.  COPD is a progressive, devastating condition of the lung assocd. with an abnormal inflammatory response to noxious particles and gases, particularly tobacco smoke.  In addn., according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), significant extrapulmonary effects, including comorbidities, may add to the severity of the disease in individual patients, and which may be addressed preferentially by orally administered remedies.  COPD shows an increasing prevalence and mortality, and its treatment remains a high, unmet medical need.  In vivo, roflumilast mitigates key COPD-related disease mechanisms such as tobacco smoke-induced lung inflammation, mucociliary malfunction, lung fibrotic and emphysematous remodelling, oxidative stress, pulmonary vascular remodelling and pulmonary hypertension.  In vitro, roflumilast N-oxide has been demonstrated to affect the functions of many cell types, including neutrophils, monocytes/macrophages, CD4+ and CD8+ T-cells, endothelial cells, epithelial cells, smooth muscle cells and fibroblasts.  These cellular effects are thought to be responsible for the beneficial effects of roflumilast on the disease mechanisms of COPD, which translate into reduced exacerbations and improved lung function.  As a multicomponent disease, COPD requires a broad therapeutic approach that might be achieved by PDE4 inhibition.  However, as a PDE4 inhibitor, roflumilast is not a direct bronchodilator.  In summary, roflumilast may be the first-in-class PDE4 inhibitor for COPD therapy.  In addn. to being a non-steroid, anti-inflammatory drug designed to target pulmonary inflammation, the preclin. pharmacol. described in this review points to a broad functional mode of action of roflumilast that putatively addresses addnl. COPD mechanisms.  This enables roflumilast to offer effective, oral maintenance treatment for COPD, with an acceptable tolerability profile and the potential to favorably affect the extrapulmonary effects of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDAicMKzimBbVg90H21EOLACvtfcHk0lie4iE9C5IfoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlWqur8%253D&md5=ada4424630713054cefe9a6f5c98121b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2010.03.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2010.03.011%26sid%3Dliteratum%253Aachs%26aulast%3DHatzelmann%26aufirst%3DA.%26aulast%3DMorcillo%26aufirst%3DE.%2BJ.%26aulast%3DLungarella%26aufirst%3DG.%26aulast%3DAdnot%26aufirst%3DS.%26aulast%3DSanjar%26aufirst%3DS.%26aulast%3DBeume%26aufirst%3DR.%26aulast%3DSchudt%26aufirst%3DC.%26aulast%3DTenor%26aufirst%3DH.%26atitle%3DThe%2520preclinical%2520pharmacology%2520of%2520roflumilast%2520%25E2%2580%2593%2520a%2520selective%2520oral%2520phosphodiesterase%25204%2520inhibitor%2520in%2520development%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2010%26volume%3D23%26spage%3D235%26epage%3D256%26doi%3D10.1016%2Fj.pupt.2010.03.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Parikh, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakraborti, A. K.</span><span> </span><span class="NLM_article-title">Phosphodiesterase 4 (PDE4) inhibitors in the treatment of COPD: promising drug candidates and future directions</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span><span class="refDoi"> DOI: 10.2174/0929867323666151117121334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.2174%2F0929867323666151117121334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=26572614" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Oiu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=129-141&issue=2&author=N.+Parikhauthor=A.+K.+Chakraborti&title=Phosphodiesterase+4+%28PDE4%29+inhibitors+in+the+treatment+of+COPD%3A+promising+drug+candidates+and+future+directions&doi=10.2174%2F0929867323666151117121334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 4 (PDE4) Inhibitors in the Treatment of COPD: Promising Drug Candidates and Future Directions</span></div><div class="casAuthors">Parikh, Naisargee; Chakraborti, Asit K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The PDE4 enzyme has been proven to be a versatile drug target for therapeutics to treat diverse disease conditions such as asthma, COPD, diabetes, Huntington's disease, and various other inflammatory disorders.  The treatment of COPD is the most studied utility for PDE4 inhibitors due to their ability to inhibit inflammatory cell responses.  Roflumilast is the only approved drug belonging to this class to treat COPD and has shown significant results in the treatment of asthmatic patients.  This perspective highlights the pharmacol. details of roflumilast and cilomilast.  Moreover, efforts have been made to justify the superiority of roflumilast over cilomilast by detailed comparison of their pharmacol., pharmacokinetic, pharmacodynamic properties and structural features.  Several other mols., with promising PDE4 inhibitory activity have also been highlighted.  Commonly assocd. side effects with this class of compds., their management, and future direction towards the development of PDE4 inhibitors with improved therapeutic index are the focus of this perspective.  More emphasis has been given towards the future development strategies to limit the side effects such as emesis and to achieve better benefit to risk ratio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHRuuoQ7II8rVg90H21EOLACvtfcHk0lie4iE9C5IfoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Oiu70%253D&md5=b7901858db904fcd9a714b2b5d9ec9ef</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.2174%2F0929867323666151117121334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867323666151117121334%26sid%3Dliteratum%253Aachs%26aulast%3DParikh%26aufirst%3DN.%26aulast%3DChakraborti%26aufirst%3DA.%2BK.%26atitle%3DPhosphodiesterase%25204%2520%2528PDE4%2529%2520inhibitors%2520in%2520the%2520treatment%2520of%2520COPD%253A%2520promising%2520drug%2520candidates%2520and%2520future%2520directions%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2016%26volume%3D23%26issue%3D2%26spage%3D129%26epage%3D141%26doi%3D10.2174%2F0929867323666151117121334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Giembycz, M. A.</span><span> </span><span class="NLM_article-title">Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimizm or wishful thinking?</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">155</span><span class="NLM_x">, </span> <span class="NLM_fpage">288</span><span class="NLM_x">–</span> <span class="NLM_lpage">290</span><span class="refDoi"> DOI: 10.1038/bjp.2008.297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1038%2Fbjp.2008.297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=18660832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFKkurbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2008&pages=288-290&author=M.+A.+Giembycz&title=Can+the+anti-inflammatory+potential+of+PDE4+inhibitors+be+realized%3A+guarded+optimizm+or+wishful+thinking%3F&doi=10.1038%2Fbjp.2008.297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?</span></div><div class="casAuthors">Giembycz, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">288-290</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  PDE4 inhibitors have been in development as a novel anti-inflammatory therapy since the 1980s with asthma and chronic obstructive pulmonary disease (COPD) being primary indications.  Despite initial optimism, none have yet reached the market.  In most cases, the development of PDE4 inhibitors of various structural classes, including cilomilast, filaminast, lirimilast, piclamilast, tofimilast, AWD-12-281 (aka GSK 842470), CDP840, CI-1018, D-4418, IC485, L-826,141, SCH 351391 and V11294A has been discontinued due to lack of efficacy.  A primary problem is the low therapeutic ratio of these compds., which severely limits the dose that can be given.  Indeed, for many of these compds. it is likely that the max. tolerated dose is either sub-therapeutic or at the very bottom of the efficacy dose-response curve.  Therefore, the challenge is to overcome this limitation.  It is, therefore, encouraging that many new(er)' PDE4 inhibitors in development are reported to have an improved therapeutic window including tetomilast, oglemilast, apremilast, ONO 6126, IPL-512602 and IPL-455903 (aka HT-0712), although the basis for their superior tolerability has not been disclosed.  In addn., other approaches are possible that may allow the anti-inflammatory activity of PDE inhibitors to be realized.  Accordingly, this Commentary endorses the view of Spina (2008), published in the current issue of the British Journal of Pharmacol., that the therapeutic utility of PDE4 inhibitors to suppress inflammation still remains a viable concept.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV0IqM4s41YrVg90H21EOLACvtfcHk0lie4iE9C5IfoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFKkurbP&md5=b7209db766a51ebbdf0bf9752635540a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.297%26sid%3Dliteratum%253Aachs%26aulast%3DGiembycz%26aufirst%3DM.%2BA.%26atitle%3DCan%2520the%2520anti-inflammatory%2520potential%2520of%2520PDE4%2520inhibitors%2520be%2520realized%253A%2520guarded%2520optimizm%2520or%2520wishful%2520thinking%253F%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D155%26spage%3D288%26epage%3D290%26doi%3D10.1038%2Fbjp.2008.297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Giembycz, M. A.</span><span> </span><span class="NLM_article-title">An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Br. J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">138</span><span class="NLM_x">–</span> <span class="NLM_lpage">152</span><span class="refDoi"> DOI: 10.1111/j.1365-2125.2006.02640.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1111%2Fj.1365-2125.2006.02640.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=16842388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVersr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=138-152&issue=2&author=M.+A.+Giembycz&title=An+update+and+appraisal+of+the+cilomilast+Phase+III+clinical+development+programme+for+chronic+obstructive+pulmonary+disease&doi=10.1111%2Fj.1365-2125.2006.02640.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Giembycz, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">138-152</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Cilomilast (Ariflo, SB 207499) is an orally active, second-generation phosphodiesterase (PDE) 4 inhibitor that is being developed by GlaxoSmithkline for the treatment of chronic obstructive pulmonary disease (COPD).  The results of Phase I and Phase II studies have demonstrated that cilomilast significantly improves lung function and quality of life to a clin. meaningful extent, which has led to a comprehensive Phase III program of research evaluating efficacy, safety and mechanism of action.  However, the results of those Phase III studies are unremarkable and disappointing, raising doubt over the future of cilomilast as a novel therapy for COPD.  This review summarizes data obtained from the Phase III clin. development program, highlights some of the potential concerns both specific to cilomilast and to PDE4 inhibitors in general and assesses the likelihood that cilomilast will reach the market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG3j4h3elSNrVg90H21EOLACvtfcHk0lhMrFWciEvPpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVersr8%253D&md5=0d8f4c3833a446ed6a43cc9b355a2c46</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2006.02640.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2006.02640.x%26sid%3Dliteratum%253Aachs%26aulast%3DGiembycz%26aufirst%3DM.%2BA.%26atitle%3DAn%2520update%2520and%2520appraisal%2520of%2520the%2520cilomilast%2520Phase%2520III%2520clinical%2520development%2520programme%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2006%26volume%3D62%26issue%3D2%26spage%3D138%26epage%3D152%26doi%3D10.1111%2Fj.1365-2125.2006.02640.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Giembycz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Field, S. K.</span><span> </span><span class="NLM_article-title">Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD</span> <span class="citation_source-journal">Drug Des., Dev. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">158</span><span class="refDoi"> DOI: 10.2147/DDDT.S7667</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.2147%2FDDDT.S7667" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=20689641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptlGrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=147-158&author=M.+A.+Giembyczauthor=S.+K.+Field&title=Roflumilast%3A+first+phosphodiesterase+4+inhibitor+approved+for+treatment+of+COPD&doi=10.2147%2FDDDT.S7667"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD</span></div><div class="casAuthors">Giembycz, Mark A.; Field, Stephen K.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">147-158</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  In Apr. 2010, the European Medicines Agency Committee for Medicinal Products for Human Use recommended approval of roflumilast, a selective phosphodiesterase 4 inhibitor, for the "maintenance treatment of severe chronic obstructive pulmonary disease (COPD, FEV1 postbronchodilator less than 50% predicted) assocd. with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment".  This decision was based, in part, on the results of several large, international, multicenter, randomized, placebo-controlled trials of either six or 12 mo' duration that had been undertaken in COPD patients.  Roflumilast 500 μg daily improved lung function and reduced exacerbations in patients with more severe COPD, esp. those with chronic bronchitis, frequent exacerbations, or who required frequent rescue inhaler therapy in the placebo-controlled trials.  It also improved lung function and reduced exacerbations in patients with moderately severe COPD treated with salmeterol or tiotropium.  Advantages of roflumilast over inhaler therapy are that it is an oral tablet and only needs to be taken once daily.  While taking roflumilast, the most common adverse effects patients experienced were gastrointestinal upset and headache.  Wt. loss, averaging 2.2 kg, occurred in patients treated with roflumilast.  Patients taking roflumilast were more likely to drop out of the trials than patients in the control groups.  Patients who discontinued therapy usually did so during the first few weeks and were more likely to have experienced gastrointestinal side effects.  Roflumilast is the first selective phosphodiesterase 4 inhibitor and will offer physicians another treatment option for patients with more severe COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSnapbPDMvA7Vg90H21EOLACvtfcHk0lhMrFWciEvPpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptlGrtLY%253D&md5=d60f2905011c4ff5706f31f789520784</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S7667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S7667%26sid%3Dliteratum%253Aachs%26aulast%3DGiembycz%26aufirst%3DM.%2BA.%26aulast%3DField%26aufirst%3DS.%2BK.%26atitle%3DRoflumilast%253A%2520first%2520phosphodiesterase%25204%2520inhibitor%2520approved%2520for%2520treatment%2520of%2520COPD%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2010%26volume%3D4%26spage%3D147%26epage%3D158%26doi%3D10.2147%2FDDDT.S7667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Schett, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sloan, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schafer, P.</span><span> </span><span class="NLM_article-title">Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases</span> <span class="citation_source-journal">Ther. Adv. Musculoskeletal Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">278</span><span class="refDoi"> DOI: 10.1177/1759720X10381432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1177%2F1759720X10381432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=22870453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1WgtbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=271-278&issue=5&author=G.+Schettauthor=V.+S.+Sloanauthor=R.+M.+Stevensauthor=P.+Schafer&title=Apremilast%3A+a+novel+PDE4+inhibitor+in+the+treatment+of+autoimmune+and+inflammatory+diseases&doi=10.1177%2F1759720X10381432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases</span></div><div class="casAuthors">Schett, Georg; Stoan, Victor S.; Stevens, Randall M.; Schafer, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Musculoskeletal Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">271-278</span>CODEN:
                <span class="NLM_cas:coden">TAMDDB</span>;
        ISSN:<span class="NLM_cas:issn">1759-720X</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterase k (PDEA) is a key enzyme in the degrdn. of cyclic adenosine monophosphate and is centrally involved in the cytokine prodn. of inflammatory cells, angiogenesis, and the functional properties of other cell types such as keratinocytes.  In this review article, apremilast, a novel small mol. inhibitor of PDE4, is introduced.  Apremilast has profound anti-inflammatory properties in animal models of inflammatory disease, as well as human chronic inflammatory diseases such as psoriasis and psoriatic arthritis.  Apremilast blocks the synthesis of several pro-inflammatory cytokines and chemokines, such as tumor necrosis factor alpha, interleukin 23, CXCL9, and CXCL10 in multiple cell types.  In contrast to the biologics, which neutralize pro-inflammatory mediators at the protein level, apremilast modulates prodn. of these mediators at the level of mRNA expression.  Apremilast also interferes with the prodn. of leukotriene B4, inducible nitric oxide synthase, and matrix metalloproteinase and reduces complex inflammatory processes, such as dendritic cell infiltration, epidermal skin thickening, and joint destruction.  As this novel PDE4 inhibitor interferes with several key processes of inflammation, it may emerge as a promising new drug for the treatment of chronic inflammatory diseases such as those of the skin and the joints.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYW_Pi4RaIhrVg90H21EOLACvtfcHk0lhMrFWciEvPpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1WgtbjF&md5=be31ae98aafeedb881815c8c1c9f22fc</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1177%2F1759720X10381432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1759720X10381432%26sid%3Dliteratum%253Aachs%26aulast%3DSchett%26aufirst%3DG.%26aulast%3DSloan%26aufirst%3DV.%2BS.%26aulast%3DStevens%26aufirst%3DR.%2BM.%26aulast%3DSchafer%26aufirst%3DP.%26atitle%3DApremilast%253A%2520a%2520novel%2520PDE4%2520inhibitor%2520in%2520the%2520treatment%2520of%2520autoimmune%2520and%2520inflammatory%2520diseases%26jtitle%3DTher.%2520Adv.%2520Musculoskeletal%2520Dis.%26date%3D2010%26volume%3D2%26issue%3D5%26spage%3D271%26epage%3D278%26doi%3D10.1177%2F1759720X10381432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Kroegel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foerster, M.</span><span> </span><span class="NLM_article-title">Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span><span class="refDoi"> DOI: 10.1517/13543784.16.1.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1517%2F13543784.16.1.109" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=109-24&issue=1&author=C.+Kroegelauthor=M.+Foerster&title=Phosphodiesterase-4+inhibitors+as+a+novel+approach+for+the+treatment+of+respiratory+disease%3A+cilomilast&doi=10.1517%2F13543784.16.1.109"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1517%2F13543784.16.1.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.16.1.109%26sid%3Dliteratum%253Aachs%26aulast%3DKroegel%26aufirst%3DC.%26aulast%3DFoerster%26aufirst%3DM.%26atitle%3DPhosphodiesterase-4%2520inhibitors%2520as%2520a%2520novel%2520approach%2520for%2520the%2520treatment%2520of%2520respiratory%2520disease%253A%2520cilomilast%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D16%26issue%3D1%26spage%3D109%26epage%3D24%26doi%3D10.1517%2F13543784.16.1.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Robichaud, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savoie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamatiou, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lachance, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolicoeur, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasori, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, C. C.</span><span> </span><span class="NLM_article-title">Assessing the emetic potential of PDE4 inhibitors in rats</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">135</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">118</span><span class="refDoi"> DOI: 10.1038/sj.bjp.0704457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1038%2Fsj.bjp.0704457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=11786486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BD38XovVegug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2002&pages=113-118&issue=1&author=A.+Robichaudauthor=C.+Savoieauthor=P.+B.+Stamatiouauthor=N.+Lachanceauthor=P.+Jolicoeurauthor=R.+Rasoriauthor=C.+C.+Chan&title=Assessing+the+emetic+potential+of+PDE4+inhibitors+in+rats&doi=10.1038%2Fsj.bjp.0704457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Assessing the emetic potential of PDE4 inhibitors in rats</span></div><div class="casAuthors">Robichaud, A.; Savoie, C.; Stamatiou, P. B.; Lachance, N.; Jolicoeur, P.; Rasori, R.; Chan, C. C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-118</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Type 4 phosphodiesterase (PDE4) inhibitors mimic the pharmacol. actions of alpha2-adrenoceptor antagonists.  This has been postulated as the mechanism by which PDE4 inhibitors induce emesis and was also demonstrated by their ability to reverse xylazine/ketamine-induced anesthesia.  We further characterized this latter effect since it appears to reflect the emetic potential of PDE4 inhibitors.  Selective inhibitors of PDE 1, 2, 3, 4 and 5 were studied in rats, on the duration of anesthesia induced by the combination of xylazine (10 mg kg-1, i.m.) and ketamine (10 mg kg-1, i.m.).  PMNPQ ((i.e. 6-(4-pyridylmethyl)-8-(3-nitrophenyl)quinoline) - PDE4 inhibitor 0.01-3 mg kg-1), like MK-912 (alpha2-adrenoceptor antagonist: 0.01-3 mg kg-1), dose-dependently reduced the duration of anesthesia.  In contrast, vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor), milrinone (PDE3 inhibitor) and zaprinast (PDE5 inhibitor) had no significant effect at the doses tested (1-10 mg kg-1).  Anal. of plasma and cerebrospinal fluid (CSF) of treated animals confirmed the absorption and distribution to the brain of the inactive inhibitors.  Neither MK-912 (3 mg kg-1) nor PMNPQ (0.1-1 mg kg-1) altered the duration of anesthesia induced via a non-alpha2-adrenoceptor pathway (sodium pentobarbitone 50 mg kg-1, i.p.).  Central NK1 receptors are involved in PDE4 inhibitor-induced emesis.  Consistently, [sar9, Met(O2)11]-substance P (NK1 receptor agonist, 6 μg i.c.v.) reduced the duration of anesthesia induced by xylazine/ketamine.  In summary, this model is functionally coupled to PDE4, specific to alpha2-adrenoceptors and relevant to PDE4 inhibitor-induced emesis.  It therefore provides a novel way of evaluating the emetic potential of PDE4 inhibitors in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhFBpxwaft4bVg90H21EOLACvtfcHk0licszwv2EuwxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovVegug%253D%253D&md5=ce6141bb9867f3b9e469bc72393d33e7</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0704457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0704457%26sid%3Dliteratum%253Aachs%26aulast%3DRobichaud%26aufirst%3DA.%26aulast%3DSavoie%26aufirst%3DC.%26aulast%3DStamatiou%26aufirst%3DP.%2BB.%26aulast%3DLachance%26aufirst%3DN.%26aulast%3DJolicoeur%26aufirst%3DP.%26aulast%3DRasori%26aufirst%3DR.%26aulast%3DChan%26aufirst%3DC.%2BC.%26atitle%3DAssessing%2520the%2520emetic%2520potential%2520of%2520PDE4%2520inhibitors%2520in%2520rats%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2002%26volume%3D135%26issue%3D1%26spage%3D113%26epage%3D118%26doi%3D10.1038%2Fsj.bjp.0704457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Wedzicha, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calverley, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabe, K. F.</span><span> </span><span class="NLM_article-title">Roflumilast: a review of its use in the treatment of COPD</span> <span class="citation_source-journal">Int. J. Chronic Obstruct. Pulm. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">90</span><span class="refDoi"> DOI: 10.2147/COPD.S89849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.2147%2FCOPD.S89849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=26792988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmt1elsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=81-90&author=J.+A.+Wedzichaauthor=P.+M.+Calverleyauthor=K.+F.+Rabe&title=Roflumilast%3A+a+review+of+its+use+in+the+treatment+of+COPD&doi=10.2147%2FCOPD.S89849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Roflumilast: a review of its use in the treatment of COPD</span></div><div class="casAuthors">Wedzicha, Jadwiga A.; Calverley, Peter M. A.; Rabe, Klaus F.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Chronic Obstructive Pulmonary Disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-90</span>CODEN:
                <span class="NLM_cas:coden">IJCOC3</span>;
        ISSN:<span class="NLM_cas:issn">1178-2005</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">COPD is a progressive condition involving chronic inflammation and parenchymal destruction with resulting airflow limitation.  COPD is assocd. with worsening airflow limitation over time and increased frequency of COPD exacerbations, leading to increased mortality and morbidity.  The effects of COPD extend beyond the lungs, as multiple comorbidities may occur with COPD, including cardiovascular disease, diabetes mellitus, osteoporosis, depression, and pneumonia.  COPD exacerbations are assocd. with a rapid worsening of baseline symptoms that requires prompt management and may necessitate hospitalization in the case of a severe episode.  Patients with COPD exacerbations require urgent management of symptoms to prevent further worsening, and preventative steps may be taken to help reduce the no. and frequency of future exacerbations.  Roflumilast is a potent and selective inhibitor of the enzyme phosphodiesterase-4 that targets the systemic inflammation assocd. with COPD.  Roflumilast has a variety of anti-inflammatory effects including decreasing inflammatory mediators and the expression of cell surface markers and inhibition of apoptosis.  Several clin. trials evaluating roflumilast in the treatment of COPD have demonstrated significant improvements from baseline vs. placebo in lung function, including increases in mean pre- and postbronchodilator forced expiratory vol. in 1 s and forced vital capacity.  Data suggest that roflumilast reduces moderate to severe exacerbations with the benefit most well established in patients with severe disease.  Given this evidence, roflumilast, as part of a combination regimen with long-acting bronchodilators, appears to be a reasonable treatment option for patients with severe to very severe COPD assocd. with chronic bronchitis and a history of exacerbations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTmDAT45ELHrVg90H21EOLACvtfcHk0licszwv2EuwxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmt1elsL0%253D&md5=82f632fd0c400d17ca28e10688997904</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S89849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S89849%26sid%3Dliteratum%253Aachs%26aulast%3DWedzicha%26aufirst%3DJ.%2BA.%26aulast%3DCalverley%26aufirst%3DP.%2BM.%26aulast%3DRabe%26aufirst%3DK.%2BF.%26atitle%3DRoflumilast%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520the%2520treatment%2520of%2520COPD%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2016%26volume%3D11%26spage%3D81%26epage%3D90%26doi%3D10.2147%2FCOPD.S89849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Matera, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogliani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calzetta, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cazzola, M.</span><span> </span><span class="NLM_article-title">Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold?</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1983</span><span class="NLM_x">–</span> <span class="NLM_lpage">1992</span><span class="refDoi"> DOI: 10.1007/s40265-014-0303-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1007%2Fs40265-014-0303-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1983-1992&author=M.+G.+Materaauthor=P.+Roglianiauthor=L.+Calzettaauthor=M.+Cazzola&title=Phosphodiesterase+inhibitors+for+chronic+obstructive+pulmonary+disease%3A+what+does+the+future+hold%3F&doi=10.1007%2Fs40265-014-0303-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs40265-014-0303-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-014-0303-8%26sid%3Dliteratum%253Aachs%26aulast%3DMatera%26aufirst%3DM.%2BG.%26aulast%3DRogliani%26aufirst%3DP.%26aulast%3DCalzetta%26aufirst%3DL.%26aulast%3DCazzola%26aufirst%3DM.%26atitle%3DPhosphodiesterase%2520inhibitors%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520what%2520does%2520the%2520future%2520hold%253F%26jtitle%3DDrugs%26date%3D2014%26volume%3D74%26spage%3D1983%26epage%3D1992%26doi%3D10.1007%2Fs40265-014-0303-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Pinner, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, A.</span><span> </span><span class="NLM_article-title">Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">66</span><span class="refDoi"> DOI: 10.1016/j.clinthera.2011.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1016%2Fj.clinthera.2011.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=22284994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVektb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2012&pages=56-66&issue=1&author=N.+A.+Pinnerauthor=L.+A.+Hamiltonauthor=A.+Hughes&title=Roflumilast%3A+a+phosphodiesterase-4+inhibitor+for+the+treatment+of+severe+chronic+obstructive+pulmonary+disease&doi=10.1016%2Fj.clinthera.2011.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Roflumilast: A Phosphodiesterase-4 Inhibitor for the Treatment of Severe Chronic Obstructive Pulmonary Disease</span></div><div class="casAuthors">Pinner, Nathan A.; Hamilton, Leslie A.; Hughes, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-66</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background: Roflumilast is a newly approved phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease (COPD) assocd. with chronic bronchitis and a history of exacerbations.  Objective: The objective of this article is to review the pharmacol., clin. efficacy, and tolerability of roflumilast in the treatment of COPD.  Methods: Articles were identified using MEDLINE (1966-August 1, 2011) and EMBASE (1947-August 1, 2011).  Searches were conducted using the terms roflumilast and COPD.  Included in the search were all English-language clin. trials that were randomized, had durations of >6 wk, and studied the effects of roflumilast on the forced expiratory vol. in 1 s (FEV1) or rates of exacerbations in patients with COPD.  Abstrs. from the annual meetings of the American Thoracic Society, American College of Chest Physicians, and European Respiratory Society were also searched to identify relevant publications.  In addn., all pertinent studies evaluating the pharmacokinetics and pharmacodynamics of roflumilast were included.  Results: A total of 6 clin. trials (4 publications) evaluating the efficacy of roflumilast were identified and included.  For the treatment of COPD, roflumilast was assocd. with a significant improvement in lung function (increase in FEV1 of 36-88 mL) when compared with placebo.  Roflumilast also reduced the rate of exacerbations in subsets of patients with chronic cough and a history of exacerbations.  Overall, health-related quality of life was not significantly affected.  Adverse effects were common in clin. trials, with 9% to 16% of patients discontinuing therapy as a result.  The most frequently reported adverse effects were gastrointestinal issues, headache, and wt. loss.  Suicide-related adverse effects have occurred in 5 patients receiving roflumilast and 1 patient receiving placebo.  Conclusion: Roflumilast significantly improved FEV1 in clin. trials but had inconsistent redns. in the rates of exacerbations.  Comparative studies with recommended therapies for COPD, particularly inhaled corticosteroids, are needed to better assess the role of roflumilast in the management of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAquCjqobFO7Vg90H21EOLACvtfcHk0licszwv2EuwxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVektb0%253D&md5=32cdf18496bb91887c4dfe5774b101da</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2011.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2011.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DPinner%26aufirst%3DN.%2BA.%26aulast%3DHamilton%26aufirst%3DL.%2BA.%26aulast%3DHughes%26aufirst%3DA.%26atitle%3DRoflumilast%253A%2520a%2520phosphodiesterase-4%2520inhibitor%2520for%2520the%2520treatment%2520of%2520severe%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DClin.%2520Ther.%26date%3D2012%26volume%3D34%26issue%3D1%26spage%3D56%26epage%3D66%26doi%3D10.1016%2Fj.clinthera.2011.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Gutke, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guse, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khobzaoui, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renukappa-Gutke, T.</span><span> </span><span class="NLM_article-title">Burnet, M. AWD-12–281 (inhaled) (elbion/GlaxoSmithKline)</span> <span class="citation_source-journal">Curr. Opin. Investig. Drugs.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1149</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=1149-58&author=H.+J.+Gutkeauthor=J.+H.+Guseauthor=M.+Khobzaouiauthor=T.+Renukappa-Gutke&title=Burnet%2C+M.+AWD-12%E2%80%93281+%28inhaled%29+%28elbion%2FGlaxoSmithKline%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGutke%26aufirst%3DH.%2BJ.%26aulast%3DGuse%26aufirst%3DJ.%2BH.%26aulast%3DKhobzaoui%26aufirst%3DM.%26aulast%3DRenukappa-Gutke%26aufirst%3DT.%26atitle%3DBurnet%252C%2520M.%2520AWD-12%25E2%2580%2593281%2520%2528inhaled%2529%2520%2528elbion%252FGlaxoSmithKline%2529%26jtitle%3DCurr.%2520Opin.%2520Investig.%2520Drugs.%26date%3D2005%26volume%3D6%26spage%3D1149%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Danto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, J.</span><span> </span><span class="NLM_article-title">A randomized, double-blind, placebocontrolled, parallel group, six-week study of the efficacy and safety of tofimilast dry powder for inhalation (DPI) in adults with COPD</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">A131</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2007&pages=A131&author=S.+Dantoauthor=G.+C.+Weiauthor=J.+Gill&title=A+randomized%2C+double-blind%2C+placebocontrolled%2C+parallel+group%2C+six-week+study+of+the+efficacy+and+safety+of+tofimilast+dry+powder+for+inhalation+%28DPI%29+in+adults+with+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDanto%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DG.%2BC.%26aulast%3DGill%26aufirst%3DJ.%26atitle%3DA%2520randomized%252C%2520double-blind%252C%2520placebocontrolled%252C%2520parallel%2520group%252C%2520six-week%2520study%2520of%2520the%2520efficacy%2520and%2520safety%2520of%2520tofimilast%2520dry%2520powder%2520for%2520inhalation%2520%2528DPI%2529%2520in%2520adults%2520with%2520COPD%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2007%26volume%3D175%26spage%3DA131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Vestbo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkinson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, J.</span><span> </span><span class="NLM_article-title">A controlled trial of 6-weeks’ treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1044</span><span class="refDoi"> DOI: 10.1183/09031936.00068908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1183%2F09031936.00068908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=19213793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtFahtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2009&pages=1039-1044&author=J.+Vestboauthor=L.+Tanauthor=G.+Atkinsonauthor=J.+Ward&title=A+controlled+trial+of+6-weeks%E2%80%99+treatment+with+a+novel+inhaled+phosphodiesterase+type-4+inhibitor+in+COPD&doi=10.1183%2F09031936.00068908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD</span></div><div class="casAuthors">Vestbo, J.; Tan, L.; Atkinson, G.; Ward, J.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1039-1044</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Anti-inflammatory drugs are lacking in chronic obstructive pulmonary disease (COPD) and inhibitors of the phosphodiesterase type-4 (PDE4) enzyme have been suggested to be an interesting class of drugs to treat inflammation in COPD.  The present authors report the findings of a phase II trial of a novel inhaled PDE4 inhibitor.  Three doses, 0.1, 0.4 and 1.0 mg b.i.d., of the compd. UK-500,001 were tested in a double-blind, placebo-controlled, 6-wk trial in 209 patients with moderate-to-severe COPD.  The primary efficacy parameter was trough forced expiratory vol. in one second after 6 wk of treatment, and secondary end-points included other lung function end-points and symptom scores assessed at 2-wk intervals.  The present study was stopped following a planned interim anal. for futility.  No effect on the primary efficacy parameter, other measures of lung function or symptom scores was obsd. at any dose of UK-500,001 after 6 wk of treatment.  However, after the first 2 wk of treatment, an improvement in a no. of outcome measures in the 1.0 mg b.i.d. dose group was obsd. compared with placebo.  The drug was well tolerated, although PDE4 inhibitor-related side-effects were obsd., esp. in the highest dose group.  The findings of the present study question the role of inhaled phosphodiesterase type-4 inhibitors in chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqfiD54uWV9bVg90H21EOLACvtfcHk0ljxd2ZAMSHkug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtFahtb4%253D&md5=73ac7894ef11b2cdd9f95fcd95b52286</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1183%2F09031936.00068908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00068908%26sid%3Dliteratum%253Aachs%26aulast%3DVestbo%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DAtkinson%26aufirst%3DG.%26aulast%3DWard%26aufirst%3DJ.%26atitle%3DA%2520controlled%2520trial%2520of%25206-weeks%25E2%2580%2599%2520treatment%2520with%2520a%2520novel%2520inhaled%2520phosphodiesterase%2520type-4%2520inhibitor%2520in%2520COPD%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2009%26volume%3D33%26spage%3D1039%26epage%3D1044%26doi%3D10.1183%2F09031936.00068908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Tralau-Stewart, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williamson, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nials, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoigne, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angell, A. D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solanke, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiseman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranshaw, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knowles, R. G.</span><span> </span><span class="NLM_article-title">GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">337</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span><span class="refDoi"> DOI: 10.1124/jpet.110.173690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1124%2Fjpet.110.173690" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=21205923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGquro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=337&publication_year=2011&pages=145-154&author=C.+J.+Tralau-Stewartauthor=R.+A.+Williamsonauthor=A.+T.+Nialsauthor=M.+Gascoigneauthor=J.+Dawsonauthor=G.+J.+Hartauthor=A.+D.+R.+Angellauthor=Y.+E.+Solankeauthor=F.+S.+Lucasauthor=J.+Wisemanauthor=P.+Wardauthor=L.+E.+Ranshawauthor=R.+G.+Knowles&title=GSK256066%2C+an+exceptionally+high-affinity+and+selective+inhibitor+of+phosphodiesterase+4+suitable+for+administration+by+inhalation%3A+in+vitro%2C+kinetic%2C+and+in+vivo+characterization&doi=10.1124%2Fjpet.110.173690"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization</span></div><div class="casAuthors">Tralau-Stewart, Cathy J.; Williamson, Richard A.; Nials, Anthony T.; Gascoigne, Michele; Dawson, John; Hart, Graham J.; Angell, Anthony D. R.; Solanke, Yemisi E.; Lucas, Fiona S.; Wiseman, Joanne; Ward, Peter; Ranshaw, Lisa E.; Knowles, Richard G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">337</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">145-154</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Oral phosphodiesterase 4 (PDE4) inhibitors such as roflumilast have established the potential of PDE4 inhibition for the treatment of respiratory diseases.  However, PDE4 inhibitor efficacy is limited by mechanism-related side effects such as emesis and nausea.  Delivering the inhibitor by the inhaled route may improve therapeutic index, and the authors describe 6-({3-[(dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-4-{[3-methyloxy] phenylamino}-3-quinolinecarboxamide (GSK256066), an exceptionally high-affinity inhibitor of PDE4 designed for inhaled administration.  GSK256066 is a slow and tight binding inhibitor of PDE4B (apparent IC50 3.2 pM; steady-state IC50 <0.5 pM), which is more potent than any previously documented compd., for example, roflumilast (IC50 390 pM), tofimilast (IC50 1.6 nM), and cilomilast (IC50 74 nM).  Consistent with this, GSK256066 inhibited tumor necrosis factor α prodn. by lipopolysaccharide (LPS)-stimulated human peripheral blood monocytes with 0.01 nM IC50 (compared with IC50 values of 5, 22, and 389 nM for roflumilast, tofimilast, and cilomilast, resp.) and by LPS-stimulated whole blood with 126 pM IC50.  GSK256066 was highly selective for PDE4 (>380,000-fold vs. PDE1, PDE2, PDE3, PDE5, and PDE6 and >2500-fold against PDE7), inhibited PDE4 isoforms A-D with equal affinity, and had a substantial high-affinity rolipram binding site ratio (>17).  When administered intratracheally to rats, GSK256066 inhibited LPS-induced pulmonary neutrophilia with ED50 values of 1.1 μg/kg (aq. suspension) and 2.9 μg/kg (dry powder formulation) and was more potent than an aq. suspension of the corticosteroid fluticasone propionate (ED50 9.3 μg/kg).  Thus, GSK256066 was demonstrated to have exceptional potency in vitro and in vivo and is being clin. investigated as a treatment for chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRV6i1BfsW87Vg90H21EOLACvtfcHk0ljxd2ZAMSHkug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGquro%253D&md5=1a4747eadf3541433b9abc043782a0ca</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1124%2Fjpet.110.173690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.110.173690%26sid%3Dliteratum%253Aachs%26aulast%3DTralau-Stewart%26aufirst%3DC.%2BJ.%26aulast%3DWilliamson%26aufirst%3DR.%2BA.%26aulast%3DNials%26aufirst%3DA.%2BT.%26aulast%3DGascoigne%26aufirst%3DM.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DHart%26aufirst%3DG.%2BJ.%26aulast%3DAngell%26aufirst%3DA.%2BD.%2BR.%26aulast%3DSolanke%26aufirst%3DY.%2BE.%26aulast%3DLucas%26aufirst%3DF.%2BS.%26aulast%3DWiseman%26aufirst%3DJ.%26aulast%3DWard%26aufirst%3DP.%26aulast%3DRanshaw%26aufirst%3DL.%2BE.%26aulast%3DKnowles%26aufirst%3DR.%2BG.%26atitle%3DGSK256066%252C%2520an%2520exceptionally%2520high-affinity%2520and%2520selective%2520inhibitor%2520of%2520phosphodiesterase%25204%2520suitable%2520for%2520administration%2520by%2520inhalation%253A%2520in%2520vitro%252C%2520kinetic%252C%2520and%2520in%2520vivo%2520characterization%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D337%26spage%3D145%26epage%3D154%26doi%3D10.1124%2Fjpet.110.173690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Nials, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tralau-Stewart, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoigne, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranshaw, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knowles, R. G.</span><span> </span><span class="NLM_article-title">In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">568</span><span class="NLM_x">–</span> <span class="NLM_lpage">578</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=25576073" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=568-578&author=A.+T.+Nialsauthor=C.+J.+Tralau-Stewartauthor=M.+H.+Gascoigneauthor=D.+I.+Ballauthor=L.+E.+Ranshawauthor=R.+G.+Knowles&title=In+vivo+characterization+of+GSK256066%2C+a+high-affinity+inhaled+phosphodiesterase+4+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNials%26aufirst%3DA.%2BT.%26aulast%3DTralau-Stewart%26aufirst%3DC.%2BJ.%26aulast%3DGascoigne%26aufirst%3DM.%2BH.%26aulast%3DBall%26aufirst%3DD.%2BI.%26aulast%3DRanshaw%26aufirst%3DL.%2BE.%26aulast%3DKnowles%26aufirst%3DR.%2BG.%26atitle%3DIn%2520vivo%2520characterization%2520of%2520GSK256066%252C%2520a%2520high-affinity%2520inhaled%2520phosphodiesterase%25204%2520inhibitor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D568%26epage%3D578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Moretto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caruso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastore, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghidini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Fanti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capaldi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carzaniga, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buccellati, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sala, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patacchini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delcanale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villetti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Facchinetti, F.</span><span> </span><span class="NLM_article-title">CHF6001 I: A novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">189</span><span class="NLM_x">, </span> <span class="NLM_fpage">A6725</span><span class="refDoi"> DOI: 10.1124/jpet.114.220541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1124%2Fjpet.114.220541" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2014&pages=A6725&author=N.+Morettoauthor=P.+Carusoauthor=R.+Boscoauthor=G.+Marchiniauthor=F.+Pastoreauthor=E.+Armaniauthor=G.+Amariauthor=A.+Rizziauthor=E.+Ghidiniauthor=R.+De+Fantiauthor=C.+Capaldiauthor=L.+Carzanigaauthor=E.+Hirschauthor=C.+Buccellatiauthor=A.+Salaauthor=C.+Carniniauthor=R.+Patacchiniauthor=M.+Delcanaleauthor=M.+Civelliauthor=G.+Villettiauthor=F.+Facchinetti&title=CHF6001+I%3A+A+novel+highly+potent+and+selective+phosphodiesterase+4+inhibitor+with+robust+anti-inflammatory+activity+and+suitable+for+topical+pulmonary+administration&doi=10.1124%2Fjpet.114.220541"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220541%26sid%3Dliteratum%253Aachs%26aulast%3DMoretto%26aufirst%3DN.%26aulast%3DCaruso%26aufirst%3DP.%26aulast%3DBosco%26aufirst%3DR.%26aulast%3DMarchini%26aufirst%3DG.%26aulast%3DPastore%26aufirst%3DF.%26aulast%3DArmani%26aufirst%3DE.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DGhidini%26aufirst%3DE.%26aulast%3DDe%2BFanti%26aufirst%3DR.%26aulast%3DCapaldi%26aufirst%3DC.%26aulast%3DCarzaniga%26aufirst%3DL.%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DBuccellati%26aufirst%3DC.%26aulast%3DSala%26aufirst%3DA.%26aulast%3DCarnini%26aufirst%3DC.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DCivelli%26aufirst%3DM.%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DFacchinetti%26aufirst%3DF.%26atitle%3DCHF6001%2520I%253A%2520A%2520novel%2520highly%2520potent%2520and%2520selective%2520phosphodiesterase%25204%2520inhibitor%2520with%2520robust%2520anti-inflammatory%2520activity%2520and%2520suitable%2520for%2520topical%2520pulmonary%2520administration%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D189%26spage%3DA6725%26doi%3D10.1124%2Fjpet.114.220541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Villetti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battipaglia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Preynat, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolzoni, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caruso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergamaschi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pisano, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puviani, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stellari, F. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cenacchi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertacche, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mileo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagnacani, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moretti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puccini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catinella, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Facchinetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sala, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civelli, M.</span><span> </span><span class="NLM_article-title">CHF6001 II: A novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration--in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">568</span><span class="NLM_x">–</span> <span class="NLM_lpage">578</span><span class="refDoi"> DOI: 10.1124/jpet.114.220558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1124%2Fjpet.114.220558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=25576073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Olsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=568-578&author=G.+Villettiauthor=C.+Carniniauthor=L.+Battipagliaauthor=L.+Preynatauthor=P.+T.+Bolzoniauthor=F.+Bassaniauthor=P.+Carusoauthor=M.+Bergamaschiauthor=A.+R.+Pisanoauthor=V.+Puvianiauthor=F.+F.+Stellariauthor=V.+Cenacchiauthor=R.+Voltaauthor=V.+Bertaccheauthor=V.+Mileoauthor=V.+Bagnacaniauthor=E.+Morettiauthor=P.+Pucciniauthor=S.+Catinellaauthor=F.+Facchinettiauthor=A.+Salaauthor=M.+Civelli&title=CHF6001+II%3A+A+novel+phosphodiesterase+4+inhibitor%2C+suitable+for+topical+pulmonary+administration%2D%2Din+vivo+preclinical+pharmacology+profile+defines+a+potent+anti-inflammatory+compound+with+a+wide+therapeutic+window&doi=10.1124%2Fjpet.114.220558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">CHF6001 II: a novel phosphodiesterase 4 inhibitor, suitable for topical pulmonary administration-in vivo preclinical pharmacology profile defines a potent anti-inflammatory compound with a wide therapeutic window</span></div><div class="casAuthors">Villetti, Gino; Carnini, Chiara; Battipaglia, Loredana; Preynat, Laurent; Bolzoni, Pier Tonino; Bassani, Franco; Caruso, Paola; Bergamaschi, Marco; Pisano, Anna Rita; Puviani, Veronica; Stellari, Fabio Franco; Cenacchi, Valentina; Volta, Roberta; Bertacche, Vittorio; Mileo, Valentina; Bagnacani, Valentina; Moretti, Elisa; Puccini, Paola; Catinella, Silvia; Facchinetti, Fabrizio; Sala, Angelo; Civelli, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">568-578, 11 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">CHF6001 [(S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoyloxy)ethyl)pyridine 1-oxide] is a novel phosphodiesterase 4 (PDE4) inhibitor designed for use in pulmonary diseases by inhaled administration.  Intratracheal administration of CHF6001 to ovalbumin-sensitized Brown-Norway rats suppressed the antigen-induced decline of lung functions (ED50 = 0.1 μmol/kg) and antigen-induced eosinophilia (ED50 = 0.03 μmol/kg) when administered (0.09 μmol/kg) up to 24 h before antigen challenge, in agreement with CHF6001-sustained lung concns. up to 72 h after intratracheal treatment (mean residence time 26 h).  Intranasal, once daily administration of CHF6001 inhibited neutrophil infiltration obsd. after 11 days of tobacco smoke exposure in mice, both upon prophylactic (0.15-0.45 μmol/kg per day) or interventional (0.045-0.45 μmol/kg per day) treatment.  CHF6001 was ineffective in reversing ketamine/xylazine-induced anesthesia (a surrogate of emesis in rat) up to 5 μmol/kg administered intratracheally, a dose 50- to 150-fold higher than anti-inflammatory ED50 obsd. in rats.  When given topically to ferrets, no emesis and nausea were evident up to 10 to 20 μmol/kg, resp., whereas the PDE4 inhibitor GSK-256066 (6-[3-(dimethylcarbamoyl)phenyl]sulfonyl-4-(3-methoxyanilino)-8-methylquinoline-3-carboxamide) induced nausea at 1 μmol/kg intratracheally.  A 14-day inhalation toxicol. study in rats showed a no-obsd.-adverse-effect level dose of 4.4 μmol/kg per day for CHF6001, lower than the 0.015 μmol/kg per day for GSK-256066.  CHF6001 was found effective and extremely well tolerated upon topical administration in relevant animal models, and may represent a step forward in PDE4 inhibition for the treatment of asthma and chronic obstructive respiratory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoc2BkhFCksErVg90H21EOLACvtfcHk0lhnprmuIFqDAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Olsb0%253D&md5=58c3c206d5429d8be54923731d5811ff</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220558%26sid%3Dliteratum%253Aachs%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DCarnini%26aufirst%3DC.%26aulast%3DBattipaglia%26aufirst%3DL.%26aulast%3DPreynat%26aufirst%3DL.%26aulast%3DBolzoni%26aufirst%3DP.%2BT.%26aulast%3DBassani%26aufirst%3DF.%26aulast%3DCaruso%26aufirst%3DP.%26aulast%3DBergamaschi%26aufirst%3DM.%26aulast%3DPisano%26aufirst%3DA.%2BR.%26aulast%3DPuviani%26aufirst%3DV.%26aulast%3DStellari%26aufirst%3DF.%2BF.%26aulast%3DCenacchi%26aufirst%3DV.%26aulast%3DVolta%26aufirst%3DR.%26aulast%3DBertacche%26aufirst%3DV.%26aulast%3DMileo%26aufirst%3DV.%26aulast%3DBagnacani%26aufirst%3DV.%26aulast%3DMoretti%26aufirst%3DE.%26aulast%3DPuccini%26aufirst%3DP.%26aulast%3DCatinella%26aufirst%3DS.%26aulast%3DFacchinetti%26aufirst%3DF.%26aulast%3DSala%26aufirst%3DA.%26aulast%3DCivelli%26aufirst%3DM.%26atitle%3DCHF6001%2520II%253A%2520A%2520novel%2520phosphodiesterase%25204%2520inhibitor%252C%2520suitable%2520for%2520topical%2520pulmonary%2520administration--in%2520vivo%2520preclinical%2520pharmacology%2520profile%2520defines%2520a%2520potent%2520anti-inflammatory%2520compound%2520with%2520a%2520wide%2520therapeutic%2520window%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D568%26epage%3D578%26doi%3D10.1124%2Fjpet.114.220558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Singh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leaker, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyce, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nandeuil, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collarini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariotti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santoro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, P. J.</span><span> </span><span class="NLM_article-title">A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients</span> <span class="citation_source-journal">Pulm. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span><span class="refDoi"> DOI: 10.1016/j.pupt.2016.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1016%2Fj.pupt.2016.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=27373438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1eisLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2016&pages=1-6&author=D.+Singhauthor=B.+Leakerauthor=M.+Boyceauthor=M.+A.+Nandeuilauthor=S.+Collariniauthor=F.+Mariottiauthor=D.+Santoroauthor=P.+J.+Barnes&title=A+novel+inhaled+phosphodiesterase+4+inhibitor+%28CHF6001%29+reduces+the+allergen+challenge+response+in+asthmatic+patients&doi=10.1016%2Fj.pupt.2016.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients</span></div><div class="casAuthors">Singh, D.; Leaker, B.; Boyce, M.; Nandeuil, M. A.; Collarini, S.; Mariotti, F.; Santoro, D.; Barnes, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">CHF6001 is an inhaled phosphodiesterase 4 (PDE4) inhibitor in development for the treatment of obstructive lung diseases.  The efficacy and safety of CHF6001 were investigated in a double blind, placebo controlled, 3-way cross-over study using the allergen challenge model.  Thirty-six atopic asthmatics who were not taking inhaled corticosteroids and who demonstrated a late asthmatic response (LAR) to inhaled allergen at screening were randomized to receive CHF6001 400 μg or 1200 μg or placebo administered once a day using a dry powder inhaler.  The three treatment periods were 9 days; allergen challenges were performed on day 9 and induced sputum was obtained after 10 h from challenge.  Washout periods between treatments were up to 5 wk.  Both CHF6001 doses significantly attenuated the LAR; the primary endpoint anal. showed that CHF6001 400 μg and 1200 μg caused redns. of 19.7% (p = 0.015) and 28.2% (p < 0.001) resp. of the weighted FEV1 AUC4-10h compared with placebo.  The difference between the CHF6001 doses was not statistically significant (p = 0.223).  Compared with placebo, CHF6001 caused greater redn. in sputum eosinophil counts, although these changes were not statistically significant.  CHF6001 was well tolerated, with similar nos. of adverse events in each treatment period.  This inhaled PDE4 inhibitor has the potential to provide clin. benefits in patients with atopic asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFxltgVfb-QrVg90H21EOLACvtfcHk0li6Cr-xlUi0xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1eisLzI&md5=cb8064827c2d80be4ae9b9d5f591c514</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2016.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2016.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DLeaker%26aufirst%3DB.%26aulast%3DBoyce%26aufirst%3DM.%26aulast%3DNandeuil%26aufirst%3DM.%2BA.%26aulast%3DCollarini%26aufirst%3DS.%26aulast%3DMariotti%26aufirst%3DF.%26aulast%3DSantoro%26aufirst%3DD.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DA%2520novel%2520inhaled%2520phosphodiesterase%25204%2520inhibitor%2520%2528CHF6001%2529%2520reduces%2520the%2520allergen%2520challenge%2520response%2520in%2520asthmatic%2520patients%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2016%26volume%3D40%26spage%3D1%26epage%3D6%26doi%3D10.1016%2Fj.pupt.2016.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">De Savi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickinson, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonough, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrill, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmour, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dearman, M. S.</span><span> </span><span class="NLM_article-title">Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4661</span><span class="NLM_x">–</span> <span class="NLM_lpage">4676</span><span class="refDoi"> DOI: 10.1021/jm5001216</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5001216" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4661-4676&author=C.+De+Saviauthor=R.+J.+Coxauthor=D.+J.+Warnerauthor=A.+R.+Cookauthor=M.+R.+Dickinsonauthor=A.+McDonoughauthor=L.+C.+Morrillauthor=B.+Parkerauthor=B.+Andrewsauthor=S.+S.+Youngauthor=P.+S.+Gilmourauthor=R.+Rileyauthor=M.+S.+Dearman&title=Efficacious+inhaled+PDE4+inhibitors+with+low+emetic+potential+and+long+duration+of+action+for+the+treatment+of+COPD&doi=10.1021%2Fjm5001216"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm5001216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5001216%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSavi%26aufirst%3DC.%26aulast%3DCox%26aufirst%3DR.%2BJ.%26aulast%3DWarner%26aufirst%3DD.%2BJ.%26aulast%3DCook%26aufirst%3DA.%2BR.%26aulast%3DDickinson%26aufirst%3DM.%2BR.%26aulast%3DMcDonough%26aufirst%3DA.%26aulast%3DMorrill%26aufirst%3DL.%2BC.%26aulast%3DParker%26aufirst%3DB.%26aulast%3DAndrews%26aufirst%3DB.%26aulast%3DYoung%26aufirst%3DS.%2BS.%26aulast%3DGilmour%26aufirst%3DP.%2BS.%26aulast%3DRiley%26aufirst%3DR.%26aulast%3DDearman%26aufirst%3DM.%2BS.%26atitle%3DEfficacious%2520inhaled%2520PDE4%2520inhibitors%2520with%2520low%2520emetic%2520potential%2520and%2520long%2520duration%2520of%2520action%2520for%2520the%2520treatment%2520of%2520COPD%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4661%26epage%3D4676%26doi%3D10.1021%2Fjm5001216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Ting, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aslanian, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, K. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prelusky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamca, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">House, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Celly, C. S.</span><span> </span><span class="NLM_article-title">Discovery of oral and inhaled PDE4 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5528</span><span class="NLM_x">–</span> <span class="NLM_lpage">5532</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.08.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1016%2Fj.bmcl.2013.08.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=24018187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVSku7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=5528-5532&author=P.+C.+Tingauthor=J.+F.+Leeauthor=R.+Kuangauthor=J.+Caoauthor=D.+Guauthor=Y.+Huangauthor=Z.+Liuauthor=R.+G.+Aslanianauthor=K.+I.+Fengauthor=D.+Preluskyauthor=J.+Lamcaauthor=A.+Houseauthor=J.+E.+Phillipsauthor=P.+Wangauthor=+Wuauthor=D.+Lundellauthor=R.+W.+Chapmanauthor=C.+S.+Celly&title=Discovery+of+oral+and+inhaled+PDE4+inhibitors&doi=10.1016%2Fj.bmcl.2013.08.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of oral and inhaled PDE4 inhibitors</span></div><div class="casAuthors">Ting, Pauline C.; Lee, Joe F.; Kuang, Rongze; Cao, Jianhua; Gu, Danlin; Huang, Ying; Liu, Zhidan; Aslanian, Robert G.; Feng, Kung-I.; Prelusky, Daniel; Lamca, James; House, Aileen; Phillips, Jonathan E.; Wang, Peng; Wu, Ping; Lundell, Daniel; Chapman, Richard W.; Celly, Chander S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5528-5532</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The optimization of oxazole-based PDE4 inhibitor 1 has led to the identification of both oral (compd. 16) and inhaled (compd. 34) PDE4 inhibitors.  Selectivity against PDE10/PDE11, off target screening, and in vivo activity in the rat are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWC60jYiR9G7Vg90H21EOLACvtfcHk0li6Cr-xlUi0xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVSku7fJ&md5=5b76d198abe24df922d239e48d8813be</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.08.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.08.056%26sid%3Dliteratum%253Aachs%26aulast%3DTing%26aufirst%3DP.%2BC.%26aulast%3DLee%26aufirst%3DJ.%2BF.%26aulast%3DKuang%26aufirst%3DR.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DGu%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DAslanian%26aufirst%3DR.%2BG.%26aulast%3DFeng%26aufirst%3DK.%2BI.%26aulast%3DPrelusky%26aufirst%3DD.%26aulast%3DLamca%26aufirst%3DJ.%26aulast%3DHouse%26aufirst%3DA.%26aulast%3DPhillips%26aufirst%3DJ.%2BE.%26aulast%3DWang%26aufirst%3DP.%26aulast%3DWu%26aulast%3DLundell%26aufirst%3DD.%26aulast%3DChapman%26aufirst%3DR.%2BW.%26aulast%3DCelly%26aufirst%3DC.%2BS.%26atitle%3DDiscovery%2520of%2520oral%2520and%2520inhaled%2520PDE4%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D5528%26epage%3D5532%26doi%3D10.1016%2Fj.bmcl.2013.08.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Armani, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amari, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Fanti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghidini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capaldi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carzaniga, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caruso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peretto, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Porta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolzoni, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Facchinetti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moretto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patacchini, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bassani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cenacchi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volta, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amadei, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capacchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delcanale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puccini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catinella, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Civelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villetti, G.</span><span> </span><span class="NLM_article-title">Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">793</span><span class="NLM_x">–</span> <span class="NLM_lpage">816</span><span class="refDoi"> DOI: 10.1021/jm401549m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401549m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=793-816&issue=3&author=E.+Armaniauthor=G.+Amariauthor=A.+Rizziauthor=R.+De+Fantiauthor=E.+Ghidiniauthor=C.+Capaldiauthor=L.+Carzanigaauthor=P.+Carusoauthor=M.+Gualaauthor=I.+Perettoauthor=E.+La+Portaauthor=P.+T.+Bolzoniauthor=F.+Facchinettiauthor=C.+Carniniauthor=N.+Morettoauthor=R.+Patacchiniauthor=F.+Bassaniauthor=V.+Cenacchiauthor=R.+Voltaauthor=F.+Amadeiauthor=S.+Capacchiauthor=M.+Delcanaleauthor=P.+Pucciniauthor=S.+Catinellaauthor=M.+Civelliauthor=G.+Villetti&title=Novel+class+of+benzoic+acid+ester+derivatives+as+potent+PDE4+inhibitors+for+inhaled+administration+in+the+treatment+of+respiratory+diseases&doi=10.1021%2Fjm401549m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm401549m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401549m%26sid%3Dliteratum%253Aachs%26aulast%3DArmani%26aufirst%3DE.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DDe%2BFanti%26aufirst%3DR.%26aulast%3DGhidini%26aufirst%3DE.%26aulast%3DCapaldi%26aufirst%3DC.%26aulast%3DCarzaniga%26aufirst%3DL.%26aulast%3DCaruso%26aufirst%3DP.%26aulast%3DGuala%26aufirst%3DM.%26aulast%3DPeretto%26aufirst%3DI.%26aulast%3DLa%2BPorta%26aufirst%3DE.%26aulast%3DBolzoni%26aufirst%3DP.%2BT.%26aulast%3DFacchinetti%26aufirst%3DF.%26aulast%3DCarnini%26aufirst%3DC.%26aulast%3DMoretto%26aufirst%3DN.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DBassani%26aufirst%3DF.%26aulast%3DCenacchi%26aufirst%3DV.%26aulast%3DVolta%26aufirst%3DR.%26aulast%3DAmadei%26aufirst%3DF.%26aulast%3DCapacchi%26aufirst%3DS.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DPuccini%26aufirst%3DP.%26aulast%3DCatinella%26aufirst%3DS.%26aulast%3DCivelli%26aufirst%3DM.%26aulast%3DVilletti%26aufirst%3DG.%26atitle%3DNovel%2520class%2520of%2520benzoic%2520acid%2520ester%2520derivatives%2520as%2520potent%2520PDE4%2520inhibitors%2520for%2520inhaled%2520administration%2520in%2520the%2520treatment%2520of%2520respiratory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D3%26spage%3D793%26epage%3D816%26doi%3D10.1021%2Fjm401549m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Card, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">England, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabrizizad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillette, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milburn, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y. J.</span><span> </span><span class="NLM_article-title">Structural basis for the activity of drugs that inhibit phosphodiesterases</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2233</span><span class="NLM_x">–</span> <span class="NLM_lpage">2247</span><span class="refDoi"> DOI: 10.1016/j.str.2004.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1016%2Fj.str.2004.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=15576036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVClur3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=2233-2247&author=G.+L.+Cardauthor=B.+P.+Englandauthor=Y.+Suzukiauthor=D.+Fongauthor=B.+Powellauthor=B.+Leeauthor=C.+Luuauthor=M.+Tabrizizadauthor=S.+Gilletteauthor=P.+N.+Ibrahimauthor=D.+R.+Artisauthor=G.+Bollagauthor=M.+V.+Milburnauthor=S.+H.+Kimauthor=J.+Schlessingerauthor=K.+Y.+J.+Zhang&title=Structural+basis+for+the+activity+of+drugs+that+inhibit+phosphodiesterases&doi=10.1016%2Fj.str.2004.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases</span></div><div class="casAuthors">Card, Graeme L.; England, Bruce P.; Suzuki, Yoshihisa; Fong, Daniel; Powell, Ben; Lee, Byunghun; Luu, Catherine; Tabrizizad, Maryam; Gillette, Sam; Ibrahim, Prabha N.; Artis, Dean R.; Bollag, Gideon; Milburn, Michael V.; Kim, Sung-Hou; Schlessinger, Joseph; Zhang, Kam Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2233-2247</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) comprise a large family of enzymes that catalyze the hydrolysis of cAMP or cGMP and are implicated in various diseases.  The authors describe the high-resoln. crystal structures of the catalytic domains of PDE4B, PDE4D, and PDE5A with ten different inhibitors, including the drug candidates cilomilast and roflumilast, for respiratory diseases.  These cocrystal structures reveal a common scheme of inhibitor binding to the PDEs: (i) a hydrophobic clamp formed by highly conserved hydrophobic residues that sandwich the inhibitor in the active site; (ii) hydrogen bonding to an invariant glutamine that controls the orientation of inhibitor binding.  A scaffold can be readily identified for any given inhibitor based on the formation of these two types of conserved interactions.  These structural insights will enable the design of isoform-selective inhibitors with improved binding affinity and should facilitate the discovery of more potent and selective PDE inhibitors for the treatment of a variety of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8l4KWCohSy7Vg90H21EOLACvtfcHk0lggfqQZzsVqZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVClur3K&md5=0fa91e4b9047e3df3946c526592be396</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2004.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2004.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DCard%26aufirst%3DG.%2BL.%26aulast%3DEngland%26aufirst%3DB.%2BP.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DTabrizizad%26aufirst%3DM.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26atitle%3DStructural%2520basis%2520for%2520the%2520activity%2520of%2520drugs%2520that%2520inhibit%2520phosphodiesterases%26jtitle%3DStructure%26date%3D2004%26volume%3D12%26spage%3D2233%26epage%3D2247%26doi%3D10.1016%2Fj.str.2004.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Baehr, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devlin, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Applebury, M. L.</span><span> </span><span class="NLM_article-title">Isolation and characterization of cGMP phosphodiesterase from bovine rod outer segments</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">254</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">11669</span><span class="NLM_x">–</span> <span class="NLM_lpage">11677</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=1979&pages=11669-11677&issue=22&author=W.+Baehrauthor=M.+J.+Devlinauthor=M.+L.+Applebury&title=Isolation+and+characterization+of+cGMP+phosphodiesterase+from+bovine+rod+outer+segments"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBaehr%26aufirst%3DW.%26aulast%3DDevlin%26aufirst%3DM.%2BJ.%26aulast%3DApplebury%26aufirst%3DM.%2BL.%26atitle%3DIsolation%2520and%2520characterization%2520of%2520cGMP%2520phosphodiesterase%2520from%2520bovine%2520rod%2520outer%2520segments%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1979%26volume%3D254%26issue%3D22%26spage%3D11669%26epage%3D11677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Thompson, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleman, M. M.</span><span> </span><span class="NLM_article-title">Multiple cyclic nucleotide phosphodiesterase activities from rat brain</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1971</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">311</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span><span class="refDoi"> DOI: 10.1021/bi00778a018</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00778a018" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1971&pages=311-6&issue=2&author=W.+J.+Thompsonauthor=M.+M.+Appleman&title=Multiple+cyclic+nucleotide+phosphodiesterase+activities+from+rat+brain&doi=10.1021%2Fbi00778a018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fbi00778a018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00778a018%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DW.%2BJ.%26aulast%3DAppleman%26aufirst%3DM.%2BM.%26atitle%3DMultiple%2520cyclic%2520nucleotide%2520phosphodiesterase%2520activities%2520from%2520rat%2520brain%26jtitle%3DBiochemistry%26date%3D1971%26volume%3D10%26issue%3D2%26spage%3D311%26epage%3D6%26doi%3D10.1021%2Fbi00778a018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span> <span class="citation_source-book">Maestro</span>, version 9.2; <span class="NLM_publisher-name">Scrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Maestro%2C+version+9.2%3B+Scr%C3%B6dinger%2C+LLC%3A+New+York%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DMaestro%26pub%3DScr%25C3%25B6dinger%252C%2520LLC%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span> <span class="citation_source-book">LigPrep</span>, version 3.4; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=LigPrep%2C+version+3.4%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DLigPrep%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Shelley, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cholleti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenwood, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timlin, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchimaya, M.</span><span> </span><span class="NLM_article-title">Epik: A software program for pk a prediction and protonation state generation for drug-like molecules</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">681</span><span class="NLM_x">–</span> <span class="NLM_lpage">691</span><span class="refDoi"> DOI: 10.1007/s10822-007-9133-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1007%2Fs10822-007-9133-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=17899391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVKrtbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2007&pages=681-691&author=J.+C.+Shelleyauthor=A.+Cholletiauthor=L.+L.+Fryeauthor=J.+R.+Greenwoodauthor=M.+R.+Timlinauthor=M.+Uchimaya&title=Epik%3A+A+software+program+for+pk+a+prediction+and+protonation+state+generation+for+drug-like+molecules&doi=10.1007%2Fs10822-007-9133-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Epik: a software program for pKa prediction and protonation state generation for drug-like molecules</span></div><div class="casAuthors">Shelley, John C.; Cholleti, Anuradha; Frye, Leah L.; Greenwood, Jeremy R.; Timlin, Mathew R.; Uchimaya, Makoto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computer-Aided Molecular Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">681-691</span>CODEN:
                <span class="NLM_cas:coden">JCADEQ</span>;
        ISSN:<span class="NLM_cas:issn">0920-654X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Epik is a computer program for predicting pKa values for drug-like mols.  Epik can use this capability in combination with technol. for tautomerization to adjust the protonation state of small drug-like mols. to automatically generate one or more of the most probable forms for use in further mol. modeling studies.  Many medicinal chems. can exchange protons with their environment, resulting in various ionization and tautomeric states, collectively known as protonation states.  The protonation state of a drug can affect its soly. and membrane permeability.  In modeling, the protonation state of a ligand will also affect which conformations are predicted for the mol., as well as predictions for binding modes and ligand affinities based upon protein-ligand interactions.  Despite the importance of the protonation state, many databases of candidate mols. used in drug development do not store reliable information on the most probable protonation states.  Epik is sufficiently rapid and accurate to process large databases of drug-like mols. to provide this information.  Several new technologies are employed.  Extensions to the well-established Hammett and Taft approaches are used for pKa prediction, namely, mesomer standardization, charge cancellation, and charge spreading to make the predicted results reflect the nature of the mol. itself rather just for the particular Lewis structure used on input.  In addn., a new iterative technol. for generating, ranking and culling the generated protonation states is employed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC6PRLT1xT8LVg90H21EOLACvtfcHk0lggfqQZzsVqZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVKrtbzP&md5=f4f429ea3894e1ad2519cdf3333a5645</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs10822-007-9133-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-007-9133-z%26sid%3Dliteratum%253Aachs%26aulast%3DShelley%26aufirst%3DJ.%2BC.%26aulast%3DCholleti%26aufirst%3DA.%26aulast%3DFrye%26aufirst%3DL.%2BL.%26aulast%3DGreenwood%26aufirst%3DJ.%2BR.%26aulast%3DTimlin%26aufirst%3DM.%2BR.%26aulast%3DUchimaya%26aufirst%3DM.%26atitle%3DEpik%253A%2520A%2520software%2520program%2520for%2520pk%2520a%2520prediction%2520and%2520protonation%2520state%2520generation%2520for%2520drug-like%2520molecules%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2007%26volume%3D21%26spage%3D681%26epage%3D691%26doi%3D10.1007%2Fs10822-007-9133-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span> <span class="citation_source-book">Glide</span>, version 5.7; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Glide%2C+version+5.7%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGlide%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winn, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storoni, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span> </span><span class="NLM_article-title">Phaser crystallographic software</span> <span class="citation_source-journal">J. Appl. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">658</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span><span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0liTfpDBCVLh6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodson, E. J.</span><span> </span><span class="NLM_article-title">Refinement of macromolecular structures by the maximum-likelihood method</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span><span class="refDoi"> DOI: 10.1107/S0907444996012255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=15299926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+macromolecular+structures+by+the+maximum-likelihood+method&doi=10.1107%2FS0907444996012255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0liTfpDBCVLh6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520macromolecular%2520structures%2520by%2520the%2520maximum-likelihood%2520method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26spage%3D240%26epage%3D255%26doi%3D10.1107%2FS0907444996012255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMU','PDB','1XMU'); return false;">PDB: 1XMU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OHJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OHJ','PDB','5OHJ'); return false;">PDB: 5OHJ</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i76"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01044">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_32771"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the ACS Publications Web site: . The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01044">10.1021/acs.jmedchem.7b01044</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings and biological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01044/suppl_file/jm7b01044_si_001.csv">CSV</a>)</p></li><li><p class="inline">Synthesis and characterization of noncommercially available acids <b>13c</b> and <b>13d</b> and preparation of intermediates <b>15</b>, <b>16</b>, <b>20</b>, <b>21</b>, <b>25</b>, <b>26</b>, <b>27</b>, <b>29</b>, <b>30</b>, <b>31</b>, <b>32</b>, <b>33</b>, and <b>34</b>. Summary of crystallographic data of the hPDE4Bcat-UCR in complex with the inhibitor (<i>S</i>*,<i>S</i>**)-<b>18e</b> and refinement statistics (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01044/suppl_file/jm7b01044_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01044/suppl_file/jm7b01044_si_001.csv">jm7b01044_si_001.csv (5.96 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01044/suppl_file/jm7b01044_si_002.pdf">jm7b01044_si_002.pdf (769.27 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB code of compound (<i>S*</i>,<i>S**</i>)-<b>18e</b>: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OHJ">5OHJ</a> (see <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>).</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-24%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01044%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01044" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679956fd5ce7d932","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
